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Orally administered medications are more preferable than those administered by other routes 
as a result of good patient compliance and formulation adjustability [1]. Oral multiparticulate 
delivery systems such as pellets consist of multiple discrete small units, each exhibiting the 
required properties. They offer better pharmaceutical and biopharmaceutical advantages 
compared with traditional single-unit dosage forms [2, 3]. These include lower gastrointestinal 
tract (GIT) irritation due to the decreased local concentration [4] as a result of more even and 
predictable distribution and transportation in the GIT regardless of the nutritional state [5, 6], 
flexibility by mixing units with different release behaviors [7], low risk of dose dumping as each 
unit represents a standalone delivery system [8, 9], spherical shape enabling the 
coating/subcoating process to be performed efficiently and hence setting the release design, 
which results in improvement of drug dissolution and increased bioavailability with low inter- 
and intra-subject variations [10–12]. In addition, the incorporation of mucoadhesive polymers 
could add extra innovative properties to multiparticulate delivery systems, some of which 
include precise site-specific delivery, long residence time in the absorptive tissues and hence 
improved bioavailability of the loaded drug [13]. Generally, the release of the incorporated drug 
depends on its content and the properties of the carrier used [14]. Therefore, they may offer a 
promising alternative for the delivery of therapeutic proteins (TPs), which are currently 
administered mainly parenterally. TPs have high potency and specificity in controlling, treating 
and preventing numerous pathological conditions, such as diabetes, infectious and inflammatory 
diseases [15]. However, their oral administration still represents a challenging goal because of 
many production and delivery obstacles. Briefly, the large and complex structure, as well as 
fragile nature act as barriers to their successful formulation into stable solid dosage forms [16, 
17], whereas poor oral absorption, susceptibility to pH change and breakdown by proteases 
represent pharmacokinetic barrier [18]. Accordingly, safe and efficient protease inhibitors (PIs), 
permeation enhancers (PEs) and conformation stabilizers are key excipients of a suitable carrier 
system [19–21], while the intensive investigation of the material characteristics and the effect of 
different processing parameters on the targeted product profile could be helpful tools in 




The main aim of this study was the development and optimization of a system for lysozyme 
delivery, based on pellets prepared by extrusion/spheronization. The main optimization 
parameters were preserving the biological activity during and after production and acquiring 
adequate sphericity and hardness for the subsequent coating processes. 
The identification of the optimal design space was based on the following hypotheses: 
I.   the optimal design space of pelletization and the thermomechanical stress on lysozyme 
are potentially affected by the material attributes, 
II.   the knowledge of the distribution of relative humidity (RH%) and temperature (T) helps 
to optimize the processing parameters. 
Therefore, wetting was performed in a high-shear granulator constructed with a specially 
designed chamber to monitor the change of RH% and T under different processing 
conditions. Firstly, the experiments were conducted according to 23 full factorial design 
with a central point at different mechanical stresses to determine the optimum design 
space and to study the impact of the material attributes on the design space.  
III.   chitosan citrate may represent a novel well-shielding multifunctional protein carrier 
system, as it provides a long residence time in the targeted absorptive tissues and 
concurrently offers PI and PE effects in a localized pattern, by ensuring an optimal acidic 
microenvironment unfavorable for peptidases and increasing calcium iron chelation and 
hence opening the tight junctions (TJs), e.g. the gates of absorption, and therefore it 
results the in improvement of overall therapeutic performance.  
Citric acid (CA)-based chitosan films were designed and thoroughly investigated in comparison 
to acetic acid (AA)-based films as a reference, and the optimal film composition was selected to 
be suitable as a functional subcoating layer. 
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3. LITERATURE SURVEY 
3.1. Pelletization and Pellets 
Pelletization is an agglomeration procedure that converts the homogenized powders of a drug 
and excipients into relatively high density, free-flowing spherical or semi-spherical units of 
narrow size distribution called pellets, having a dimension of 500-1500 µm [22–24]. 
Pelletization techniques are mainly categorized into four basic groups: agitation method 
(balling), compaction (compression and extrusion/spheronization), layering (powder, solution 
and suspension) and globulation including spray-drying and spray-congealing [25–27]. Other 
alternative methods include high shear pelletization, wet spherical agglomeration, spherical 
crystallization, melt pelletization, cryopelletization and freeze pelletization [28]. 
Among the production methods, the extrusion and spheronization method is used extensively 
and is widely considered as a potential future method due to its ability to produce denser spheres 
with higher drug-loading capacity while retaining their small size. Moreover, the flexible tuning 
of both the composition and process settings helps to meet the required quality, and hence the 
process is considered pharmaceutically more efficient than other pelletization methods [29–32]. 
On the other hand, the main disadvantage is its multistep nature, which is relatively complicated 
and time-consuming [33]. 
Microcrystalline cellulose (MCC) is the most commonly used polymer as pellet former 
acting as an excellent binder with high internal porosity, due to its high capacity to strongly 
retain water molecules [34–36]. Usually, water is used as a granulating liquid to wet the drug-
MCC powder mixture during kneading in higher quantity than usual in conventional granulation 
[37]. The suitable quantity of water should be carefully determined, as over-wetting affects the 
quality of the extrudate as well as both the shape and mechanical properties of the particles [38, 
39]. Nevertheless, the quantity of the required granulating liquid is less than normal in the case 
of formulations containing polyols such as mannitol or sorbitol [40]. Generally, the impeller 
torque value oscillation of the high shear granulator represents an efficient way to determine the 
end point of wet kneading [41].  
Mannitol is a polyol, which could be used with MCC for various purposes, such as a diluent 
or pore-forming agent, thereby improving the release performance of the loaded-drug [42, 43]. 
Moreover, mannitol has been reported to stabilize proteins against aggregation during high shear 
granulation through stabilizing their conformation [44, 45].  
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3.2. Pellet Coating 
To achieve a better therapeutic effect, pellets are usually coated to control the release of the 
incorporated drug or to target the release to a specific GI absorptive site (e.g. enteric coating and 
colon targeting delivery systems) [46–48]. The coated particles are then filled into hard gelatin 
capsules or compressed into tablets as a final dosage form [49]. Recently, targeted drug delivery 
to the colon has received increased attention from pharmaceutical technologists, since both local 
and systemic effects of drugs, particularly proteins and peptides, may be achieved [50]. 
Furthermore, colon targeted drug delivery guarantees maximum release in the colonic region 
with less fluctuation in drug concentration at the absorptive site [51]. For this purpose, mostly 
acrylic polymers (e.g., Eudragit®) are used as pH-sensitive polymers. The release of the active 
pharmaceutical ingredient (API) occurs close to the colon in the pH range of 6.5 to 7.5 [52–54].  
Generally, the enteric coating of pellets is performed to protect the stomach from the toxic 
effect of the drug, or to shield the acid-unstable drug from gastric acidity [55]. Most of the 
coating polymers are applied as aqueous or organic solutions/dispersions, and the aqueous ones 
are more preferred for many reasons, e.g. non-toxicity, no need to recover and non-explosiveness 
[56]. 
3.3. Challenges of Oral Protein Delivery 
The flourishing in biotechnology leads to the development of numerous macromolecular 
drugs which have found a place in controlling and treating various diseases, such as certain 
infections, malignant tumors and immunological disorders [57–59]. More than a hundred TPs 
are available commercially, and more than 50 have been approved by the Food and Drug 
Administration (FDA) for commercialization [60, 61]. They represent attractive drug candidates 
due to their specificity, exceptional efficacy and low toxicity, which are basically attributed to 
their complex structures, but concurrently poses the main challenge for their development as oral 
delivery systems [62–64]. 
3.3.1. Pharmaceutical Processing Challenges 
The formulation of stable oral delivery systems for these biopharmaceuticals represents a 
challenging goal to pharmaceutical technologists because they possess a fragile nature, making 
them more vulnerable to misfolding, aggregation and denaturation, which results in lost or 
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diminished biological activity [65]. This instability should be carefully evaluated and managed, 
especially for the processes involving high mechanical shear stress with an elevated moisture 
content [15, 66]. Accordingly, the incorporation of a protein stabilizer in the formulation is a 
useful approach to stabilize proteins during their processing and storage [67]. In addition, the 
implementation of process analytical technology (PAT) could be a crucial tool. 
3.3.2. Oral Administration Challenges  
The main obstacle for orally administered TPs is low bioavailability attributed to the 
undesirable bio- and physiochemical properties, such as large molecular weight or inactivation 
by gastrointestinal secretions and first pass effect, which results in low penetration and pre-
systemic degradation [68–71]. The lumen of the small intestines contains various proteolytic 
enzymes secreted by the pancreas, mucosal cells and the border of the epithelial cells. Moreover, 
the enzymes produced by the microflora in the colon should be taken into consideration [72–74]. 
Orally administered drugs penetrate across the membranes through the following pathways: 
paracellularly, transcellularly and through the microfold. Paracellular absorption is the main 
pathway for the absorption of proteins, but it is tightly closed by non-static TJs along the 
intestines. However, some penetration enhancers have the ability to loosen the proteins of the 
TJs [75–78]. The epithelial mucosal layer also acts as a rigid coat to the intestinal lumen [79]. It 
has different thickness and turnover values regarding the anatomical position [80], possesses a 
negative charge and lipophilic nature [81], and thus acts as a physical barrier [82].  
Based on the above-mentioned barriers, most researchers recommend the incorporation of 
PIs and PEs in a suitable delivery system, i.e. a multifunctional delivery system. The utilization 
of mucoadhesive polymers also represents a rational approach to further improve the 
performance of the orally administered systems [17, 83–86]. However, the concurrent 
administration of TPs with PIs and PEs should be carefully designed, as these agents can 
interfere with dietary proteins and may cause non-specific absorption or damage the integrity of 
the mucosal layer. In addition, the effectiveness of these agents is not similar along the GIT due 
to the variation of numerous parameters, such as pH, proteolytic activity or membrane thickness 
[87–90]. Accordingly, a less damaging, rational and safe method would be the transient opening 
of TJs by an effective concentration of PIs and PEs applied in localized delivery systems, such 
as mucoadhesive systems [91, 92].  
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3.4. Mucoadhesive Delivery Systems 
Mucoadhesion is the adherence of a polymeric carrier to the mucosal layer of the epithelium, 
which enables the polymer to tightly stick to the biological substrate for a substantial period of 
time [93–95] as a result of multiple steps of interactions with the mucosal surfaces [96, 97]. It 
includes GIT, oral cavity, nasal, ocular, pulmonary, vaginal and rectal drug delivery systems [98, 
99]. They are considered as attractive carrier systems for either local or systemic delivery of 
poorly absorbed drugs, such as proteins [87, 100]. Additionally, they may isolate 
proteins/peptides from the degrading environment [101–103] and promote the absorption of 
incorporated drugs [104–106]. Moreover, they may control the release of the incorporated 
molecules through their gel-forming property and ensure the concurrent release of the drug and 
the EI and PE in a localized pattern [107, 108]. Accordingly, mucoadhesive carrier systems 
reduce the possible toxicity of EI and PE while improving the overall therapeutic performance 
of the dosage form. 
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4. MATERIALS AND METHODS 
4.1. Materials 
Lysozyme, also known as muramidase, was used as a model protein. It is a harmless natural 
antimicrobial enzyme protein obtained from plants, animals and microorganisms as a single 
chain polypeptide with a globular shape consisting of 129 amino acids with an approximate 
molecular weight of 14.3 kDa [109–112]. The diversity in the source renders lysozyme the most 
affordable and cost-effective protein for the investigations [113]. Hen-egg white is a common 
source used in the studies of lysozyme [114]. Two brands of the hen egg-white-derived enzyme, 
with greatly different stabilities were involved into the study. Lysoch-40000 (Handary SA, 
Brussels, Belgium) described as “lyso-1” may be stored under ambient conditions up to 24 
months while (CAT. HY-B2237/CS-7671, MedChemExpress, Hungary) described as “lyso-2” 
should be stored frozen (-20°C). According to our hypothesis, the poorer thermal stability may 
negatively affect enzymatic activity, but with careful design, it is still possible to produce pellets 
of the required quality. Scanning electron micrographs (Fig. 1a, b) showed no considerable 
differences in the size or morphology of lyso-1 and lyso-2. 
The antimicrobial activity of lysozyme is attributed to the destruction and lysation of the cell 
wall of Gram-positive bacteria and some fungi [115–117] through the hydrolysis of β-1,4-
linkage of N-acetyl-D-glucosamine and N-acetylmuramic acid residue of the peptidoglycan of 
the bacterial cell walls [118]. Recent studies confirmed its activity against some Gram-negative 
bacteria, including Pseudomonas aeruginosa [119]. In addition, lysozyme has a great potential 
in the treatment of diseases of inflammatory origin [120] by reducing the lipopolysaccharide 
(LPS)-induced inflammatory responses, and some studies suggested the alleviation of the 
inflammation by suppressing the inflammatory cytokine levels in both serum and organs [121, 
122]. Moreover, some researchers reported anti-inflammatory action at the gene expression level 
[123]. 
Spray-dried mannitol (SDM) (Pearlitol SD-200, Roquette Pharma, France) and crystalline 
mannitol (CM) (Hungaropharma Ltd., Hungary) were utilized as conformation stabilizers 
against thermal shocks caused by the raised mechanical stress or during the drying of the protein 
formulation [124–126]. The CM has big columnar/tabular crystals with sharp edges, and wide 
particle size distribution (Fig. 1c), while SDM has spherical particles with more narrower size 
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distribution (Fig. 1d), which may be considered as aggregates of columnar microcrystals. Further 
difference that while CM is pure β form, SDM is a mixture of α and β forms, which exerted 
smaller elasticity in compression studies. Microcrystalline cellulose (MCC, Avicel pH 101, FMC 
Biopolymer, Philadelphia, USA) was used as pellet former and drug carrier.  
 
Figure 1. Scanning electron micrographs of lyso-1 (a), lyso-2 (b), CM (c) and SDM (d) 
 
Lyophilized Micrococcus lysodeikticus (Sigma-Aldrich, USA) was used as a model Gram-
positive bacterium to investigate the biological activity of the prepared pellets. 
Chitosan 80/1000 (Heppe Medical Chitosan GmbH., Germany) was applied as a functional 
subcoating polymer. Acetic acid (AA) 99.8% (Sigma-Aldrich, Germany) and citric acid 
monohydrate (CA) (Molar Chemicals Kft, Hungary) were primarily used as solubility enhancers 
for chitosan. Glycerol (G), propylene glycol (PG) (Hungopharma Ltd., Hungary), and 
polyethylene glycol 400 (PEG-400) (Sigma-Aldrich, Germany) were used as plasticizers. Mucin 
75-95% (Roth, Germany) was used as a substrate for the mucoadhesivity investigation and 
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diiodomethane (VWR Prolabo, USA) was used as a non-polar liquid for the surface free energy 
(SFE) investigation. 
Chitosan is a linear biopolymer composed of randomly distributed ß (1, 4) - linked D-
glucosamine and N-acetyl-D-glucosamine obtained by partial deacetylation of chitin [127–129]. 
Its unique properties such as biocompatibility, biodegradability, non-toxicity and low 
immunogenicity make chitosan the second most abundant natural polymer in the world [130, 
131], and due to its weak alkaline nature, chitosan is solubilized by aqueous acidic media and 
produces highly viscous solutions suitable for the preparation of free films and coatings [132]. 
In addition, it possesses superior mucoadhesivity due to the presence of reactive hydroxyl and 
amino groups [133], which enable ionic interaction with sialic acid residues of the mucosa [134]. 
Thus, it could be involved in opening TJs and assisting the penetration of macromolecular drugs 
[135, 136]. The reversible opening of TJs has been approved and is regarded as the safest 
approach to penetration enhancement [137, 138]. Furthermore, its incorporation may enable the 
controlled release of the incorporated macromolecule, EI and PE [139]. Accordingly, chitosan 
is considered to be an effective positively charged and harmless PE along the intestinal lumen 
[137, 138, 140]. 
In addition, the incorporation of CA instead of AA will tailor the properties of chitosan, as 
CA can be used as plasticizing agent. Moreover, CA has been described to increase the 
absorption of proteins by various mechanisms, e.g. by effective suppression of luminal proteases 
[141] and permeation enhancement by calcium chelation, which results in the opening of TJs 
[142–144]. Accordingly, it could be a logical approach when multiparticulates are suitably 
subcoated by a multifunctional layer to improve bioavailability by the different ways discussed 
above. However, it is necessary to thoroughly investigate CA-based chitosan solutions/films by 






4.2.1.1. Design of Experiments 
The experiments were performed according to 23 full factorial design with a central point. 
The impeller speed (x1), liquid addition rate (x2) and extrusion speed (x3) were studied as 
independent factors, while the optimization parameters were enzyme activity (y1), pellet 
hardness (y2), moisture content (y3), roundness (y4) and aspect ratio (y5). The effect of factors 
and their interactions on the optimization parameters were evaluated statistically by using 
Statistica v. 13.5. Software (Tibco Statistica Inc, CA, USA). 
4.2.1.2. Homogenization  
100 g of powder mixtures composed of Lyso-1 or Lyso-2, CM or SDM and MCC in a ratio 
of 1:4:5, respectively, were homogenized in a Turbula mixer (Willy A. Bachofen 
Maschinenfabrik, Switzerland) for 10 minutes. The composition of the homogenized powder 
mixtures is shown in Table 1. 
Table 1. Composition of the mixtures 
Excipients C1 (g) C2 (g) C3 (g) 
Lyso-1 10  10 - 
Lyso-2 - - 10 
CM 40  - 40 
SDM - 40 - 
MCC 50  50 50 
Lyso-1: lyophilized lysozyme, Lyso-2: spray-dried lysozyme, C 1, C 2 and C 3: first, 
second and third composition, respectively 
 
4.2.1.3. Estimation of Water Quantity 
The exact quantity of the granulating liquid is critical since the liquid quantity will affect the 
quality of the extrudate as well as the hardness and sphericity of the particles [145, 146]. 
Accordingly, the Enslin number was estimated, which is a simple measurement and is equal to 
the quantity of water absorbed by 1 g of the powder mixture (ml/g). The equipment is simple 
and consists of a G4 glass filter and a pipette with 0.01 accuracy. 0.5 g of each homogenized 
powder mixture was dispersed as a monolayer over a filter paper placed horizontally at the 
bottom of the glass filter, and the maximum water uptake was determined; the experiment was 
performed three times and the average was taken. 
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4.2.1.4. Wet Granulation 
The homogenized mixtures of the powder samples were wetted and kneaded in a ProCepT 
4M8 high shear granulator (ProCepT nv. Zelzate, Belgium) at different impeller speeds (x1) and 
liquid addition rates (x2). The impeller and the chopper were located vertically; the processing 
parameters are illustrated below in Table 2. 60 ml of purified water was added at different rates 
(-1, 0 and +1 level), followed by 60s wet massing time. Wet granulation and kneading were 
performed in a specially designed Teflon granulation chamber (Opulus Ltd., Hungary) equipped 
with three immersed PyroDiff® sensors (channel 1, 2 and 3) located at different heights from the 
bottom of the chamber and at different distances from the chamber wall, as demonstrated in 
Figure 2. They were directly connected to a computer via an interface and four calibrated 
PyroButton-TH® sensors equipped on the chamber wall at different positions (at the bottom, 42 
mm, 65 mm and 87 mm from the bottom). The sensors were programmed to continuously 
measure the change in temperature and relative humidity (RH) in every 2 seconds during 
granulation, at the temperature and humidity resolution of 0.06°C and 0.04% RH, respectively, 
in addition to the infrared temperature sensor of the high-shear granulator. The obtained wetted 
masses were preserved in tightly closed containers until extrusion/spheronization. 
 
 






Table 2. Processing parameters of the kneading, extrusion and spheronization 
Kneading  Process-1 Process-2 Process-3 Process-4 Process-5 
Impeller speed (x1) 500 (-1) 500 (-1) 1500 (+1) 1500 (+1) 1000 (0) 
Liquid addition rate 
ml/min (x2) 
5 (-1) 10 (+1) 5 (-1) 10 (+1) 7.5 (0) 
Purified H2O (ml) 60 60 60 60 60 
Chopper speed 500 500 500 500 500 
Extr./spheron. Process-1 Process-2 Process-3 Process-4 Process-5 
Extrusion speed (x3) 70 (-1) 120(+1) 70 (-1) 120(+1) 70 (-1) 120(+1) 70 (-1) 120(+1) 95 (0) 
Spher. speed (rpm) 2000 2000 2000 2000 2000 2000 2000 2000 2000 
Spher. time (minute) 1 1 1 1 1 1 1 1 1 
Spher. amount (g) 17 17 17 17 17 17 17 17 17 
Sample code LysC-11 LysC-12 LysC-21 LysC-22 LysC-31 LysC-32 LysC-41 LysC-42 LysC-c 
*C: referring to the composition; 1, 2 and 3 for the first (C1), second (C2) and third (C3) composition, 
respectively 
4.2.1.5. Extrusion and Spheronization 
The kneaded wet masses were extruded with a single-screw extruder (Caleva Process 
Solutions Ltd., UK), which was equipped with an axial screen of 4-mm thickness and had 16 
dies with a diameter of 1 mm. The extruder was equipped with a laboratory-developed water-
cooling jacket to maintain the temperature constant during extrusion. Extrusion was performed 
at different extrusion rates (x3) (70, 95 and 120 rpm) and at a constant feeding rate. The obtained 
extrudates were preserved in moisture-retentive containers to prevent water loss.  
The extruded samples were spheronized with a Caleva MBS spheronizer (Caleva Process 
Solutions Ltd., UK). 17 g of each extruded sample was spheronized at a speed of 2000 rpm for 
1 min (according to the preformulation study). The obtained spheroids were dried for 24 hours 
under ambient conditions (22±1°C, 31±2% RH). 
 
4.2.1.6. Measurement of Pellet Activity  
The biological activity (y1) of the prepared pellets was measured via the degradation of 
lyophilized Micrococcus lysodeikticus by using a Genesys 10 S UV-VIS Spectrometer 
(ThermoScientific, MA, USA). 70 mg of lyophilized bacteria was suspended in 100 ml of 
phosphate buffer (pH 6.24); the basic absorption at 450 nm was around 0.7. The absorption of 
the bacterial suspension was measured for 5 minutes before each test to reduce the error arising 
from bacterial sedimentation. 100 mg of pellet or 10 mg of crude lysozyme was dissolved in 25 
ml of phosphate buffer. 0.1 ml of pellet/or crude lysozyme solution was added to 2.5 ml of 
bacterial suspension and shaken for 20 seconds in a quartz cuvette, then the change in bacterial 
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absorption was measured for 5 minutes. Pellet activity was calculated from the percentage 
degradation of the bacterial cells relative to crude lysozyme activity as a reference by SigmaPlot 
Software (version 12). 
4.2.1.7. Hardness and Deformation 
Deformation force (y2) and behavior was investigated with a custom-made texture analyzer. 
The equipment and its software were developed at the University of Szeged, Institute of 
Pharmaceutical Technology and Regulatory Affairs. The equipment consists of a sample holder 
at the base and a probe moving vertically at a constant speed of 20 mm/min. The test was 
conducted in the force range of 0-50 Newtons. The deformation characteristics and breakage 
force of pellets (n=20 for each sample) were obtained and the average and SD were calculated.  
4.2.1.8. Moisture Content  
The moisture content (y3) of the prepared pellets was measured by using a Mettler-Toledo 
HR73 (Mettler-Toledo Hungary Ltd., Hungary) halogen moisture analyzer. The moisture 
content of approximately 0.5 g of each sample was measured in triplicate at a drying temperature 
of 105°C until a constant weight was obtained. 
4.2.1.9. Size and Shape Study 
The size and shape (y4 and y5) of the prepared samples were investigated by using a system 
consisting of a stereomicroscope and a ring light with a cold light source (Carl Zeiss, 
Oberkochen, Germany). The images were analyzed with Leica Quantimet 500 C image analysis 
software (Leica Microsystems, Wetzlar, Germany), and the area, length, breadth, perimeter, 
convex perimeter, roundness and aspect ratio of 100 pellets were measured or calculated. The 
roundness and aspect ratio are the most common shape parameters used to characterize the shape 
of pellets and are calculated by the applied Leica Q500MC software using the following 
equations: 
 
Roundness = Perimeter2/(4*π*Area*1.064)  (1) 
 




where Perimeter is the total length of boundary of the feature, Area is calculated from the total 
number of detected pixels within the feature, while dmax and dmin are the longest and shortest 
Feret diameter measured. 
 
4.2.1.10. Scanning Electron Microscopy 
The morphology and size of the raw materials were investigated by Scanning Electron 
Microscope (SEM) (Hitachi 4700, Hitachi Ltd., Tokyo, Japan). The samples were coated with a 
conductive gold thin layer by a sputter coating unit (Polaron E5100, VG Microtech, UK), images 
were taken at an accelerating voltage of 10.0 kV, the used air pressure was 1.3– 13 mPa during 
the analyses. The particle size was determined using Image J 1.47 t (National Institute of Health, 
Bethesda, MD, USA) software. 
 
4.2.2. Design of Chitosan Films 
4.2.2.1. Preparation Method 
Chitosan films were prepared with the solvent casting method, by dissolving the polymer (2 
w/v%) in aqueous AA solution (2 v/v%) as prescribed by Liu et al. [147] as a reference, and with 
the use of CA (2.5, 3, 3.5, 4, 5 and 7 w/v%). Plasticizers were added to AA, CA 2.5% and CA 
7%-based solutions in approx. five to ten times excess (5 w/v% and 10 w/v%) compared to the 
polymer, to significantly modify the surface characteristics, which could be crucial when the 
films are applied as subcoating. The exact compositions of the prepared solutions/films are 
shown below in Table 3, while the molar ratios can be found in Annex 5 Table S1.  
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5 2 2.5 - - - - 7 2 
10 2 2.5 - - - - 7 2 
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5 2 2.5 - - - - 7 2 




A magnetic stirrer was used to obtain 100 mL of homogeneous solutions. Heating to 50–
58°C for two hours was required to dissolve chitosan if a low amount of CA (2.5 and 3 w/v%) 
was applied, as the pH of these solutions was around pH 4, whereas for AA and CA (3.5–7 
w/v%) based solutions (pH of ~2.75) heating was not required. After the whole polymer was 
dissolved, the obtained solutions were left to stand for 3 h to enable the entrapped air bubbles to 
evolve. A portion (~ 25 mL) of each solution was taken to test the minimum film forming 
temperature (MFFT), while the remaining amount was cast into gasket rings (19.635 cm2 x 0.5 
cm) as 10 g/ring. The cast solutions were dried under ambient conditions (25.5 ± 1°C and 28 ± 
1 RH%) for 48 h, the dried films were carefully released from the plates and preserved in tightly 
closed containers for further investigations. 
4.2.2.2. Investigation of Minimum Film Forming Temperature 
Minimum Film Forming Temperature (MFFT) was investigated with a Rhopoint MFFT-60 
Bar tester (Rhopoint, UK) in the temperature range of 15–60 ºC. After temperature equilibrium 
had been established, a cube applicator was used to make 5 parallel films of 75 µm thickness 
over the temperature bar. The hinged Perspex cover was returned down to provide atmospheric 
and thermal equilibrium whilst enabling the visual inspection of the applied films. The films (n 
= 5) were then let completely dry, and the result was recorded manually by inspecting the cracked 
regions on the applied film forms on the graduating scale of the equipment. 
4.2.2.3. Infrared Spectroscopy 
The infrared spectra of the films and raw materials were obtained by using an Avatar 330 
(ThermoScientific, USA) Fourier transform infrared (FT-IR) apparatus coupled with a Zn/Se 
HATR (horizontal attenuated total reflectance) accessory. Each film was directly placed on an 
ethanol-cleaned crystal of the equipment; the scanning was run in the wavelength range of 600–
4000 cm−1, the spectra were collected from 128 scans to obtain smooth spectra, at the spectral 
resolution of 4 cm−1 and applying CO2 and H2O corrections. 
4.2.2.4. Film Thickness 
The thickness of the films was measured at 10 randomly selected points on each film (n = 
10) by using a screw micrometer (Mitutoyo Co. Ltd, Japan) with sensitivity of 0.001 mm, and 
the means and SDs were calculated. 
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4.2.2.5. Hardness and Mucoadhesion Investigations 
The hardness of films and mucoadhesive forces were investigated with the same equipment 
described in Section (4.2.1.7), but with a different assembly of the moving probe and sample 
holder. For the hardness test, a needle-like probe with a half-sphere end was fixed at the top 
movable part of the assembly and set to move downward at a controllable speed toward the tested 
film, which was tightly fixed on the sample holder, enabling the moving probe to pass through 
the fixed film until the film cracked. This test was repeated ten times for each film (n = 10), and 
the means and SDs were calculated. 
On the other hand, for mucoadhesivity a rod-like probe with an outer diameter of 9 mm 
represented the sample holder. A double-faced adhesive tape was used to fix the polymer film 
with an equivalent area on its surface. At the bottom of the equipment, a circular flat disc with 
an outer diameter of 35 mm was fixed, on which a few drops of freshly prepared 1 mg/ml mucin 
solution were spread. The equipment was adjusted to move downward to press the film with 50 
± 1 N force for 30 s to mucin. The probe then moved upwards, which resulted in the drop-down 
of the force curve until the fixed film started to detach from mucin, which is represented as a 
sharp peak on the force-time curve, as shown in (Fig. 9), where the peak maximum represents 
mucoadhesivity. This test was repeated five times (n = 5), and the means and SDs were 
calculated. 
4.2.2.6. Calculation of Surface Free Energy 
The measurement of SFE allows the evaluation of the wetting behavior and the applicability 
of the tested polymer for the coating process as the SFE of a mucoadhesive polymer should be 
adequate to enable wetting with the mucosal surface [148]. SFEs were calculated indirectly from 
the means of the contact angles (Ɵ) of two liquids [149] with known surface tension, dispersive 
and polar components by using the optical contact angle measuring apparatus (OCA20, 
DataPhysics Instrument GmbH, Germany), via the application of the sessile drop method. 
Distilled water (γtot = 72.8 mN/m, γd = 21.8 mN/m, γp = 51.0 mN/m) and diiodomethane (γtot = 
50.8 mN/m, γd = 50.8 mN/m, γp = 0 mN/m) were used as polar and non-polar reagents, 
respectively. One drop of each liquid (10 µL of distilled water and 5 µL of diiodomethane) was 
applied via a motor-driven micro-syringe on the prepared thin, plain and smooth film of chitosan 
and the angles were measured automatically for 30 s. The starting (0 s) and equilibrium (30 s) 
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contact angles (n = 10 of each liquid) were recorded, and the means and SDs were calculated 
separately. The results were introduced into OCA-20, SFE-calculating-program by introducing 
the means and SDs of first and equilibrium contact angles in every combination by applying the 
method of Wu. (Eq. 3): 
 (3) 
where Ɵ is the contact angle, γl is the liquid surface tension, γs is the solid surface energy, and 
the superscripts indicate their polar (γp) and dispersive components (γd). As the surface free 
energy of the film is the sum of the dispersive part and the polar part, the polarity (percent of 
hydrophilic groups formed during film formation) of the prepared films can be calculated by the 
following formula (Eq. 4): 
Polarity % = (Polar part/ Surface energy) x 100 (4) 
4.2.2.7. Thermal Analysis 
Thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC) were 
carried out by using TG/DSC1 equipment (Mettler-Toledo Inc., Switzerland). The samples were 
heated from 25 to 500°C in a non-hermetically sealed 40 µl aluminium pan. Heating was at a 
constant rate of 10°C·min-1. The mass of the samples was 10±2 mg, and the measurements were 
performed in nitrogen atmosphere at a rate of 70 ml·min-1.  
4.2.2.8. Statistical Analysis 
The gathered data were analyzed according to a factorial ANOVA method by using Tibco 




5. RESULTS AND DISCUSSION 
5.1. Determination of the Design Space  
5.1.1. Investigation of the Change in T and RH%  
The variation of the recorded values was attributed to the location of the sensor and its 
distance from the impeller rotational axis, as illustrated above (Fig. 2), and the detected local 
temperatures may be considerably higher than the general temperature recorded by the 
granulator’s own built-in sensor. The variation of T and RH% with the various experimental 
settings can be found in (Annex 3.) 
As expected, at a lower (-1) level of impeller speed, the internal chamber temperature was 
relatively low and constant throughout the wet kneading period, which is advantageous for 
processing thermolabile molecules. Under these conditions, the liquid addition rate has less 
impact on the temperature value, as demonstrated in Figure 3. 
 
Figure 3. Temperature change in the kneading phase 
 
When operating at a higher (+1) level of impeller speed (processes 3 and 4), the liquid 
addition rate exhibited more considerable influence on the temperature distribution inside the 
chamber, although it was only partially able to compensate for the temperature elevation which 
was induced by mechanical friction between the kneaded mass, impeller and chamber wall. 
Overall, the temperature change mostly depends on impeller speed and exhibited a linear relation 
with the investigated parameters (Eq. 5). 
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y∆T= 15.409+10.643x1-3.176x2-1.633x1x2 (5) 
R²= 0.99836 Adj R²= 0.99344 MS Residual= 0.828245 
In contrast, the variation of system RH did not follow the expectations since the increasing 
liquid addition rate resulted in a reduced increment of RH. This unexpected phenomenon may 
be due to the insufficient equilibration time of MC% on the solid-air interface. The highest 
increment in the system RH% values was recorded in the central point (Fig. 4). The low adj. R2 
and the high curvature coefficient of the corresponding Equation 6. indicates poor model quality, 
which may be due to a strong nonlinear relationship between the tested factors and RH%.   
 
 
Figure 4. Relative humidity change in the kneading phase 
 
yRH%=53.6158-2.3742x1-2.2925x2 (6) 
R²= 0.80017 Adj R²=0.20067 MS Residual=31.4534 Curvature=10.148 
The increasing impeller speed also decreases the general increment in the system RH%, which 
may indicate that more intensive mixing promotes the uniform distribution of moisture, which 
increases the amount of the surface adsorbed fraction. Nevertheless, at a lower impeller speed, 
RH% was comparable in the entire granulation chamber, but the increasing impeller speed 
resulted in greater RH% variation with a rapid increase in RH% values throughout the 
granulation chamber (Figs. S3 and S4 in Annex 3). This may be due to the increased evaporation 
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rate in the elevated temperature regions, which is supported by the similar distribution of 
temperature and RH% values (Figs. S2 and S4 in Annex 3). 
The results confirmed the original hypothesis that there are differences in the distribution of 
T and RH% inside the granulation chamber, which may result in the formation of hot spots, 
which represent the critically degrading microenvironment for sensitive drugs. Nevertheless, it 
should be noted that despite the similar tendencies, generally better enzyme activities were 
recorded when granulation was carried out in a glass chamber (92.67% vs. 58.98% of enzyme 
activity). This phenomenon may be explained by the different thermal conductivity of Teflon 
and glass (0.25 W/mK vs. 0.96-1.05 W/mK, respectively), which is resulted in a more uniform 
heat distribution in the glass chamber. 
5.1.2. Investigation of the Impact of Material Attributes  
Despite the considerable variation in T and RH% distribution, the detected maximum 
temperatures (Fig. 5) are good indicators of material behavior during the kneading phase. It is 
clearly visible that at low shear rates (processes 1 and 2) there is no difference in the recorded 
temperature. In contrast, at high levels of impeller speed and low levels of liquid addition, C2 
exhibited considerably lower maximum temperature compared to C1 and C3. Schaefer and 
Mathiesen reported that the increase in T in high shear granulation is mainly attributed to the 
conversion of the mechanical energy input into the heat of friction within the moist mass [150]. 
Therefore, the lower temperature elevation upon high mechanical attrition may be due to the 




Figure 5. Maximum recorded temperature under different processing conditions for the 
various compositions (C1, C2 and C3) 
 
The T excess arising in the case of C1 may be compensated by the cooling effect of an 
increased liquid addition rate as long as it is related only to the presence of CM. However, if CM 
is combined with lyso-2 in C3, the further increasing friction results in much higher T than a 
composite containing lyso-1 (C1 and C2), despite the increased liquid addition rate. In 
conclusion, in spite of the general physicochemical similarities and the similar liquid uptake 
pattern (0.6 ml/g) of the SD and C form of raw materials, the material attributes showed obvious 
differences in thermal behavior upon the applied mechanical stress, especially at higher shear 
rates. This finding is supported by Hulse et al., who reported that despite the similarity in the 
thermal behavior of CM and its different forms such as SDM, a full characterization is required 
as a preformulation step because these polymorphs are dissimilar in their physical properties 
[151]. Overall, the method of raw material production (i.e. conventional crystallization or spray-
drying) has an effect on the thermomechanical response upon exposure to higher mechanical 




Table 4. Physical properties and biological activity of C-1-pellets 










Lys1-11 95.92 15.55   ±1.67 0.93   ±0.02 1.13   ±1.13 1.14  ±1.10 
Lys1-12 92.75 13.03   ±1.10 0.51   ±0.03 1.11  ±0.08 1.13  ±0.06 
Lys1-21 88.56 13.00   ±1.17 0.62   ±0.02 1.17  ±0.10 1.18  ±0.10 
Lys1-22 111.56 11.60   ±1.24 0.44   ±0.01 1.15  ±0.10 1.16  ±0.10 
Lys1-31 90.68 14.64   ±1.54 0.59   ±0.02 1.15  ±0.07 1.16  ±0.07 
Lys1-32 76.46 12.50   ±1.55 0.41   ±0.03 1.14  ±0.07 1.15  ±0.06 
Lys1-41 96.30 14.00   ±1.05 0.63   ±0.02 1.14  ±0.09 1.14  ±0.06 
Lys1-42 85.93 13.60   ±1.41 0.40   ±0.01 1.1 5  ±0.12 1.14  ±0.07 
Lys1-C 88.99 14.04   ±1.05 0.77   ±0.02 1.13  ±0.10 1.13  ±0.05 
 
Table 5. Physical properties and biological activity of C-2-pellets 










Lys2-11 89.84 13.01   ±1.50 1.00  ±0.03 1.12  ±0.06 1.17  ±0.07 
Lys2-12 109.96 12.33   ±1.21 0.47  ±0.02 1.12  ±0.06 1.17  ±0.08 
Lys2-21 89.43 11.12   ±1.57 1.10  ±0.02 1.10  ±0.04 1.15  ±0.07 
Lys2-22 97.30 10.20   ±1.53 0.82  ±0.02 1.11  ±0.06 1.17  ±0.08 
Lys2-31 88.49 16.10   ±2.50 0.56  ±0.01 1.17  ±0.22 1.20  ±0.12 
Lys2-32 91.91 14.44   ±2.53 0.40  ±0.01 1.16  ±0.14 1.22  ±0.10 
Lys2-41 102.50 15.13   ±2.40 0.59  ±0.02 1.14  ±0.10 1.17  ±0.08 
Lys2-42 103.08 13.21   ±1.50 0.42  ±0.01 1.16  ±0.16 1.20  ±0.10 
Lys2-C 84.15 14.76   ±1.63 0.79  ±0.03 1.15  ±0.10 1.21  ±0.10 
 
Table 6. Physical properties and biological activity of C-3-pellets 










Lys3-11 79.00 15.23  ±1.64 0.93  ±0.03 1.17  ±0.13 1.18  ±0.11 
Lys3-12 76.47 13.35  ±2.02 0.55  ±0.02 1.17  ±0.10 1.16  ±0.07 
Lys3-21 84.81 15.26  ±2.10 0.94  ±0.04 1.17  ±0.13 1.17  ±0.10 
Lys3-22 74.51 13.28  ±1.58 0.65  ±0.02 1.16  ±0.10 1.17  ±0.10 
Lys3-31 87.18 15.95  ±2.61 0.67  ±0.05 1.16  ±0.08 1.24  ±0.10 
Lys3-32 77.66 14.21  ±2.26 0.59  ±0.03 1.20  ±0.16 1.28  ±0.14 
Lys3-41 92.79 12.83  ±2.18 0.97  ±0.03 1.21  ±0.14 1.22  ±0.12 
Lys3-42 79.17 11.01  ±1.32 0.72  ±0.07 1.22  ±0.11 1.20  ±0.10 
Lys3-C 66.67 13.77  ±1.48 0.83  ±0.03 1.24  ±0.20 1.23  ±0.10 
 
5.1.3. Biological Activity 
The statistically obtained equations describing the relationship between factors x1, x2 and x3, 
and enzyme activity (y1) are listed below. The statistically significant factor coefficients are 
shown in bold. The second subscript number of the optimization parameters (y) refers to the 
composition (C1, C2 or C3). The coefficients of the variables and their interactions showed the 
change in the optimization parameters when the variable value increased from 0 to +1 level. In 
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order to get a good fit by increasing the adjR2 values, some unnecessary elements were omitted 
from the equations. 
y11=92.267-0.597x1+3.314x2-4.926x3+3.749x1x2-5.550x1x3-2.786x1x2x3  (7) 
adjR2=0.9814 MSResidual=1.667  Curv. coeff.=-3.282 
y12=96.56+4.00x1+1.51x2-1.89x1x2-3.00x1x3+4.78x2x3+1.18x1x2x3 (8) 
adjR2=0.9995 MSResidual=0.0369 Curv. coeff.=-12.41 
y13=81.45-4.50x1+1.37x2+2.75x3-1.49x1x2-1.29x1x3+0.46x1x2x3 (9) 
adjR2=0.9771 MSResidual=1.3337 Curv. coeff.=-14.78 
 
The average enzyme activity was relatively high (92.267% and 96.56%) for C1 and C2 (Eqs. 
7 and 8, respectively). However, while there were no statistically significant coefficients for C1, 
for C2 the increment of both impeller speed and liquid addition rate significantly (p<0.05) 
increased the enzyme activity (Eq. 8). A further difference is that in the case of C1, the increasing 
liquid addition rate has a clearly positive effect (coefficients b2 and b12) on enzyme activity by 
compensating for the temperature excess caused by higher friction. In contrast, for C2 the 
negative value of coefficient b12 indicates the negative effect of the high dosing rate when low 
shear rates are applied. This supports the previous conclusion made by Sovány et al. that the 
over-wetting of the enzyme increases its sensitivity to thermo-mechanical stress [15, 59]. The 
higher biological activity of C2 and the considerably lower enzyme activity of C3 support the 
argument concerning the impact of critical material attributes, especially the deformability of 
particles, on the quality of the macromolecular product. Consequently, the variation in the 
properties of formulation excipients or a macromolecular drug results in different biological 
activities and different thermal behaviors in response to elevated mechanical stress, and the 
differences in factor coefficients and interactions indicate that it will also have a considerable 
impact on the design space.  
5.1.4. Mechanical Properties and Moisture Content 
All the prepared samples showed fairly good breaking force (10.20 to 16.10 N), making them 
suitable for the subsequent coating process, which requires the granules to be hard enough to 





adjR2=0.9654 MSResidual=0.0481 Curv. coeff.=0.5500 
y22=13.19+1.528x1-0.778x2-0.648x3+0.228x1x2-0.248x1x3-0.063x2x3 (11) 
adjR2=0.9999 MSResidual=0.0001 Curv. coeff.=1.568 
y23=13.89-0.390x1-0.795x2-0.928x3-0.785x1x2+0.038x1x3-0.023x2x3  (12) 
adjR2=0.999 MSResidual=0.0005 Curv. coeff.=-0.1200 
Despite the considerably high values of the coefficients, none of the factors showed statistical 
significance in the case of C1 (Eq. 10). In contrast, their effects on C2 and C3 were significant 
(Eqs. 11 and 12). Increasing the impeller speed increases the hardness of C1 and C2 while 
decreasing the breaking force of C3, which indicates that increasing friction has a negative 
influence on the bonding ability of mechanically resistant particles. The increment of both the 
liquid addition rate (x2) and extrusion speed (x3) decreases hardness in all cases, which may be 
related to the less uniform distribution of water and particle density, which considerably 
influences the internal texture of the pellets. The deformation of the pellets starts with a 
viscoelastic deformation to the increasing load. No visible change in the shape of the pellets may 
be observed during this stage. In the next phase, plastic deformation of the pellets results in 
complete crushing of the pellets (Fig. 6). In some cases, a multi-stage deformation process was 
observed (Fig. 6b), where the first peak indicates the presence of microfractures due to small 
inconsistencies or structural defects in the pellet texture without visible deformations or breakage 
of the pellets. Therefore, peak C, which is equal to the crushing strength, was considered as pellet 
hardness in all cases. 
 
Figure 6. Typical pellet deformation curves, A and B: viscoelastic stages of deformation and 
C: the final plastic deformation step 
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The results revealed that the observed differences in the stability, polymorphs or mechanical 
properties of the raw materials did not affect the water uptake pattern of the various compositions 
(0.6 ml/g). Therefore, the physical interactions upon liquid (water) addition and mixing were 
almost similar for all formulations (C1-C3) processed under the same experimental conditions 
and confirmed by the comparable moisture content of the formulations processed under the same 
conditions. In case of C1 and C2, a weaker model quality was observed, which may be related 
to the higher values of curvature coefficients of these compositions, which indicates certain 
nonlinearity of the effect of the factors. Due to the weaker fit, the resulting models should be 
evaluated with cautions. The most considerable effect was exerted by the extruder speed (x3), 
but it was found significant only for C1 (Eq. 11). The results indicate higher extrusion rates may 
repulse water from the wet mass and so decrease the final MC of the pellets.  
 
y31=0.566-0.059x1-0.044x2-0.126x3+0.051x1x2-0.036x1x2x3  (13) 
adjR2=0.8544 MSResidual=0.0045 Curv. coeff.=0.2038 
y32=0.670-0.178x1+0.063x2-0.143x3-0.050x1x2+0.060x1x3-0.033x1x2x3  (14) 
adjR2=0.8899 MSResidual=0.0072 Curv. coeff.=0.1200 
y33=0.753-0.015x1 +0.068x2-0.125x3+0.040x1x2+0.043x1x3-0.033x1x2x3  (15) 
adjR2=0.9688 MSResidual=0.0008 Curv. coeff.=0.0775 
According to the literature, Colley et al. reported that increasing the moisture content of 
pellets is accompanied by increasing their breaking force up to a certain moisture content, and 
then further moisture will reduce their breaking hardness [152]. However, the increase in the 
moisture content in a formulation containing macromolecules is problematic because it reduces 
long-term stability and adversely affects biological activity [153]. Generally, the moisture 
content of all the prepared samples was good (max. 1.1%) and could be maintained under 
appropriate packaging and storage conditions. 
5.1.5. Roundness and Aspect Ratio 
The preformulation study showed a maximum spheronization time of one minute, therefore 
it was kept constant for all the prepared samples as a result of the incorporation of higher amounts 
of polyols, which are hygroscopic and have a tendency to develop electrostatic charges, therefore 
increasing the spheronization time will lead to the sticking of the pellets [154, 155]. The 
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roundness of all the produced samples of C1 and C2 was good (˂1.2), while C3 showed slightly 
higher values (≤ 1.28). 
As known, the closer roundness is to 1, the closer the sample shape is to circular, thus 
allowing pellets to be coated effectively. According to the literature, the sphericity of pellets is 
markedly affected by the quantity of the granulating liquid and the duration of spheronization 
time [156]. The liquid addition rate had a significant effect on pellet roundness for C1 and C2 
(Eqs. 16 and 17). Interestingly, the increasing liquid addition rate increased the roundness of C1 
and C3, while decreasing the roundness of C2. This could be attributed to the different material 
characteristics, especially to the different deformation characteristics of SDM. The fact that 
impeller speed affected roundness significantly only for C2 and the significance of the curvature 
coefficient of the same composition indicate that the uniformity of liquid distribution had a 
significant impact on the sphericity of C2. Impeller speed also had a significant effect on the AR 
of C2 and C3 (Eqs. 20 and 21), it was directly proportional to AR, and the interaction of the 
tested factors was not significant.  
y41=1.143+0.010x2-0.005x3-0.010x1x2+0.005x1x3 (16) 
adjR2=0.8252 MSResidual=0.00005 Curv. coeff.=-0.013 
y42=1.135+0.023x1-0.008x2+0.005x2x3+0.003x1x2x3 (17) 
adjR2=0.9733 MSResidual=0.00002 Curv. coeff.=0.015 
y43=1.183+0.015x1 +0.005x2 +0.005x3 +0.010x1x2 +0.008x1x3 -0.005x2x3 (18) 
adjR2=0.9419 MSResidual=0.00005 Curv. coeff.=0.058 
y51=1.15+0.005x2-0.005x3-0.013x1x2+0.003x1x3+0.003x1x2x3 (19) 
adjR2=0.9072 MSResidual=0.00003 Curv. coeff.=-0.0200 
y52=1.181+0.016x1-0.009x2+0.009x3-0.004x1x2+0.004x1x3+0.004x2x3 (20) 
adjR2=0.9774 MSResidual=0.00001 Curv. coeff.=0.0275 
y53= 1.203+0.033x1-0.013x2-0.013x1x2-0.005x2x3-0.001x1x2x3 (21) 




5.1.6. Evaluation of the Changes on the Process Design Space  
It is clear from the results of the previous chapters that the different compositions showed 
considerable differences in the response to changes in process parameters, which greatly 
influenced the size and position of the process design space (DS) in the modelled knowledge 
space. The DS was determined according to the recommendations of the Appendix 2 of the ICH 
Q8 guideline, using the following acceptance criteria in case of various CQAs: enzyme activity 
>75%, pellet hardness >15 N, moisture content <1%, aspect ratio <1.2, roundness <1.2. The 
contour plots of CQAs (Fig. S5-S49, Annex 3) and the scheme of the determination of the DS 
(Fig S50, Annex 3) can be found in the supplementary material, while Figure 7. shows the 
position of DS of different compositions at different extruder speeds. 
 
 





The results showed that the enzymatic activity and the moisture content were the less limiting 
factors, and the DS was mostly determined by the overlapping portions of the acceptance areas 
of hardness and shape parameters. Since increasing the extruder speed generally reduced the 
hardness and worsened shape parameters, this resulted in a decrease in the size of the DS of all 
compositions. The results showed that DS only partially overlap in the case of different 
formulations. A liquid feed rate of 4-5 ml/min and an impeller speed of 1100-1300 rpm and an 
extruder speed of 70 rpm can be used as controls for samples C1 and C2, while for sample C3 a 
liquid feed rate of 4-5 ml/min and 750-800 rpm impeller speed can be used at an extruder speed 
of 70-95 rpm. 
 
5.2. Characterization of Chitosan Solutions/Films 
 
5.2.1. Properties of Chitosan-Based Solutions  
The pH of the obtained AA-based solutions varied in the range of 2.75 ± 0.25, and all the 
solutions were transparent and comparable with those made with CA. The addition of plasticizers 
slightly increased the pH, but the pH of G 10% solution was comparable with the plasticizer-
free reference solution. The pH values of the obtained CA 2.5%-based solutions were in a 
relatively higher pH range of 4.12-5.37, which explains why heating was necessary to dissolve 
the polymer. Nevertheless, the visual appearance of the solutions and the films with and without 
different plasticizers was comparable with that of the AA-based ones. To eliminate the problems 
of elevated pH, a series of CA-based solutions was made in the range of 2.5–7 w/v%. The pH of 
the solutions was decreased from 4.25 to 2.58 with the increment of CA concentration, which 
was comparable with the pH of AA-based solutions and enabled the dissolution of the polymer 
without heating.  
5.2.2. Physical Properties of the Prepared Films 
MFFT was less than 15 ºC for all the investigated compositions, as shown below in Table 7. 
All the films applied on the temperature bar were dried as smooth, transparent and continuous 
films, i.e. no cracking or other failures were observed, which confirms the applicability of the 
compositions for the coating/subcoating of protein-containing solid dosage forms, since the low 
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MFFT allows a flawless coating process to be performed under gentle temperature conditions 
(between 30–45 ºC), which may generally decrease the risk of the temperature-induced 
misfolding of the processed polymers. Furthermore, the low MFFT enabled the drying of the 
cast films under ambient conditions.  




















2 - - 0 <15 0.07 ± 0.02 44.63 ± 3.40 42.30 ± 3.60 01.20 ± 1.70 
2 - G 
 
5 <15 0.21 ± 0.04 2.39 ± 0.90 9.00 ± 4.62 13.83 ± 3.64 
2 - 10 <15 0.32 ± 0.10 2.91 ± 1.10 8.34 ± 1.63 11.15 ± 0.54 
2 - PG 
 
5 ˂ 15 0.33 ± 0.01 6.66 ± 0.71 19.49 ± 3.20 06.41 ± 2.34 
2 - 10 ˂ 15 0.13 ± 0.02 6.81 ± 0.72 10.37 ± 2.27 07.80 ± 1.90 
2 - PEG 400 
 
5 ˂ 15 0.21 ± 0.01 20.88 ± 1.70 13.68 ± 3.40 7.92 ± 2.71 
2 - 10 ˂ 15 0.43 ± 0.03 18.48 ± 1.70 8.69 ± 2.89 13.27 ± 3.96 
- 2.5 - 0 ˂ 15 0.13 ± 0.01 36.01 ± 3.70 47.57 ± 3.03 0.75 ± 1. 26 
- 3 - 0 ˂ 15 0.15 ± 0.10 35.65 ± 3.36 35.41 ± 2.22 0.86 ± 2.54 
- 3.5 - 0 ˂ 15 0.14 ± 0.01 48.52 ± 0.50 42.68 ± 3.10 1.14 ± 3.34 
- 4 - 0 ˂ 15 0.16 ± 0.04 32.83 ± 4.78 41.10 ± 2.93 1.99 ± 2.82 
- 5 - 0 ˂ 15 0.23 ± 0.02 39.20 ± 5.40 30.32 ± 1.84 1.05 ± 2.46 
- 7 - 0 ˂ 15 0.27 ± 0.02 8.40 ± 1.98 25.65 ± 3.90 9.15 ± 3.84 
- 2.5 
G 
5 ˂ 15 0.17 ± 0.02 1.04 ± 0.27 14.52 ± 1.28 0.86 ± 3.43 
- 2.5 10 ˂ 15 0.20 ± 0.01 1.93 ± 0.89 13.71 ± 0.46 1.14 ± 3.03 
- 2.5 
PG 
5 ˂ 15 0.21 ± 0.01 1.39 ± 0.43 13.77 ± 1.78 1.99 ± 2.50 
- 2.5 10 ˂ 15 0.22 ± 0.01 4.95 ± 0.68 9.91 ± 2.18 1.05 ± 0.92 
- 2.5 
PEG 400 
5 ˂ 15 0.26 ± 0.02 8.12 ± 3.95 8.67 ± 2.10 2.15 ± 1.56 
- 2.5 10 ˂ 15 0.34 ± 0.01 6..22 ± 1.92 7.86 ± 3.86 2.75 ± 2.01 
- 7  
G 
5 ˂ 15 0.10 ± 0.01 0.58 ± 0.64 11.07 ± 2.76 11.83 ± 4.52 
- 7 10 ˂ 15 0.14 ± 0.01 0.64 ± 0.64 13.24 ± 1.10 17.36 ± 3.67 
- 7  
PG 
5 ˂ 15 0.16 ± 0.01 1.33 ± 0.14 15.80 ± 0.84 8.33 ± 1.80 
- 7 10 ˂ 15 0.18 ± 0.01 1.27 ± 0.25 12.20 ± 1.22 10.46 ± 2.67 
- 7 
PEG 400 
5 ˂ 15 0.23 ± 0.02 2.75 ± 1.10 18.13 ± 2.57 4.55 ± 0.73 
- 7 10 ˂ 15 0.33 ± 0.02 6.22 ± 1.80 16.79 ± 1.35 3.25 ± 2.22 
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The thicknesses of the prepared films are shown in Table 7. Plasticizer-free AA-based 
chitosan films showed the least thickness (0.07 mm), in accordance with the literature [157]. The 
thickness of CA-based chitosan films was minimum the double and proved to be directly 
proportional to the CA concentration (0.13–0.27 mm), indicating a dilatation in the polymer 
backbone as a result of cross-linking by CA. A similar direct relation between lactic acid quantity 
and the thickness of the chitosan film was also reported by Bujang et al. [158].  
The addition of a plasticizer also increases film thickness up to a certain limit, in the order of 
G<PG<<PEG-400 in all cases (Table 7). The increment in film thickness upon the addition of 
the plasticizer is attributed to a good distribution of these plasticizers within the chitosan 
backbone. The significantly (p < 0.001) greater thickness obtained with PEG-400 may be due to 
the higher molecular weight and longer chain length of this plasticizer, which resulted in greater 
distance between chitosan chains and in higher water retention capacity. Generally, the film 
thickness of chitosan films may be manipulated and optimized by the amount of the plasticizer 
and the amount of chitosan itself, as also shown by Nady and Kandil [159]. The results also 
support that differences in film thickness may also contribute to the difference in the moisture 
content (MC) of the various samples as a weak positive correlation was revealed between these 
two parameters. The MC of plasticizer-free chitosan films showed no significant difference and 
ranged from approximately 1% up to 5% CA content. However, after a certain threshold, MC 
increases and may reach 9.15%, as recorded for the CA 7%-based film. This may also be 
explained by the cross-linking between CA and chitosan, which may result in the entrapment of 
water molecules within the polymer backbone. The addition of plasticizers significantly (p < 
0.0001) increased MC in all the cases because of physical interactions enabling the solvent to be 
entrapped within the polymer skeleton and also due to their hygroscopic and moisture retentive 
behavior. From this aspect, G exhibited significantly higher MC (p < 0.01) than PG or PEG, 
which may be connected to the presence of unbounded OH groups. It is also notable that MC 
showed considerable pH dependency since the CA 2.5%-based samples exhibited significantly 
lower MC (p < 0.0001) than others, which may be due to a lower degree of ionization.  
Plasticizer-free films made with CA in different quantities (2.5, 3, 3.5, 4 and 5 w/v%) showed 
a high breaking force in the range of 32.83–48.52 N, which was comparable with AA-based 
chitosan films. Nevertheless, a dramatic increase was observed in the time of elongation (Fig. 8) 
due to a viscoelastic change in the texture of the films, found to be proportional to the amount 
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of CA. However, when CA reaches 7 w/v%, a sharp reduction of hardness may be observed with 
a marked increase in elasticity. 
In conclusion, CA may be a good plasticizer for chitosan and the ideal mechanical property 
may be achieved when it is used in the 3.5–5 w/v% range. Earlier, Wan et al. [160] prepared 
CA-based hydroxy propyl-methylcellulose (HPMC) and CA-based sodium 
carboxymethylcellulose (NaCMC) films containing theophylline, and they concluded that the 
films made with 10% of CA were brittle and CA should be over 30% to obtain a good plasticizing 
effect. On the other hand, Shi et al. stated that CA used in a concentration of 5 wt% increases 
the tensile strength of polyvinyl alcohol/starch films, and above this concentration (5–30 wt%) 
the excess of CA acts as a plasticizer and hence reduces tensile strength [161]. 
In the present study CA exerts a plasticizing effect above 3 w/v% but results in a significant 
decrease of hardness only above 7 w/v%, which equals 150% and 350% CA content compared 
to the polymer, respectively, which is higher compared to the above. Nevertheless, the different 
behavior may be attributed to the weak alkaline nature of chitosan, forming stronger interactions 
and requiring much more CA than needed by HPMC, NaCMC and polyvinyl alcohol/starch. 
Independently of the original hardness, the addition of plasticizers significantly (p < 0.0001) 
decreased the hardness of all investigated films (Table 7), in the order of PEG-400<<PG<G. 
Nevertheless, despite the significant decrease in hardness, a notable viscoelastic deformation 
was observed, which resulted in an increase of the required time of elongation. A comparable 
finding for chitosan/G was obtained by Zaini et al. [162]. 
 




As regards the hardness of films made with PEG-400, it was significantly (p<0.0001) better 
compared to the other plasticizers. However, it is notable that the addition of PEG-400 affected 
hardness inversely compared to PG or G, and a further decrease in hardness was observed when 
the added quantity of PEG-400 was increased. In contrast, the increasing amount of PG and G 
resulted in a slight but not significant increase in hardness. 
Regarding mucoadhesion, the plasticizer-free AA-based chitosan films exhibited a high 
force of detachment (42.30 N) (Table 7), whereas plasticizer-free CA 2.5 w/v%-based films 
showed even higher values (47.57 N), possibly due to the lower degree of ionization, which 
enables the formation of strong ionic interactions between the unionized amino groups of 
chitosan and the sialic acid parts of mucin molecules [163, 164]. In contrast, the increment of 
CA content or the addition of a plasticizer significantly (p<0.0001) reduced mucoadhesive force 
(Fig. 9). This could be attributed to the interactions between chitosan and the plasticizers, which 
decrease the number of free functional groups, or to the covering of the pores on the film surface 
and retarding the wetting process. Compared to the other films, CA 3.5, 4 and 5 w/v%-based 
films are the most applicable depending on their tensile strength and mucoadhesion in these 
concentration ranges, as CA showed an ideal plasticizing effect as well as a good cross-linking 
effect on the chitosan molecule. 
 
Figure 9. Mucoadhesion curves of CA 2.5% (a), CA 4% (b), CA 5% (c) and CA 7%-based 
chitosan films 
The obtained SFEs of the prepared films are shown below in Table 8. The plasticizer-free 
AA-based film exhibited moderate SFE (~27 mN/m), while CA-based films showed 
significantly higher SFE around 40 mN/m without any considerable difference regarding the CA 
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content. The polarity of CA-based films was also higher than that of the AA-based ones. 
However, the increasing CA content significantly decreased polarity, which may be related to 
the pH of the solution. The addition of PEG-400 increased SFE as well as polarity, in both 5 and 
10 w/v% concentrations, which may be due to the presence of polar oxygen in the PEG 
backbone, which will be present on the film surface after the cross-linking of the chitosan chains, 
or in a manner enabling the polymer to dissolve in a relatively high amount of CA, resulting in 
ester formation and at the same time saving some polar functional groups (OH groups) on the 
surfaces when the films get dry.  
 









γtotal (mN/m) γd (mN/m) γp (mN/m) Polarity (%) 
2 - - 0 26.58 ± 2.25 14.82 ± 0.65 11.80 ± 2.15 44.40 
2 - 
G 
5 15.55 ± 1.94 9.22 ± 0.78 6.33 ± 1.80 40.71 
2 - 10 13.21 ± 1.85 8.21 ± 0.78 5.00 ± 1.70 37.85 
2 - 
PG 
5 14.95 ± 2.12 8.12 ± 0.94 7.33 ± 1.90 49.03 
2 - 10 15.75 ± 1.84 12.39 ± 0.86 3.40 ± 1.38 21.61 
2 - 
PEG 400 
5 44.71 ± 2.74 22.38 ± 0.90 22.20 ± 2.60 49.65 
2 - 10 47.30 ± 3.00 25.66 ± 1.50 22.10 ± 2.56 46.72 
- 2.5 - 0 41.50 ± 1.90 18.33 ± 0.90 23.13 ± 1.70 55.73 
- 3 - 0 44.31 ± 1.65 24.44 ± 0.70 19.87 ± 1.50 44.84 
- 3.5 - 0 37.97 ± 1.80 17.12 ± 0.68 20.90 ± 1.63 55.04 
- 4 - 0 43.34 ±  1.72 17.12 ± 0.74 20.76 ± 1.55 48.00 
- 5 - 0 42.54 ± 1.71 23.98 ± 0.86 18.31 ± 1.50 43.04 
- 7 - 0 39.40 ± 2.65 22.80 ± 2.01 16.59 ± 1.64 41.40 
- 2.5 
G 
5 29.60 ± 2.02 16.54 ± 1.33 13.05 ± 1.50 44.10 
- 2.5 10 27.23 ± 2.72 16.69 ± 2.01 10.54 ± 1.70 38.71 
- 2.5 
PG 
5 47.66 ± 1.84 29.38 ± 1.12 18.30 ± 1.50 38.40 
- 2.5 10 36.85 ± 1.80 19.15 ± 0.90 17.82 ± 1.54 48.40 
- 2.5 
PEG 400 
5 57.40 ± 1.73 35.73 ± 1.00 21.70 ± 1.42 37.80 
- 2.5 10 54.14 ± 1.60 35.16 ± 0.82 19.00 ± 1.33 35.10 
- 7 
G 
5 40.10 ± 1.85 27.58 ± 1.27 12.50 ± 1.64 31.20 
- 7 10 38.57 ± 1.52 24.98 ± 0.72 13.60 ± 1.33 35.30 
- 7 
PG 
5 37.30 ± 2.04 26.78 ± 1.58 10.25 ± 1.31 27.50 
- 7 10 36.63 ± 1.72 26.84 ± 1.15 9.80 ± 1.25 26.80 
- 7 
PEG 400 
5 65.77 ± 2.11 34.37 ± 1.55 31.40 ± 1.43 47.74 
- 7 10 68.11 ± 1.81 36.77 ± 1.23 31.35 ± 1.32 46.03 
On the other hand, films made with the addition of G and PG demonstrated a strong decrease 
in both SFE and polarity. This may be attributed to the inclusion of the polar groups of these 
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plasticizers with the carboxyl group of the acid, or involvement in hydrogen bonding with 
chitosan and hydrocarbon backbone on the surface decreases polarity, surface porosity and 
therefore reduces wettability. All of these events also participate in the reduction of the 
mucoadhesivity of these films. As wetting is the first step of the mucoadhesion process, 
Casariego et al. reported that the addition of a hydrophilic plasticizer such as glycerol and 
sorbitol reduces the wettability and adhesion coefficient of chitosan films [165]. 
 
5.2.3. Investigation of the Chemical Structure and Interactions 
The FT-IR spectrum of chitosan is shown in Figure 10, which reveals the fundamental 
absorption bands. The stretching vibrations of the OH and NH groups of chitosan are shown by 
a broad band between 3800–3400 cm−1 and 3300– 3000 cm−1, respectively. The peak around 
2870 cm−1 belongs to the symmetric stretching of the –CH3 group in the acetyl side chain, while 
that of 2715 cm−1 to the symmetric -CH2 stretching in the ring. The strong absorption band at 
1660 cm−1 belongs to the C=O stretching of the acetylated carbonamide group. The absorption 
bands around 1592 cm−1, at 1423 cm−1 and 1377 cm−1 belong to the presence of N–H, C–H and 
O–H bending vibrations, respectively. The peak at 1170 cm−1 is attributed to the asymmetric 
stretching of the (C–O–C) bridge. Chitosan was dissolved in AA 2 v/v% due to the ionization of 
the non-acetylated amide groups, as shown by the right shift of the N–H stretching and the left 
shift of the N–H bending absorption bands. The appearance of a new band at 1750 cm−1 indicates 
the esterification and hydrogen bonding of some hydroxyl groups, similarly to the right shift of 
the broad O–H stretching peak at 3600–3000 cm−1 and the left shift of the OH bending. The 
addition of plasticizers resulted in no considerable change in the texture, but some signs of weak 
hydrogen bonds were noticed in the order of G>PEG-400>PG, which may be due to the number 




Figure 10. FT-IR spectra of raw materials and AA-based films 
The FT-IR spectra of CA-based chitosan films made with varying amounts of CA (Fig. 11) 
indicate the presence of strong H-bonds between the –OH groups of the polymer and the 
carboxyl groups of the acid with a right shift of the –OH stretching peak between 3600–3300 
cm−1. The more intensive right shift of the N–H stretching signal between 3300–3000 cm−1, the 
stronger left shift of the NH bending at 1590 cm−1 and the increasing intensity of the new broad 
peak at 2000 cm−1 indicate the stronger ionization of the amino groups with increasing CA 
content. 
 
Figure 11. FT-IR spectra for 2.5, 3, 4, and 7 w/v% CA-based chitosan films 
In all the shown film spectra, the presence of the peak around 1400 cm−1 was due to 
carboxylate anion absorption (–COO¯ ), indicating citrate salt formation. According to Llanos et 
al., the peak around 1588 cm−1 is due to the protonation of amine group NH+3 and its intensity 
can be used to estimate the degree of protonation [166], while according to Lusiana et al., the 
appearance of a peak around 1580–1590 cm−1 indicates the modification of the amine groups in 
chitosan from primary amine to secondary amine upon the addition of acid [167]. However, 
according to our knowledge, the secondary amine did not show N–H absorption in this range. 
On the other hand, He et al. reported a characteristic peak around 1588 cm−1 due to the N–H 
Wavenumbers [1/cm]





























bending vibration of primary amine -NH2 [168], which opinion corresponds with our point of 
view. 
When chitosan was dissolved in CA (Figs. 12 and 13), the addition of plasticizers also 
resulted in the formation of weak H bonds, but in this case in the order of PG>G>PEG-400, 
which also confirms the differences in the texture formation and interactions of AA- and CA-
based films. However, no considerable difference was observed between CA 2.5% and CA 7% 
films in this manner, which indicates that polymer-plasticizer interactions may be related mostly 
to the bonding of -OH groups, and therefore the increasing ionization grade of chitosan does not 
considerably affect the strength of these interactions. 
 
Generally, it can be concluded that the addition of polyhydroxy alcohols such as G, PG and 
PEG-400 will result in the formation of weak H bonds with the hydroxyl groups of chitosan, and 
the white opalescent color of chitosan/PEG-400-based films was only due to physical 
interactions and may not be connected with more intensive chemical change [169]. 
 
Figure 12. FT-IR spectra of raw materials and CA 2.5%w/v-based chitosan films 
 
Figure 13. FT-IR spectra of raw materials and CA 7%w/v-based chitosan films 
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5.2.4. Thermal Stability 
The TG-DSC curves of CA (2.5%)-based chitosan films made with/without 5% G, PG and 
PEG-400 are shown in Figure 14. The CA-based films showed minimal moisture content 
compared to the others made with plasticizers which possess a hygroscopic nature. The melting 
point of CA shifted to a higher temperature (from 168 to 182.8°C), as illustrated by the 
endothermic peak (-90.1 Jg–1) because of cross-linking with the polymer. Obviously, films made 
with PG had the lowest thermal stability overall compared to those made with G and PEG-400. 
The latter showed the thermally most stable composite, which is attributed to the stability of 
PEG-400. Clearly, this composite showed the least weight loss upon heating and the highest 
decomposition temperature of 426.2°C with an enthalpy of 95 Jg–1. Generally, PEG-based films 
are the best composites as regards long-term stability. 
 
Figure 14. TG/DSC curves of 2.5 w/v% CA-based chitosan films made with/without 5w/v% 
of plasticizers 
Overall, it can be stated that CA is an ideal dissolution aid and plasticizer for chitosan-based 
films. CA-based films, without additional plasticizer, may be chosen to formulate oral 
mucoadhesive films for macromolecule delivery due to their high mucoadhesivity, while the 
values of hardness and SFE are relatively adequate to ensure good mechanical properties and 
good wetting, which enables the films to tightly adhere to the mucosal surface.  
However, if the film is utilized as the subcoating of an intestinosolvent coat, the PEG 
plasticized film seems to be best solution due to its greater hardness and higher surface free 
energy, which will enable better spreading and adhesion of the intestinosolvent coat on the 




The present study covered the investigation of the effects of material characteristics on the 
design space of the production of lysozyme-containing pellets and the development of chitosan-
based films suitable for their subsequent coating process.  
The results revealed that material attributes had considerable effects on the process design 
space. Accordingly, the investigation of the critical material attributes during the early stage of 
the development is essential both for APIs and excipients since they have a potential impact on 
the process temperature, and therefore on the biological activity of biopharmaceuticals. 
Nevertheless, despite their different deformability, both CM and SDM elicited a considerable 
conformation stabilizing property against high shear-stress and allowed only reversible 
modification in the lysozyme structure, which was confirmed by the fact that the protein regained 
its active conformation and activity after a few days. 
The specially designed granulation chamber represented a novel tool of process analytical 
technology (PAT) and quality by design (QbD). It allowed the precise monitoring of the changes 
in temperature and RH% during high shear kneading, helping to optimize process parameters for 
the requirements of macromolecular or other thermolabile drugs.  
The results also confirmed the importance of the chamber wall material, since the granulation 
chamber made from Teflon demonstrated a lower temperature upon elevated mechanical 
attritions than a glass-constructed chamber because of their different thermal conductivity. 
Therefore, this parameter should also be taken into account, since it may influence the 
temperature distribution inside the chamber. 
In the second phase of the study, CA-based chitosan solutions/films were intensively 
characterized, and their applicability as a multifunctional subcoating polymer as well as their 
suitability as oral films with respect to AA-based films as a reference were successfully done. It 
was proven that CA-based chitosan films may be successfully prepared with the direct 
dissolution of the polymer in CA solution, and the obtained films exhibited properties 
comparable to AA-based ones. Nevertheless, CA-based films offer possibility to tailor 
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mucoadhesivity of chitosan and synergistically intensification of the penetration enhancing and 
protease inhibiting effects.  
The MFFT and SFE of chitosan citrate films, which are essential for optimizing the coating 
process but had never been reported in the literature before, were also investigated. Both AA- 
and CA-based films showed MFFT less than 15°C, which ensures the required integrity of the 
coat even at low drying temperatures. The slightly higher SFE of CA-based formulations enables 
better tunability to achieve the required properties of the subcoating layer. The increasing CA 
content decreases hardness but increases elasticity, which was directly proportional to the CA 
quantity. CA 3.5-5% w/v-based chitosan solutions (without additional plasticizer) represent 
novel solutions for the coating process or for developing novel oral mucoadhesive films for 
macromolecule delivery as at these concentrations they showed an excellent cross-linking, 
plasticizing effect, MFFT, film thickness, higher force of both deformation and mucoadhesion 
and suitable moisture content, thus simplifying the formulation, and they seem to be satisfactory 
to make an acidic microenvironment sufficient to inhibit the peptidases.  
The addition of high amounts of various additional plasticizers, e.g. G, PG and PEG, 
dramatically reduces hardness, wettability and mucoadhesivity for both CA- and AA-based films 
while enhancing elasticity; therefore, these films can be utilized as coats for site-specific drug 
delivery or even for food preservation. Furthermore, high-dose plasticizers were effective in 
modifying the SFE of the films, which may be essential to optimize film properties if they are 
used for the coating/subcoating of various substrates. Moreover, the size of SFE does not seem 
to be related to wettability in the presence of G, PG and PEG for either AA- or CA-based films, 
as the variation in SFE just minimally affects mucoadhesivity, which mainly depends on the 
wetting process. Overall, CA-based chitosan films plasticized by PEG-400 represent the best 





PRACTICAL USEFULNESS  
 
The experimental work of this study has allowed the following conclusions: 
Factorial design is highly essential for the design and the investigation of critical processing 
factors and for the good understanding of the effect of material characteristics and their impacts 
on the critical product quality (CPQ). 
The extrusion/spheronization method of pelletization is a very good technique for the 
development of lysozyme-loaded pellets because of a wide range of flexibly adjustable process 
parameters. 
Various forms of mannitol (CM and SDM) are suitable enzyme stabilizers despite the 
different deformability patterns.  
The specially designed granulation chamber is a novel tool for precisely monitoring the 
temperature and RH at different locations within the chamber and for correlating the effect of 
applied mechanical attritions and generated temperature with the product properties. 
The high shear granulator is an ideal granulation method to preserve the homogeneity of the 
mixtures, thus reducing batch-to-batch variation. 
CA-based chitosan solutions/films cross-linked with different plasticizers produce 
solutions/films with properties such as mucoadhesivity and SFE. This enables the utilization of 
these solutions/films for various pharmaceutical applications in the development of oral 
mucoadhesive films, or the development of multifunctional subcoating/coating for the delivery 
of poorly absorbable drugs. 
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Review of recently used techniques and materials to improve
the efficiency of orally administered proteins/peptides
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Abstract
Objectives The main objective of present review is to explore and evaluate the effectiveness of recently developed methods to
improve the bioavailability of orally administered biopharmaceutical drugs.
Methods A systematic search of sciencedirect, tandfonline and Google Scholar databases based on various sets of keywords was
performed. All results were evaluated based on their abstracts, and irrelevant studies were neglected during further evaluation.
Results At present, biopharmaceuticals are used as injectable therapies as they are not absorbed adequately from the different
routes of drug administration, particularly the oral one. Their insufficient absorption is attributed to their high molecular weight,
degradation by proteolytic enzymes, high hydrophilicity and rigidity of the absorptive tissues. From industrial aspect incorpo-
ration of enzyme inhibitors (EIs) and permeation enhancers (PEs) and mucoadhesive polymers into conventional dosage forms
may be the easiest way of formulation of orally administered macromolecular drugs, but the effectiveness of protection and
absorption enhancement here is the most questionable. Conjugation may be problematic from regulatory aspect. Encapsulation
into lipid-based vesicles sufficiently protects the incorporated macromolecule and improves intestinal uptake but have consid-
erable stability issues. In contrast, polymeric nanocarriers may provide good stability but provides lower internalization efficacy
in comparison with the lipid-based carriers.
Conclusion It can be concluded that the combination of the advantages of mucoadhesive polymeric and lid-based carriers in
hybrid lipid/polymer nanoparticles may result in improved absorption and might represent a potential means for the oral
administration of therapeutic proteins in the near future.
Keywords Biopharmaceuticals . Enzyme inhibitors . Permeation enhancers . Mucoadhesive
Introduction
Various diseases like diabetes, malignant tumors and some
types of infections have been managed by peptides and pro-
teins. In addition, peptides and peptidomimetics can serve as
immunomodulating agents [1]. They produce their response
either by antigenic properties or by stimulating the immune
system as an agonist. Some intensively investigated peptides,
such as cyclosporine, tuftsin, muramyl dipeptide (MDP) and
thymic peptide analogues have already been used as therapeu-
tic peptides [2]. Host defense peptides (HDPs) were accepted
on a large scale as immune system stimulators and modula-
tors, their effects include wound healing and the induction of
both intra- and extracellular bactericidal effect through phago-
cytosis [3]. Consequently, biopharmaceuticals, including hor-
mones, enzymes and immunomodulators, play an important
role through the controlling of various functions, therefore
they are useful in clinical practice to treat or prevent human
disorders pathophysiological processes [4]. These days vari-
ous macromolecules are intensively examined and more than
thirty have been accepted by the Food and Drug
Administration (FDA) for commercialization [5].
The design, formulation and peroral administration of ther-
apeutically active biomolecules have represented a difficulty
as well as a target for several years, and until now only a few
biopharmaceuticals (insulin derivatives, interferon alpha,
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calcitonin, growth hormone, etc.) are known to be in clinical
development [6, 7], and even less macromolecule is commer-
cialized currently for oral administration (Table 1).
As a class, biopharmaceutical drugs, such as proteins and
peptides, have the advantages of higher potency and specific-
ity compared to small molecular drugs. These advantages are
related to their rigid and complex structure, which at the same
time represents the greatest obstacle in designing and formu-
lating an oral delivery system of these macromolecules [8].
Accordingly, in the past significant interest was focused on the
delivery of oral macromolecules in the hope of controlling
different diseases and achieving better patient compliance by
employing advanced pharmaceutical biotechnology for pro-
duction and development [9]. Recently, the formulation of
polymers with mucoadhesive properties as intestinal patches
containing safe surfactant, as an oral insulin delivery system,
has been one of the most studied techniques [10].
Biocompatible and biodegradable polymeric nanocarriers
and lipid based nanoparticles have also come forth as promis-
ing oral delivery platforms for these biopharmaceuticals, as
these systems give protection against proteases as well as con-
trol the release of proteins [11, 12]. The increasing importance
of proteins/peptides can be explained as a result of three main
developments: evolution in the analytical methods, which has
promoted the discovery of a huge number of peptides and
hormones applicable as biopharmaceuticals; good knowledge
about the role of these molecules in the regulation of human
pathophysiology; and the development of biotechnology and
genetic engineering, which enables the production of biomol-
ecules in a bulk quantities [13].
Barriers to oral absorption
Any orally administered drug will face many barriers while
passing along the gastrointestinal tract (GIT) before reaching
the targeted absorptive capillaries at the absorption site of the
sub-epithelial tissue. Themost frequently encountered barriers
are stomach acidity and the intestinal milieu, the tight junc-
tions (TJs), which prevent the paracellular way, the external
cells of the GIT and finally the subepithelial tissues [14]. The
epithelium layer of the intestinal tract is a group of consoli-
dated cells which act as a cover for the GIT and as mucosal
immunological defense against the invading pathogens and
harmful chemicals. The most common absorptive areas
throughout the intestine are the microvilli covered apical sur-
faces of enterocytes, which are negatively charged. The dis-
tance between microvilli is around 25 nm, thus they prevent
the passage of larger molecules [15]. Therefore, these cells act
as a physical-, whereas the degrading enzymes represent a
biochemical barrier. Therefore the understanding of the these
barrier mechanisms and finding the way to overcome the lim-
itations of macromolecule transportation are essential to de-
velop effective oral protein/peptide delivery systems [16, 17].
The crossing of the cell barrier is possible via various ways;
passively through diffusion, crossing the hydrophobic TJs or
transepithelial cells, transcellularly via facilitated transport
and by carrier-mediated transport (Fig. 1) [18]. Moreover,
the absorption of both some biomolecules and some drugs
may vary along the various parts of the GIT due to variation
in the pH values, surface areas, activity of proteases and per-
meability of the absorptive site. Therefore, the determination
of the proper region of the GIT for the chosen peptide/protein
will be the primary step in the design and development of an
oral dosage form with improved bioavailability [19].
Intestinal digestive environment
The greatest difficulty encountered in the case of orally ad-
ministered bioactive macromolecules is the lumen of the small
intestine, where there is high concentration of proteolytic en-
zymes secreted by the pancreas and by mucosal cells. Another
main enzymatic obstacle is the border of the epithelial cells,
which contains around fifteen degrading enzymes with high
selectivity for the breakdown of the macromolecular biomol-
ecules [20]. In addition, the colon contains various enzymes
produced by the local microflora, which should also be taken
into account [21]. Generally, the degradation of administered
biomolecules depends on numerous mechanisms adopted by
these enzymes, and the overall result is that the byproducts of
macromolecule degradation, such as short peptide chains and
amino acids, have no ability to produce the required effect
[22].
Tight junction (TJ)
As mentioned above, drugs may penetrate across the mem-
branes through the following pathways: paracellular pathway,
transcellular pathway and through transport via microfold
cells. Recently, some researchers have investigated the appli-
cability of the absorption of drug entities from the small intes-
tines via receptor-mediated, clathrin-mediated and even
caveolae-mediated endocytosis. Most drugs are transported
transcellularly, but for hydrophilic molecules (like proteins
and peptides) paracellular absorption is the main pathway.
However, this gate is tightly closed by tight junctions (TJs)
[23, 24]. TJ proteins are associated with higher paracellular
permeability, which is highly explicit throughout the small
Table 1 Macromolecules commercialized for oral administration
Trade name Drug Company
Leftose Lysozyme Wellchem
Linzess Linaclotide Allergan
Trulance Plecanatide Synergy Pharmaceuticals
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intestines [25]. TJs contain four types of unique transmem-
brane proteins: occludin, claudins, junctional adhesion mole-
cules (JAMs) and tricellulin [26]. TJs are not static protein
structures, they serve as penetration regulators of the mole-
cules across the intestinal epithelium. Some penetration en-
hancers have the ability to loosen the TJs and thus facilitate
the paracellular absorption of drug molecules [27].
Mucous barrier
The mucosa is covered by the mixture of mucins, ions and
proteins; therefore, it is a rigid layer which acts as a coat to the
intestinal lumen and is bound to the surface by a glycoprotein
structure (about 500-nm thick). The primary role of the mu-
cosal layer is the regulation of pH at the lumen surface and
thus results in the formation of an acidic microenvironment
[28]. The mucosal layer has different thickness and turnover
values regarding the anatomical position, pathophysiological
status and interaction with the external environment [29].
Generally, the mucous layer acts as a physical barrier as a
result of its negative charges and lipophilic nature, whereas
the general hydrophilicity of mucus also acts as an interactive
barrier, which retards the movement of the molecules within
and through the mucus. The dynamic behavior of the mucosal
layer is due to its continuous secretion and sloughing from the
surface of the mucosal membrane, therefore mucus represents
a rigid gel barrier to drug delivery [30].
Formulation aids and techniques
for improving bioavailability
Due to limiting factors such as large molecular weight, hydro-
philic nature, inactivation due to stomach secretions and in-
testinal proteases, first pass effect, and tendency to aggrega-
tion, the bioavailability of orally administered proteins/
peptides is usually recorded less than 1% [31]. Numerous
approaches have been taken by researchers to improve the oral
delivery of therapeutic proteins, like insulin. The most studied
strategies include the use of permeation improvers, protease
inhibitors, mucoadhesive polymers, polymeric nanoparticles,
liposomal encapsulation, modification of the structure and mi-
crosphere encapsulation [7, 24].
Permeation enhancers approach (PEs)
The use of permeation enhancers represents the most common
approach of protein delivery, their use can modulate the charac-
teristics of the absorptive epithelium and may facilitate both
transcellular or paracellular absorption. Therefore, it is an appli-
cable strategy to enhance the bioavailability of administeredmac-
romolecules [32]. These agents were first investigated twenty
years ago to enhance the absorption of pharmacologically active
molecules with poor bioavailability due to their low permeability
as well as in an attempt to develop non-injectable systems for
insulin delivery [33]. The enhancing effect through the
Fig. 1 General pathways of
absorption across the small
intestines
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paracellular pathway is due to the opening of TJs, whereas the
transcellular pathway ensues from the increased permeability of
the plasma membrane. Both pathways may be possible for one
enhancer, but the number of enhancers that increase transcellular
membrane permeability is 10 times higher than the number of
those increasing paracellular absorption [34]. Calcium chelators
act by stirring the cells through calcium depletion, which results
in loosening the attachments of the TJs. In contrast, surfactants
work through the disruption of the barrier function of the epithe-
lium [35]. The less damaging paracellular pathway by a transient
opening of TJs seems to be more rational and safer when com-
pared to the disruption of the cell membrane structure.
Nevertheless, the successful improvement of oral bioavailability
in vivo necessitates the concurrent delivery of the drug and effi-
cient concentrations of the absorption promoter to the intended
absorption site [36]. It is also notable that the effectiveness of
absorption enhancers is not the same along the GI tract due to the
variations of numerous parameters, such as membrane thickness,
morphology of the cells, proteolytic activity, lipid composition
and fundamental protein interactions [37]. Moreover, despite the
effective promotion of the oral absorption of poorly absorbable
molecules, the use of PEs should be evaluated carefully as they
can cause non-specific absorption and they must be avoided in
the case of patients suffering from irritable bowel disease, celiac
disease and inflammatory bowel disease [38]. Therefore, PEs
offer the greatest potential when incorporated in localized deliv-
ery systems, like hydrogels and intestinal patches, to avoid non-
specific absorption [39].
The general classes of PEs are demonstrated below in
Table 2.
Besides the promotion of the transport of small drug mol-
ecules, sodium salicylate and EDTA have also demonstrated
an improved oral bioavailability of insulin in dogs and rabbits
[50]. They increase the paracellular transport of drug entities
through affecting the permeability of TJs by chelating the
membrane-bound calcium ions [51].Medium chain fatty acids
(as shown in Table 1) and gel-forming polymer media for
example, octreotide may be also utilized to improve the effi-
ciency of orally administered macromolecules [33]. Chitosan
is a positively charged polymer commonly considered as an
effective and harmless penetration enhancer for therapeutic
macromolecules along the intestinal lumen via a reversible
integrity modulation of epithelial TJs in a concentration de-
pendent manner [52–54]. Phenyl piperazine at a concentration
of 0.1%w/w has also been considered as a safe and effective
transepithelial permeation enhancer amongst fifty-one studied
promoters from eleven discrete chemical categories [39].
Sodium dodecyl sulfate (SDS) has also been reported as an
effective, potent and safe absorption enhancer in oral formu-
lations, as neither the change the epithelial surface, nor toxic
luminal absorption has been reported [55]. Bile salts may
serve as effective aids in drug formulation since they may
improve absorption through both transcellular and intercellu-
lar paths. An investigation has shown the enhancement of
heparin absorption by either the chemical conjugation of hep-
arin or physical mixing with bile acids [55–57].
Enzyme inhibitors (EIs) approach
One of the key issues to achieve appropriate oral activity is to
protect the therapeutic peptides against luminal breakdown
caused by the presence of various proteases. The inhibition
of these proteolytic enzymes is achieved mainly by two mech-
anisms: local modulation of the pH away from the optimum
ranges of peptidases or binding to target enzymes and limiting
their activity [58]. In recent studies the use of numerous tryp-
sin and α-chymotrypsin inhibitors have been investigated,
such as soybean trypsin inhibitor, camostat mesylate, pancre-
atic inhibitor, amastatin, bestatin, aprotinin, boroleucine,
bestatin, and aminopeptidase inhibitors, such as puromycin,
to control the effect of these enzymes [16, 59]. The coadmin-
istration of oral insulin and EIs resulted in an improved hypo-
glycemic effect, which may be explained either by protecting
insulin from the degradation activity of proteases or enhancing
the absorption of insulin, or both at the same time [60].
Similarly, the concurrent administration of insulin microcrys-
tals with protease inhibitor resulted in improved bioavailabil-
ity also in the case of pulmonary delivery, and the absorption
Table 2 Classification of permeation enhancers [33, 40–49]
Class Example Mechanism and pathway
Surfactants polysorbates, poloxamer 407, Tween 80, labrasol,
sodium dodecyl sulphate, lauryl methyl glucamide
inhibiting the effect of P-glycoprotein andmodulating TJs,
transcellular and paracellular pathways
Chitosan derivatives Di- and tri-methyl chitosan, carboxymethyl chitosan Strong mucoadhesion, opening tight junctions, maily
paracellular pathway
Multicarboxylic acids Citric acid, ethylenediaminetetraacetic acid (EDTA) Chelating the calcium ions at the absorptive tissues
and loosening the TJs, mainly paracellular pathway
Bile acid salts Sodium cholate, glycocholate, taurocholate and
deoxycholate
Enhancing lymphatic uptake or modulating TJs, both
transcellular and paracellular pathways
Fatty acids and fatty alcohols Stearic acid, octanoic acid, palmityl alcohol
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enhancement was the highest with soybean trypsin inhibitor
among all the tested inhibitors [61]. Duck and chicken
ovomucoids (DkOVM and CkOVM) have been reported as
a unique class of protease inhibitors. Dissolution stability in-
vestigations showed that the percentage of insulin remaining
for absorption increased dramatically against the action of
proteases (trypsin and chymotrypsin) when administered with
CkOVM and DkOVM [62].
As it was mentioned above, another technique to inhibit
enzyme activity is to modify the pH at the targeted absorption
site as the activity of proteases is extremely sensitive to pH
change; intestinal proteases are active at a relatively elevated
pH, thus lowering the pH at this site may decrease the activity
of the enzymes present [63]. A pH modulator like citric acid
(CA) can be utilized to suppress lumen peptidases, and it has
been reported to be a helpful excipient for the oral delivery of
some peptides, as the proteolytic action is particularly elevated
in the upper part of the intestines [58]. Nevertheless, safety
issues should be taken into consideration for formulations that
contain any kind of protease inhibitors as these agents may
interact with dietary proteins or rupture the integrity of the
mucosal surfaceand cause upregulated enzyme secretion after
long-term treatment [64, 65]. Moreover, the use of enzyme
inhibitors may increase the amount of the intact drug at the
absorption site but will not help passing through biological
membranes. Therefore, the combination of the various ap-
proaches may be essential to have an appropriate therapeutic
effect. In a recent study, enteric-coated capsules have been
developed for oral insulin delivery, consisting of a greasy
mixture of omega-3 fatty acids, containing insulin, EI such
as aprotinin and chelating agent or bile acid salt as PE acid.
This formulation has passed Phase II-a of clinical trials and is
progressing into Phase II-b [66].
Bioadhesive polymer approach
Bioadhesion is a circumstance resulting from the attractive
forces generated between a polymer and the surface of biolog-
ical substrates, which enables the polymer to tightly stick to
the biological substrate for various periods of time, depending
on the nature of the forces participating [67]. As regards the
phenomenon of mucoadhesion, two phases can be distin-
guished: the adhesion phase between the polymer and the
mucosa, which enables the polymer to diffuse and dilate,
and the integration phase as a result of the development of
different adhesion forces (Fig. 2) [67, 68].
To date, six hypotheses have been proposed to express the
phenomena behind the two stages of mucoadhesion, which
are:
(a) The electronic theory is based on the transfer of electrons
amongst the polymer backbone and the substrate, leading
to the development of binding forces.
(b) The wetting theory proposes the higher affinity of the
surrounding liquid to substrate surface to the surrounding
liquid medium resulting in case of lower angle of
contact.
(c) The cohesive theory describes that bioadhesion phenom-
ena are basically attributed to the interactions arising be-
tween similar molecules.
(d) The adsorption theory expects the existence of molecular
attraction based on van der Waals or H-bonding between
the surfaces of the biological substrate and the polymer.
(e) The diffusion hypothesis supposes the formation of a
networked structure as a result of the polymer backbone
spreading on the mucosal surface along the adherent
interface.
(f) The mechanical hypothesis describes the adhesion devel-
oping between the substrate and the polymer as a result of
the interlinking of the polymer’s structure with the micro-
holes present on the biological surface [69].
The effectiveness of various drugs may be improved by
applying mucoadhesive delivery systems, which stay in direct
contact with the targeted mucosal surface, hence they release
the incorporated macromolecule directly to the absorptive tis-
sues, thus enhancing the delivery efficiency, and they can be
used either for local or systemic effects. Therefore,
mucoadhesive polymeric systems are attractive carriers for
protein delivery as their properties may be tuned as a result
of various changes in their network structure or swelling be-
havior as a response to various surrounding triggers, e.g. the
change of pH, electric field, temperature, light or ionic
strength [59]. In addition, they may isolate protein/peptide
from the degradation effect of the low gastric pH as well as
of proteolytic enzymes [70–72]. Moreover, they control the
release of incorporated molecules from the delivery system
and provide the concurrent release of the drug and the enzyme
inhibitor. Furthermore, they also localize the effect of enzyme
inhibitors as well as make the drug closer to the absorption site
for a sufficient time [73]. This effectiveness was confirmed in
recent studies, where mucoadhesive devices containing a mix-
ture of polymers with mucoadhesive character were devel-
oped. These enteric coated devices were entirely coated with
water impermeable backing layer except on one side, where
the device will adhere to the intestinal mucosal membrane,
making the release of incorporated macromolecules possible
in a unidirectional pattern. These devices provide protection
from luminal proteases; therefore, they prevent the loaded
drug from enzymatic degradation. Moreover, the investiga-
tions showed that the developed devices are safe and can
tolerate the shear stress of peristalsis due to strong
mucoadhesion, and were reported as an efficient alternative
to insulin injection in controlling diabetes [74, 75].
There are numerous available and commonly used
mucoadhesive polymers including chitosan, carbopol,
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cellulose derivatives and alginate. Nevertheless, the selection
of the polymer type and its molecular mass should be done
very carefully before utilizing it in the formulation, as the
release of the peptide may be retarded because of steric hin-
drance if polymers with a higher molecular weight are used
[76]. Most of the polymers which exhibit the strongest inter-
action with mucins are hydrophilic and positively charged
under the pH conditions of the GIT. Chitosan (poly [ß-(1–4)-
2-amino-2-deoxy-D-glucopyranose]), a positively charged
polymer derived by the partial deacetylation of chitin [77],
was described to form a strong matrix with mucus glycopro-
tein, enabling it to release insulin and significantly controlling
the plasma glucose levels in normal rats for 24 h [78]. In
addition, chitosan can sustain drug release, extend the duration
of drug treatment time and concurrently enhance the
mucoadhesive force of drug particles to the mucosal mem-
brane at the absorption site [79].
Chitosan and its derivatives have been utilized by many
researchers for protein/peptide delivery particularly because,
besides their mucoadhesive properties, they are recognized as
effective and safe absorption enhancers, which considerably
improves their capacity for the delivery of hydrophilic mac-
romolecules through the (nasal and peroral) mucosa [80]. The
mechanism of permeation enhancement is attributed to the
free positive charges, enabling strong adhesion with the
absorptive substrate and leading to the modulation of the TJ
proteins [81]. As it was discussed above, the interaction be-
tween the mucosal membrane (mucin) and polymers is mostly
based on non-covalent bonds, but some polymers are also able
to form covalent bonds [82]. This novel class of
mucoadhesive polymers, often called multifunctional poly-
mers, have recently replaced conventional polymers on the
market thanks to their distinctive attributes, such as consider-
ably improved mucoadhesive characteristics and similarly im-
proved permeation enhancing effects [83]. These novel poly-
mers (like poly (acrylic acid)–homocysteine, chitosan–
iminothiolane, chitosan–thioglycolic acid, poly (acrylic ac-
id)–cysteine, chitosan–thioethylamidine, alginate–cysteine,
poly (methacrylic acid)–cysteine and sodium carboxymethyl-
cellulose–cysteine) have been produced by thiomerization.
This improves their water uptake, which – along with intra-
and interchain disulfide linkages – improves viscosity,
strengthens cohesiveness and mucoadhesion, which are in
turn responsible for the prolonged residence of the polymeric
system at mucosal surfaces [84, 85]. The newly developed
preactivated polysulfonate thiomers also showed a distinct
improvement in the paracellular transport of both low and
high molecular weight hydrophilic penetration markers along
the monolayer cells of Caco-2 of newly enucleated rat gut;
therefore thiolated polymers are recommended as potential
Fig. 2 The attachment and consolidation stages of a positively charged mucoadhesive polymer
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carriers, particularly for orally administered macromolecules
[86].
Prodrug approach
Prodrugs are inactive forms of therapeutic molecules pro-
duced via the chemical modification of the original molecule,
which turns into the active form of the molecule during ad-
ministration, commonly by the effect of enzymatic reactions
or other possible reactions inside the body [7]. The primary
goals of the prodrug approach can be outlined as follows:
targeted release, ameliorating absorption or membrane perme-
ability and decreasing metabolism or side effects [87]. The
generation of prodrugs from proteins/peptides appears to be
an attractive approach concerning the improvement and opti-
mization of their delivery because all the basic objectives of
this approach may be fulfilled with the modification of the
structure of biopharmaceuticals [88]. These hydrophilic mol-
ecules require a certain increase in lipophilicity to penetrate
the epithelial cell membrane and thus to cross the cells [89].
Chemical alteration on a reactive amino acid like lysine and
cysteine or other amino acids will not only give rise to
sustained absorption and reduce the amount of drug required
to produce the therapeutic effect but will also improve stability
as well as decrease immunogenicity [90, 91], and based on the
size of the conjugated molecule renal ultrafiltration may be
decreased due to the increased molecular size of the polypep-
tide [92]. The nature of the conjugated molecule may be var-
ied in a wide range such as direct modification by the use of
acetylation, C-amidation, N-pyroglutamate conjugation,
PEGylation (PEG) or glycosylation [93], or via the sugar part
of the glycoprotein [13]. Other strategies used for prodrug
formation include d-amino acid substitution, olefenic substi-
tution, carboxyl reduction, dehydro-amino acid substitution,
retro inversion modification and thiomethylene modification
[94]. Substantial success was achieved in producing protein
prodrugs, but due to the structural complexity of proteins, this
tool was unsatisfactory when attempting to modify most pro-
teins, and successful modification also faced the problem of
overall low yield [95].
Mimetic peptides approach
Parallel peptides are peptides with abnormal arrangement of
synthesized amino acids or incorporation of different new
linking bonds between those amino acids. The inclusion of
these chemical changes provides the preservation of peptides
against peptidases, which have high specificity towards nor-
mal peptides, but the main drawback of this approach is the
change or loss of the biological activity which should be
retained as the initial one [96].
Fatty acids-conjugation (lipidation) approach
Lipidation is the chemical alteration of a hydrophilic biomol-
ecule, made by the addition of a lipophilic entity mainly via
the acylation reaction to improve both the delivery and the
pharmacological efficiency of macromolecular drugs by
influencing membrane transport, metabolic stability and bio-
availability [97]. The covalent modification of proteins can be
done with various lipophilic substances, including
isoprenoids, lipid acids and fats. Accordingly, the lipidation
process has a great role in tailoring as well as in localizing
proteins [98]. Large numbers of proteins, including many pro-
teins utilized in the therapy of human diseases, are modified
by covalently linking fatty acids and/or isoprenoid groups,
which play a basic role in regulating their structure and func-
tion. Palmitate and myristate are the two fatty acids most com-
monly linked to proteins [99]. Reversible lipidation represents
an effective way to retain the basic biological activity of the
lipidized molecule. Lately, a reversible lipidation method has
been accomplished to guarantee the re-formation of the ther-
apeutic peptide from its lipidized form subsequent to oral ab-
sorption [89].
Cell penetration peptide (CPP) conjugation approach
CPP is a peptide with a high penetration capacity across the
absorptive cell membranes, thus a conjugation of the CPP to
macromolecular drugs like proteins will improve their kinet-
ics. Furthermore, a macromolecule and CPP can be adminis-
tered as a simple mixture [100]. At present, various non-
injection routes including nasal, pulmonary and oral routes
have been developed by utilizing a conjugate of CPP with
antidiabetic peptide for controlling blood glucose level.
Most of such research reported that after a suitable CPP con-
jugation with antidiabetic peptide hypoglycemic activity
could be retained. Furthermore, they show better stability
and resistance to proteolytic degradation [101].
Protein-polymer conjugation
In comparison with lipidation, the covalent conjugation of
proteins with various polymers offers the advantage of the
wider range of the targetable side chains, which results in
altered solubility, lipophilicity, targetability, crystallinity and
taste. Consequently, pharmaceutical and biotechnological
companies are conducting numerous studies and testing new
techniques to find the ideal modification [97]. Short chains of
both chitosan and polyethylene glycol (PEG) represent the
most utilized conjugates because they overcome the issue of
low solubility and improve the formulation stability in the GIT
[102]. Lee et al. developed a conjugate of insulin and low
molecular weight chitosan (LMWC) in an attempt to enhance
the oral delivery of insulin. The conjugates were found to have
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good ability to manage the plasma glucose level for several
hours in diabetic rat models, and they are considered as a
potential future technique for improving the efficacy of orally
administered therapeutic peptides and proteins [103].
Moreover, a conjugate of insulin and low relative molecular
mass protamine as CPP has been incorporated into
mucoadhesive nanoparticles (MNPs), and the composite
showed an effective delivery of insulin following oral appli-
cation. MNPs were found to render the loaded conjugates in
direct contact with the intestinal absorptive tissues. As a result
of their high permeation, it is possible for the released conju-
gates to be absorbed without digestion, and hence higher bio-
availability of insulin in diabetic rats has been obtained [104].
Lipid-based drug delivery system (LBDDS) approach
Lipid excipients are commonly involved in a formulation to
increase the absorption of drug molecules along the intestines
by different mechanisms, including limiting intestinally medi-
ated proteolysis, increasing membrane permeability and en-
hancing intestinal lymphatic uptake [105]. Therefore an
emerging interest was observed concerning LBDDSs over
the past two decades despite the pharmaceutical difficulties
entailed by these candidates [106]. Lipid-based carrier sys-
tems as drug vehicles are composed of physiological lipids
and offer several advantages, including high biocompatibility
and controlled release based on the nature of natural lipids, no
susceptibility to erosion phenomena compared to polymeric
systems, easy and simple manufacturing by compressing or
moulding, and slow water uptake after administration, which
may offer a less damaging environment for the loaded proteins
[107]. Thus, they have most of the advantages without the
risks and regulatory concerns involved in the direct conjuga-
tion of proteins with lipids.
Liposomal encapsulation approach
Liposomes are defined as microscopic vesicles with a spheri-
cal shape, consisting of two compartments, an inner aqueous
sinus surrounded by one or multiple homocentric lipid bilay-
ers. The liposomal membrane consists of reasonably biocom-
patible, biodegradable and non-immunogenic natural and/or
synthetic lipids usually stabilized with cholesterol, which also
extends the circulating time [108, 109]. The versatile nature of
liposomes enables lipophilic drugs to be incorporated within
the lipid bilayers, while lipophobic molecules like proteins
may be solubilized inside the internal aqueous core [110].
Therefore liposomal carriers were utilized for the successful
encapsulation of various therapeutic molecules like
tropicamide, artemether, paclitaxel, acyclovir, cyclosporine,
dithranol and chloroquine diphosphate [111]. In addition, they
represent excellent carriers for the delivery of protein antigens
as theymay be functionalized to mimic pathogens, which may
induce the immune system due to their enhanced uptake by
antigen presenting cells through various mechanisms, and the
increased exposure of liposome encapsulated antigens to the
lymphocytes of the immune system [112]. In recent years,
several liposome-based vaccines have been designed to deliv-
er oral antibodies to target several diseases caused by viruses
and bacteria, such as Salmonella enteritidis and influenza-A
viral vaccines. Thus, liposomes have shown high capacities to
deliver various antigens, such as peptides/proteins and DNA
[113].
Compared to various lipid carries, liposomes have high
capacity to enclose and protect labile molecules against the
hazardous GIT environment which would result in denatur-
ation, and they may also increase absorption into enterocytes
via the stimulation of their chylomicron production, thus pro-
moting drug transport [114]. Protein drugs of interest may be
both enclosed inside the liposomes or chemically attached to
the outer surface of the vesicles. The simple enclosure of a
macromolecule can be attained by the incubation of a macro-
molecular drug alongside the vesicles at or somewhat below
the transformation temperature of the constituting lipids,
whereas triggered (active) loading of biopharmaceuticals can
be achieved by the gentle swirling of liposomes in the pres-
ence of a buffered alcoholic solution of the proteins at elevated
temperature for a specified period of time [115].
Despite their numerous advantages, liposomes pose con-
siderable issues regarding physical, chemical and biological
stability, and these issues should be investigated and evaluated
thoroughly in the course of research, during and after prepa-
ration to achieve a good background stability profile.
Similarly, the development of general guidelines for the sta-
bility testing of liposomes would also be necessary [116]. The
chemical stability of lipids against hydrolysis or in the case of
unsaturated lipid chains also against oxidation is a point of
concern, especially during the storage period. Therefore, it is
recommended to store liposomes frozen or in a lyophilized
powder form, but in this case the re-check of their size distri-
bution, drug load and morphology before use is essential
[117]. Furthermore, the development of liposomal protein de-
livery systems has to face other challenges as well, such as low
protein loading efficiency, especially when using a small ves-
icle size (range of 50~150 nm), or the instability of the encap-
sulated protein during preparation, particularly under harsh
processing conditions or when using organic solvents [118].
Overall, numerous issues such as the presence of organic sol-
vent residues, physical and chemical instabilities, sterilization
and pyrogen control (when designed as injectable), variation
in size distribution, difficulties in batch to batch reproducibil-
ity and shortened half-life due to pancreatic lipase and bile
salts should be overcome during the formulation of liposomes.
This explains why only a limited number of liposome-based
drug formulations for oral delivery may be found on the mar-
ket today [119, 120]. A further issue is that liposomes
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designed to tolerate the harsh GI environment may exhibit
decreased permeability across GIT epithelia, which constitute
the main barrier to absorption [121]. However, the rational
design approach to attain therapeutic goals might represent
the rate-determining step in the development of more ad-
vanced liposome-based oral therapeutics in the future [122].
Solid lipid nanoparticles (SLNs)
To overcome the previously discussed drawbacks of lipo-
somes, two different research groups have developed SLNs
loaded with insulin for application via the oral route [123,
124]. SLNs are nanosized lipid carriers with particle sizes of
50–1000 nm, which remain solid at ambient and body tem-
peratures. SLNs usually contain physiological lipids, for ex-
ample, glyceride mixtures and steroids. They are stabilized by
biocompatible surfactants and represent an alternative to lipo-
somes and other nanoparticles [35, 125]. These loaded SLN
formulations exhibited good efficiency to improve the gastro-
intestinal absorption of insulin, which was confirmed by the
plasma sugar level of the tested rats, which was lower than that
of the rats receiving oral insulin solution and unloaded SLNs
(control) for one day. Accordingly, loaded SLNs showed a
partial protection of insulin against luminal proteases, there-
fore they are considered as stable carriers to deliver oral insu-
lin with good results of controlling plasma glucose level [123,
124].
SLNs are increasingly used as the protective delivery sys-
tems of labile drugs as well as to control/sustain the release of
incorporated molecules due to their low toxicity and superior
physical stability compared to other lipid-based carrier sys-
tems [126]. In addition, SLNs may have excellent reproduc-
ibility even with the use of various organic solvent-free
methods. Besides their relatively easy manufacturing, SLNs
may positively affect drug uptake through various ways, such
as enhancing the extent of solubility, hindering drug precipi-
tation upon dilution, suppressing efflux transporters, increas-
ing both membrane permeability and lymphatic uptake.
Nevertheless, despite the numerous advantages, the low load-
ing efficiency, particularly for hydrophilic drugs, and the pos-
sible expulsion of drugs after polymeric transition during stor-
age still pose considerable problems to scientists [127, 128].
In spite of these drawbacks, their flexibility in preparation and
the simplicity of large-scale production may encourage the
widespread use of SLNs [129].
Further enhancement of the orally administered medicinal
proteins may be accomplished if the lipid-based nanocarriers
are conjugated with polymers. In a recent study, poly lactic-
co-glycolic acid (PLGA)–lipid lipospheres were developed,
which consisted of a PLGA lipophilic interior and a self-
assembled lipophilic layer at the interface. These lipospheres
demonstrated high crossing efficiency along the microfold
cells (an in vivomodel), resulting in the efficient improvement
of the intestinal absorption for the loaded protein molecules
over regular polymeric nanoparticles [130]. Another research
group recently developed and formulated low molecular
weight (LMW) chitosan-lipid nanoparticle composites to de-
liver siRNA into the cytoplasm. The formulation gave prom-
ising results as it takes benefit of the mucoadhesive and
permeation-enhancing properties of chitosan as well as uti-
lizes the hydrophobic reservoir capacity of the hydrophobic
core of the hybrid particles [131].
Polymeric nanoparticles approach
From the pharmaceutical aspect, both polymeric micro- and
nanoparticles are of emerging interest since they show better
stability and therefore better preservation capacity against the
degrading effect of the GI environment compared to the car-
riers of fatty origin, such as liposomes [132]. The effective-
ness of protein drugs may be improved successfully with both
micro- and nanoencapsulation [133] via protection from hy-
drolysis and proteolytic enzymes and the improvement of
their absorption, in addition to their mucoadhesive properties
and permeation enhancing characteristics [134]. However, it
was observed that while microparticles are absorbed only
through the microfold cells, nanoparticles may also utilize
the same pathway and are also able to penetrate cell mem-
branes, therefore the quantity of nanosized carriers penetrating
through the intestinal membrane is higher compared to micro-
spheres [134]. The penetration and absorption enhancement
properties may be further improved by tailoring its surface
characteristics to adjust mucoadhesion property, lymphatic
and cellular uptake and site-specif ic absorption.
Nanoparticles are derived mainly from the most common
polymers, like poly (lactic-co-glycolic acid) PLGA, poly lac-
tic acid (PLA) and poly sebacic acid (PSA). These polymers
perform their mucoadhesivity through different possible
methods of interactions, such as covalent and non-covalent
bonding or the involvement of both [135]. From this aspect,
especially chitosan and its derivatives showed high safety,
biocompatibility, biodegradability and represent multifunc-
tional polymers since besides their extremely good
mucoadhesive properties, their penetration enhancing effect
was also reported [133]. Because of this multifunctionality,
chitosan NPs are promising drug delivery carriers suitable
for a wide group of drugs, including labile drugs and macro-
molecules [136, 137]. The combination of various polymers
and the utilization of oppositely charged polyelectrolytes like
chitosan, polyacrylic acid, alginate, polyalkylamine hydro-
chloride in the formulation of layer by layer (LBL) coated
nanoparticles may also offer further improvement and show
a great impact on both macromolecular drug stability and the
oral absorbability of protein from the GIT [138]. All in all,
mucoadhesive polymer nanoparticles were successfully used
for the delivery of the extracellular products (ECPs) of Vibrio
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anguillarum to deliver oral vaccination in turbots [139], where
it was confirmed that the process of insulin uptake seemed to
be a joint process of both insulin crossing the intestinal cells
and the uptake of the insulin loaded nanoparticles by aggre-
gated lymphoid nodules. However, Yao et al. showed themain
limitations of nanoparticulate carrier systems are usually as-
sociated with limited loading efficiency and particle agglom-
eration due to thermodynamic instability [140], which was
also observed by Gao et al., who found that the efficiency of
loading was only 57.8 ± 2.54% for the turbot vaccination
[139].
Self-assembling bubbles carrier approach
Besides the previously discussed approaches, recent studies
by the research group of Chuang E-Y introduced a very inno-
vative bubble carrier system as delivery vehicle for the oral
delivery of insulin, with possible application as a technique for
the oral application of other medicinal macromolecules [141].
This self-assembling bubble carrier composed of pentetic ac-
id, carbonate, surface active agent and insulin was enclosed in
oral capsules and enterically coated to bypass gastric acidity.
Once the formulation reaches the lower part of GIT fluids, it
breaks down and releases acid and bicarbonate, which react
quickly and produce carbon dioxide, which acts as a transport-
er for the involved insulin. The obvious elevation in plasma
insulin level accompanied with a decrease in plasma glucose
level was noticed in diabetic rats. Accordingly, self-
assembling bubble carriers represent an effective and safe
method suitable to deliver other biologically activemacromol-
ecules [55].
Conclusion
The oral delivery of biopharmaceuticals is a challenging re-
search area as a result of many difficulties, for example, the
rigid physical barriers of absorptive tissues for these high mo-
lecular mass, hydrophilic drugs, and the degradation by gas-
tric juice and intestinal metabolizing enzymes, all together
acting as pharmacokinetic barriers and are responsible for
the absorption of a tiny amount of the orally administered
dose. Accordingly, the first step in the formulation requires
comprehensive knowledge about these barriers. For this rea-
son, most attempts focused on overcoming the enzymatic bar-
rier within the lumen and on improving the permeation of
macromolecules.
This review reveals the versatility of methods and involved
excipients to overcome the bioavailability problem. From in-
dustrial aspect, the combination of mucoadhesive polymers,
EIs and PEs in a conventional dosage form appears to be the
most applicable approach, as the concurrent release of these
excipients may form appropriate microenvironment to obviate
the protease barrier and achieve facilitated absorption of the
loaded macromolecules. Especially if the effect is localized on
the absorption site by the mucoadhesivity of the carrier which
increases the chance for absorption. However, the incorpora-
tion of these agents may be critical and hence careful screen-
ing is required. Nevertheless, some molecules such as phenyl
piperazine (0.1%w/w), SDS, chitosan and its derivatives were
investigated recently and regarded as potential enhancers with
reliable safety. The use of multifunctional excipients such as
CA to inhibit enzymatic activity by the careful modification of
the pH in which peptidases are more active at the targeted
absorption site as well as to facilitate paracellular absorption
by modulating the permeability of TJs due to the chelating of
membrane-bound calcium may further increase the safety of
the carrier.
PEGylation by attaching one or more PEG series was de-
veloped to increase the circulating time and hide the linked
macromolecule from the enzymatic attack, but PEGylation
and other prodrug models may conflict with the general reg-
ulatory rules and may require more intensive testing of the
produced conjugate.
The utilization of lipid-based nanocarriers (e.g. liposomes
or SLNs) for the delivery of macromolecules seems to be an
efficient technique for oral administration as it provides pro-
tection and internalization through the stimulation of intestinal
lipoprotein transporters and the possibility to encapsulate hy-
drophilic and hydrophobic molecules at the same time. On the
other hand, the difficulty to reproduce in the same manner,
physical and chemical instability during storage, low loading
capacity and degradation by pancreatic lipase represent the
main limitations and may restrict their utilization as oral mac-
romolecule carriers. From the aspect of reproducibility, SLNs
are better than liposomes. However, due to the lack of the
hydrophilic interior, they provide poor drug loading capacity
for hydrophilic macromolecules and hence, the expulsion of
hydrophilic drugs was observed during storage, which consid-
erably decreases the shelf-life of these products.
From the aspect of stability and loading capacity,
mucoadhesive polymeric micro/nanocarriers may offer better
solution compared to lipid nanocarriers, due to their more
hydrophilic structure. However, despite their protecting effect
against both luminal and mucosal secretions and enzymes
their effectiveness in enhancement of therapeutic effect may
be limited due to their lower internalization efficiency.
Nevertheless, among them, chitosan micro/nanoparticles
proved to be prospective drug delivery carriers as they offer
many advantages, including safety, biocompatibility, biode-
gradability, micro/nanosized nature and the ability to open
reversibly TJs, which may facilitate drug uptake through the
cell membrane, while their mucoadhesive property increases
the residence time at the site of absorption.
Accordingly, it can be concluded that formulation of
hybridlipid/polymeric micro/nanoparticles would be the most
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appropriate carrier systems for the oral delivery of therapeutic
macromolecules as it may provide appropriate loading capac-
ity and stability with improved internalization capacity.
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Abstract: The present work aimed to investigate the impact of the critical material attributes on
the design space of the production of lysozyme pellets with suitable biological and
physical properties for the subsequent coating process. The effect of two brands of
both lysozyme and conformation stabilizing mannitol on the behavior of the
composition in an extrusion/spheronization process was studied, while the experiments
were designed according to 2  3  factorial design. The kneading of the mass was
carried out in a high shear granulator equipped with a specially designed granulation
chamber (Opulus Ltd, Hungary) constructed with seven built-in sensors for the
measurement of temperature and relative humidity (RH). The special chamber is a
novel tool for the identification of the critical points during processing a thermolabile
drug by providing the online monitoring of critical environmental parameters and could
be used to accurately determine the effect of critical process parameters and material
attributes. The prepared samples were investigated for their biological and physical
properties. It was found that the critical material attributes have a potential effect on the
production process and product quality, and highly influence the size of the process
design space. Therefore, the screening of the formulation materials is a key factor in
macromolecular drug development.
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Abstract 15 
The present work aimed to investigate the impact of the critical material attributes on the design 16 
space of the production of lysozyme pellets with suitable biological and physical properties for the 17 
subsequent coating process. The effect of two brands of both lysozyme and conformation 18 
stabilizing mannitol on the behavior of the composition in an extrusion/spheronization process was 19 
studied, while the experiments were designed according to 23 factorial design. The kneading of the 20 
mass was carried out in a high shear granulator equipped with a specially designed granulation 21 
chamber (Opulus Ltd, Hungary) constructed with seven built-in sensors for the measurement of 22 
temperature and relative humidity (RH). The special chamber is a novel tool for the identification 23 
of the critical points during processing a thermolabile drug by providing the online monitoring of 24 
critical environmental parameters and could be used to accurately determine the effect of critical 25 
process parameters and material attributes. The prepared samples were investigated for their 26 
biological and physical properties. It was found that the critical material attributes have a potential 27 
effect on the production process and product quality, and highly influence the size of the process 28 
design space. Therefore, the screening of the formulation materials is a key factor in 29 
macromolecular drug development. 30 
 31 
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 34 
1. Introduction 35 
Flourishing in the biotechnological field has produced numerous macromolecules, such as proteins 36 
and peptides, which play a great role in managing and treating various diseases, e.g. autoimmune, 37 
neurodegenerative and cancer diseases [1]. Their oral delivery remains an attractive alternative to 38 
invasive routes because it offers cost-effectiveness as well as patient convenience and compliance 39 
[2,3]. To date, they are administered parenterally due to their low bioavailability from other 40 
alternative routes of administration, including the oral route [4]. Egg-white lysozyme occurs in 41 
many vertebrates and insects, and this diversity of the source renders it the most affordable enzyme 42 
[5]. It is harmless to human cells and effectively lyses or inhibits the growth of several pathogens 43 
responsible for food spoilage and food-borne diseases; therefore it has a substantial role as a 44 
preservative in the food industry [6]. Lysozyme is commonly known as an antimicrobial agent 45 
mainly against Gram-positive bacteria and some fungi. Bactericidal activity was due to an 46 
approved membrane disturbing effect on the peptidoglycan layers of the bacterial cell wall [7–9]. 47 
Due to presence of an outer membrane consisting of lipopolysaccharide, lysozyme is ineffective 48 
against Gram-negative bacteria, and consequently various methods are available to expand the 49 
activity, such as conjugation and combination with a permeation enhancing agent [10]. Therefore, 50 
its successful formulation in a stable oral solid dosage form may contribute to managing and 51 
controlling many diseases caused as a result of food contamination. 52 
Compared to single unit solid dosages, multiparticulate dosages, for example pellets, are acquiring 53 
definite priority for many reasons, such as anticipated gastric emptying time, reduced riskiness of 54 
dose dumping, spherical shape and hence easiness to coat, adjustable release designs, as well as 55 
even and predictable distribution through the gastrointestinal tract (GIT), resulting in enhanced 56 
drug dissolution, which leads to increased bioavailability with low inter- and intra-subject 57 
variations [11–13]. Accordingly, multiparticulates are the most suitable for the development of an 58 
orally ingested solid dosage form to deliver a macromolecular drug. 59 
The pelletization process is an agglomeration procedure that converts the homogenized powders 60 
of a drug and excipients into relatively high density, free-flowing spherical or semi-spherical units 61 
of narrow size distribution called pellets, with a dimension of 500-1500 μm [14–16]. Among the 62 
pellet production methods, the extrusion and spheronization method is used frequently and is 63 




with higher drug-loading capacity while retaining their small size, and thus the process is 65 
considered more efficient than other pelletization methods [17–19]. For pellets to be layered or 66 
coated, roundness [20] and aspect ratio [21] are the most investigated parameters to evaluate the 67 
suitability of pellets for sub-coating/coating processes as well as for estimating flowability. 68 
However, in the case of a macromolecular drug such as lysozyme, the mechanical and thermal 69 
stresses encountered during processing into an effective dosage form should be carefully evaluated 70 
[22] since these stresses might have a reverse effect on enzyme activity when the moisture content 71 
is high, especially during high shear pelletization [23]. Accordingly, the implementation of a 72 
specially instrumented chamber for the analysis of temperature and relative humidity and the 73 
design of experiment as tools of quality by design could be vital to assessing the risk factors 74 
encountered during the pelletization process and represent helpful tools for understanding the 75 
effect of different process parameters and material characteristics on the quality of the produced 76 
pellets. 77 
Similarly, polyols such as glycerol, propylene glycol, trehalose and mannitol can be used 78 
to stabilize lysozyme conformation through their exclusion from the vicinity of macromolecules, 79 
and thus the interaction with proteins is unfavourable. Among them, mannitol was found to 80 
stabilize lysozyme mainly against aggregation [24,25]. Therefore, mannitol can be used to preserve 81 
the lysozyme conformation by preventing the misfolding of the enzyme, and hence the activity 82 
during the various processing steps of pelletization might be maintained.  83 
The present study is the continuation of a previous experiment series [1,22], aimed at 84 
developing a multiparticulate system for lysozyme delivery. The aim of the present phase of the 85 
study is to investigate the impact of the material attributes on the process design space, and 86 
furthermore to clarify the impact of mechanical and thermal stress encountered during the various 87 
production steps on the enzyme activity of the prepared pellets. 88 
 89 
2. Materials and methods 90 
2.1. Materials 91 
Two brands of Egg-white lysozyme (Mw: 14.3 kDa), with different stabilities Lysoch-40000 92 
(Handary SA, Brussels, Belgium) here referred to as “Lyso-1” and a CAT. HY-B2237/CS-7671 93 
(MedChemExpress, Hungary), referred to as “Lyso-2” were used as model proteins. The scanning 94 
electron micrographs (Fig 1a, b) showed no considerable differences in the size or morphology of 95 




may be stored under ambient conditions up to 24 month, while Lyso-2 should be stored at -20 °C. 97 
According to our hypothesis, the poorer thermal stability may negatively affect enzymatic activity, 98 
but with careful design, it is still possible to produce pellets of the required quality. Conventional 99 
crystalline (Hungaropharma Ltd., Budapest, Hungary) and directly compressible spray-dried 100 
(Pearlitol SD-200, Roquette Pharma, France) mannitol (referred to as CM and SDM, respectively) 101 
served as conformation stabilizers. The CM have big columnar/tabular crystals with sharp edges, 102 
and wide particle size distribution (Fig. 1c), while SDM have spherical particles with more 103 
narrower size distribution (Fig. 1d), which may be considered as aggregates of columnar 104 
microcrystals. Further difference that while CM is pure β form, SDM is a mixture of α and β forms, 105 
which exerted smaller elasticity in compression studies. Microcrystalline cellulose (Avicel pH 101, 106 
FMC Biopolymer, Philadelphia, USA; Mw: approx.. 160 kDa) referred to as MCC, was utilized 107 
as pellet former and drug carrier, lyophilized Micrococcus lysodeikticus (Sigma-Aldrich, USA) 108 
was used as standard reagent for lysozyme activity investigation. 109 
 110 
2.2. Methods 111 
2.2.1. Design of Experiments  112 
The experimental design was made according to 23 full factorial design with one central point. The 113 
impeller speed (x1), liquid addition rate (x2) and extrusion speed (x3) were studied as independent 114 
factors, while the optimization parameters were: enzyme activity (y1), pellet hardness (y2), 115 
moisture content (y3), roundness (y4) and aspect ratio (y5). The effect of factors and factor 116 
interactions on the optimization parameters was evaluated statistically by using Statistica v. 13.5. 117 
software (Tibco Statistica Inc, Palo Alto, CA, USA).   118 
2.2.2. Homogenization  119 
100 g of powder mixtures composed of Lyso-1 or Lyso-2, CM or SDM and MCC in a ratio of 120 
1:4:5, respectively, were homogenized in a Turbula mixer (Willy A. Bachofen Maschinenfabrik, 121 
Basel, Switzerland) for 10 minutes. The composition of the homogenized powder mixtures is 122 
shown in Table 1. 123 
 124 
2.2.3. Estimation of water quantity 125 
The amount of the granulating liquid used to produce a moisturized plastic mass of a powder 126 
mixture to be ideal for extrusion/spheronization is critical, since the liquid quantity will affect the 127 
quality of the extrudate, as well as the hardness and the sphericity of the particles [26,27]. 128 




number, which is a simple measurement and equals the quantity of water absorbed by 1 g of the 130 
powder mixture (ml/g). The equipment is simple and consists of a G4 glass filter and a pipette with 131 
0.01 accuracy. 0.5 g of each homogenized powder mixture was dispersed as a monolayer over a 132 
filter paper which was placed horizontally at the bottom of the glass filter, and the maximum water 133 
uptake was determined. The experiment was performed three times. 134 
 135 
2.2.4. Wet granulation 136 
The homogenized mixtures of the powder samples were wetted and kneaded in a ProCepT 4M8 137 
high shear granulator (ProCepT nv. Zelzate, Belgium) at different impeller speeds (x1) and liquid 138 
addition rates (x2). The impeller and chopper were located vertically; the processing parameters 139 
are illustrated in Table 2 below. 60 ml of purified water was added at different rates (-1, 0 and +1 140 
level), followed by 60 s wet massing time. Wet granulation and kneading were performed in a 141 
specially designed Teflon granulation chamber (Opulus Ltd., Szeged, Hungary) equipped with 142 
three immersed PyroDiff® sensors (channel 1, 2 and 3) located at different heights from the bottom 143 
of the chamber and at different distances from the chamber wall, as demonstrated in Figure 2. They 144 
were connected directly to a computer via an interface, and four calibrated PyroButton-TH® 145 
sensors (ISO 17025) were equipped on the chamber wall at different positions (at the bottom, 146 
42mm, 65mm and 87mm from the bottom). The sensors were programmed to continuously 147 
measure the change in temperature and relative humidity (RH) in every 2 seconds during the 148 
granulation, at a temperature and humidity resolution of 0.0626 °C and 0.04% RH, respectively. 149 
In addition, the infrared temperature sensor of the high shear granulator was set to continuously 150 
measure the temperature during granulation. The kneaded wet mixtures were preserved in tightly 151 
closed containers until extrusion/spheronization. 152 
 153 
 154 
2.2.5. Extrusion and spheronization 155 
The kneaded wet masses were extruded with a single-screw extruder (Caleva Process Solutions 156 
Ltd., Sturminster Newton, UK), equipped with an axial screen of 4-mm thickness and having 16 157 
dies with a diameter of 1 mm. The extruder was equipped with a laboratory-developed water-158 
cooling jacket to maintain the temperature constant during extrusion. Extrusion was performed at 159 
different extrusion rates (x3) (70, 95 and 120 rpm) and at a constant feeding rate of 5 g/min. The 160 




The extruded samples were spheronized with a Caleva MBS spheronizer (Caleva Process 162 
Solutions Ltd., Sturminster Newton, UK). 17 g of each extruded sample was spheronized at a speed 163 
of 2000 rpm for 1 minute (according to the preformulation study). The obtained pellets were dried 164 
for 24 hours under ambient conditions (22°C±1, 31±2 % RH). 165 
 166 
2.2.6. Pellet activity investigation 167 
The biological activity (y1) of the prepared pellets was measured via the degradation of 168 
lyophilized Micrococcus lysodeikticus by using a Genesys 10 S UV-VIS Spectrometer 169 
(ThermoScientific, Waltham, MA, USA). 70 mg of lyophilized bacteria was suspended in 100 ml 170 
of phosphate buffer (pH 6.24), the base absorption at 450 nm was around 0.7. The absorption of 171 
the bacterial suspension was measured for 5 minutes before each test to reduce the error arising 172 
from bacterial sedimentation. 100 mg of pellet or 10 mg of crude lysozyme were dissolved in 25 173 
ml of phosphate buffer. 0.1 ml of pellet/or crude lysozyme solution was added to 2.5 ml of bacterial 174 
suspension and shaken for 20 seconds in a quartz cuvette, then the change in bacterial absorption 175 
was measured for 5 minutes. Pellet activity was calculated from the percentage degradation of the 176 
bacterial cells relative to crude lysozyme activity as a reference. 177 
 178 
2.2.7. Hardness and deformation 179 
Deformation force (y2) and behaviour were investigated with a custom-made texture 180 
analyzer; the equipment and its software were developed at the University of Szeged, Institute of 181 
Pharmaceutical Technology and Regulatory Affairs. The equipment consists of a sample holder at 182 
the base and a probe moving vertically at a speed of 20mm/min. The test was conducted in the 183 
force range of 0-50 Newtons. The deformation characteristics and breakage force of pellets (n=20 184 
for each sample) were obtained and the average and SD were calculated.  185 
 186 
2.2.8. Moisture content  187 
The moisture content (y3) of the prepared pellets was measured by using a Mettler-Toledo 188 
HR73 (Mettler-Toledo Hungary Ltd., Budapest, Hungary) halogen moisture analyzer. The 189 
moisture content of approximately 0.5 g of each sample was measured in triplicate at the drying 190 
temperature of 105°C until a constant weight was obtained. 191 
 192 




The size and shape (y4 and y5) of the prepared samples were investigated by using a system 194 
consisting of a stereomicroscope and a ring light with a cold light source (Carl Zeiss, Oberkochen, 195 
Germany). The images were analyzed with Leica Quantimet 500 C image analysis software (Leica 196 
Microsystems, Wetzlar, Germany), and the area, length, breadth, perimeter, convex perimeter, 197 
roundness and aspect ratio of 100 pellets were measured or calculated. The roundness and aspect 198 
ratio are the most common shape parameters used to characterize the shape of pellets and are 199 
calculated by the applied Leica Q500MC software using the following equations: 200 
 201 
Roundness = Perimeter2/(4*π*Area*1.064)       (1) 202 
 203 
Aspect ratio = dmax/dmin         (2) 204 
 205 
where Perimeter is the total length of boundary of the feature, Area is calculated from the total 206 
number of detected pixels within the feature, while dmax and dmin are the longest and shortest 207 
Feret diameter measured. 208 
 209 
2.2.10. Scanning Electron Microscopy 210 
The morphology and size of the raw materials were investigated by Scanning Electron Microscope 211 
(SEM) (Hitachi 4700, Hitachi Ltd., Tokyo, Japan). The samples were coated with a conductive 212 
gold thin layer by a sputter coating unit (Polaron E5100, VG Microtech, UK), images were taken 213 
at an accelerating voltage of 10.0 kV, the used air pressure was 1.3– 13 mPa during the analyses. 214 
The particle size was determined using Image J 1.47 t (National Institute of Health, Bethesda, MD, 215 
USA) software. 216 
 217 
3. Results and Discussion 218 
3.1. Investigation of the change in temperature and RH% during the kneading phase 219 
In our previous studies [1,22] an unexpected effect of the applied kneading parameters was 220 
observed on the enzyme activity of the prepared pellets. One of the key objectives of the present 221 
study was to clarify the reason for this effect via the use of a special kneading chamber, which 222 
enabled the determination of the variations of temperature and relative humidity at representative 223 
points of the chamber. In order to reveal if the chamber wall (Teflon) has any effect on the 224 
behaviour of the materials, we repeated the previous experiments obtained in a glass chamber with 225 




The variation of the recorded values was attributed to the sensor location and its distance 227 
from the impeller rotation axis, as illustrated above (Fig. 2), and the detected local temperatures 228 
may be considerably higher than the general temperature recorded by the granulator’s own built-229 
in sensor [23]. The variation of temperature and humidity with the various experimental settings 230 
can be found in the supplementary material.  231 
As expected, at a lower (-1) level of impeller speed, the internal chamber temperature was 232 
relatively low and constant throughout the wet kneading period, which is advantageous for 233 
processing thermolabile molecules. Under these conditions, the liquid addition rate has less impact 234 
on the temperature value, as demonstrated in Figure 3, where the difference between the starting 235 
and final temperatures is displayed throughout the various experimental settings. 236 
 237 
When operating at a higher (+1) level of impeller speed (process 3 and 4), the liquid 238 
addition rate exhibited more considerable influence on the temperature distribution inside the 239 
chamber, although it was only partially able to compensate for the temperature increase which was 240 
induced by mechanical friction between the kneaded mass, impeller, and chamber wall. Overall, 241 
the temperature change mostly depends on impeller speed, and it exhibited a linear relation with 242 
the investigated parameters (Eq. 3). 243 
 244 
yΔT= 15.409+10.643x1-3.176x2-1.633x1x2       (3) 245 
R²= 0.99836 Adj R²= 0.99344 MS Residual= 0.828245 246 
 247 
In contrast, the variation of system relative humidity did not follow the expectations since 248 
the increasing liquid addition rate resulted in a reduced increment of relative humidity. This 249 
unexpected phenomenon may be due to the insufficient equilibration time of the moisture content 250 
on the solid-air interface. The highest increment in the system RH% values was recorded in the 251 
central point (Fig. 4). The low adj. R2 and high curvature coefficient of the corresponding Equation 252 
4. indicates poor model quality, which may be due to a strong nonlinear relationships between the 253 






yRH%=53.6158-2.3742x1-2.2925x2        (4) 257 
R²= 0.80017 Adj R²=0.20067 MS Residual=31.4534 Curvature=10.148 258 
 259 
The increasing impeller speed also decreases the general increment in the system RH%, 260 
which may indicate that more intensive mixing promotes the uniform distribution of moisture, 261 
which increases the amount of the surface adsorbed fraction. Nevertheless, at a lower impeller 262 
speed, RH% was comparable in the whole granulation chamber, but increasing impeller speed 263 
resulted in greater RH% variation with a rapid increase in RH% values throughout the granulation 264 
chamber (Figs S3 and S4 in the supplementary material). This may be due to the increased 265 
evaporation rate in the regions with elevated temperature, which is supported by the similar 266 
distribution of temperature and RH% values (Figs S1 and S3 in the supplementary material). 267 
The results confirmed our original hypothesis that there are differences in the distribution 268 
of temperature and relative humidity inside the granulation chamber, which may result in the 269 
formation of hot spots, which represent the critically degrading microenvironment for sensitive 270 
drugs. Nevertheless, it should be noted that despite the similar tendencies, generally better enzyme 271 
activities (See chapter 3.2) were recorded than previously in the glass chamber (92.67% vs. 272 
58.98% (5) of enzyme activity). This phenomenon may be explained by the different thermal 273 
conductivity of Teflon and glass (0.25 W/mK vs. 0.96-1.05 W/mK), which will result in less 274 
localized thermal elevation and therefore the formation of bigger hot spots in the glass chamber. 275 
 276 
3.2. Investigation of the impact of material attributes on pellet quality 277 
Despite the considerable variation in temperature and humidity distribution, the detected 278 
maximum temperatures (Fig. 5) are good indicators of material behavior during the kneading 279 
phase. 280 
 281 
It is clearly visible that at low shear rates (process 1 and 2) there is no difference in the 282 
recorded temperature. In contrast, at high levels of impeller speed and low levels of liquid addition, 283 
C2 exhibited considerably lower maximum temperature compared to C1 and C3. Schaefer and 284 
Mathiesen and Kristó et al. reported that the increase in temperature in high shear granulation is 285 




moist mass [23,28]. Therefore, the lower temperature elevation upon high mechanical attrition 287 
may be due to the better deformation properties of SDM over CM. 288 
The temperature excess arising in the case of C1 may be compensated for by the cooling 289 
effect of an increased liquid addition rate while it is related only to the presence of CM. However, 290 
if CM is combined with lyso-2 in C3, the further increasing friction results in a much higher 291 
temperature than a composite containing SD lyso-1 (C1 and C2), despite the increased liquid 292 
addition rate. In conclusion, in spite of the general physicochemical similarities and similar liquid 293 
uptake pattern (0.6 ml/g) of the SD and C form of raw materials, the material attributes showed 294 
obvious differences in thermal behavior upon the applied mechanical stress, especially at higher 295 
shear rates. This finding is supported by Hulse et al., who reported that despite the similarity in the 296 
thermal behavior of CM and its different forms such as SDM, a full characterization is required as 297 
a preformulation step because these polymorphs are dissimilar in their physical properties [29]. 298 
Overall, the method of raw material production (i.e. conventional crystallization, or spray drying) 299 
has an effect on the thermomechanical response upon exposure to higher mechanical stress and 300 
may considerably influence the critical quality attributes of the final product (Tables 3-5).  301 
 302 
3.2.1. Biological activity 303 
For a macromolecular drug (such as lysozyme) to be formulated into multiparticulates, 304 
biological activity is the most important criterion that should be retained for the finished product, 305 
particularly when manufacturing processes operate at high shear rates, usually accompanied with 306 
an elevation of temperature and high attrition. Accordingly, biological activity might be 307 
diminished as a result of protein folding or denaturation.  308 
The statistically obtained equations describing the relationship between factors x1, x2 and 309 
x3, and the optimization parameter (y1) are listed below. The statistically significant factor 310 
coefficients are shown in bold. The second subscript number of the optimization parameters (y) 311 
refers to the composition (C1, C2 or C3). The coefficients of the factors (variables) and their 312 
interactions show the changes in the optimization parameters when the value of the variable 313 
increased from 0 to +1 level. In order to get a good fit by increasing the adjR
2 values, some 314 
unnecessary elements have been omitted from the equations. 315 
y11=92.267-0.597x1+3.314x2-4.926x3+3.749x1x2-5.550x1x3-2.786x1x2x3    (5) 316 
adjR




y12=96.56+4.00x1+1.51x2-1.89x1x2-3.00x1x3+4.78x2x3+1.18x1x2x3    (6) 318 
adjR
2=0.9995 MSResidual=0.0369 Curv. coeff.=-12.41 319 
y13=81.45-4.50x1+1.37x2+2.75x3-1.49x1x2-1.29x1x3+0.46x1x2x3    (7) 320 
adjR
2=0.9771 MSResidual=1.3337 Curv. coeff.=-14.78 321 
 322 
The average enzyme activity was relatively high (92.267% and 96.56 %) for C1 and C2 323 
(Eqs. 5 and 6, respectively). However, while there were no statistically significant coefficients for 324 
C1, for C2 the increment of both impeller speed and liquid addition rate significantly (p<0.05) 325 
increased the enzyme activity (Eq. 6). A further difference is that in the case of C1 the increasing 326 
liquid addition rate clearly has a positive effect (coefficients b1 and b12) on enzyme activity by the 327 
compensation of the temperature excess caused by higher friction. In contrast, for C2 the negative 328 
value of coefficient b12 indicates the negative effect of a high dosing rate when ow shear rates are 329 
applied. This supports our previous conclusion [1,22,23] that the over-wetting of the enzyme 330 
increases its sensitivity to thermomechanical stress. The higher biological activity of C2 and the 331 
considerably lower enzyme activity of C3 support our argument concerning the impact of the 332 
critical material attributes, especially the deformability of particles, on the quality of the 333 
macromolecular product. Consequently, the variation in the properties of formulation excipients 334 
or a macromolecular drug results in different biological activities and different thermal behaviors 335 
in response to the elevated mechanical stress, and the differences in factor coefficients and 336 
interactions indicate that it will exert considerable impact on the design space too.  337 
 338 
3.2.2 Mechanical properties and moisture content 339 
All the prepared pellet samples showed fairly good breaking force (10.20 to 16.10 340 
Newtons), making them to be qualified for the subsequent coating process, which requires the 341 
granules to be hard enough to withstand the mechanical attrition encountered during the coating 342 




y21=13.49+0.195x1-0.440x2-0.808x3+0.555x1x2+0.173x1x3+0.358x2x3   (8) 347 
adjR




y22=13.19+1.528x1-0.778x2-0.648x3+0.228x1x2-0.248x1x3-0.063x2x3   (9) 349 
adjR
2=0.9999 MSResidual=0.0001 Curv. coeff.=1.568 350 
y23=13.89-0.390x1-0.795x2-0.928x3-0.785x1x2+0.038x1x3-0.023x2x3    (10) 351 
adjR
2=0.999 MSResidual=0.0005 Curv. coeff.=-0.1200 352 
 353 
Despite the considerably high values of the coefficients, none of the factors showed 354 
statistical significance in the case of C1 (Eq. 8). In contrast, their effects on C2 and C3 were clearly 355 
significant (Eqs. 9 and 10). Increasing the impeller speed increases the hardness of C1 and C2 356 
while decreasing the breaking force of C3, which indicates that increasing friction has a negative 357 
influence on the bonding ability of mechanically resistant particles. An increase in both liquid 358 
addition rate (x2) and extrusion speed (x3) decreases hardness in all cases, which may be related to 359 
the less uniform distribution of water and particle density, which considerably influences the 360 
internal texture of the pellets. The deformation of the pellets starts with a viscoelastic deformation 361 
to the increasing load. No visible change in the shape of the pellets may be observed during this 362 
stage. In the next phase, plastic deformation of the pellets results in complete crushing of the pellets 363 
(Fig. 6). In some cases, a multi-stage deformation process was observed (Fig. 6b), where the first 364 
peak indicates the presence of microfractures due to small inconsistencies or structural defects in 365 
the pellet texture without visible deformations or breakage of the pellets. Therefore, peak C, which 366 
is equal to the crushing strength, was considered as pellet hardness in all cases.  367 
The results revealed that the observed differences in the stability, polymorphs or 368 
mechanical properties of the raw materials did not affect the water uptake pattern of the various 369 
compositions (0.6 ml/g). Therefore, the physical interactions upon liquid (water) addition and 370 
mixing were almost similar for all formulations (C1-C3) processed under the same experimental 371 
conditions and confirmed by the comparable moisture content of the formulations processed under 372 
the same conditions. In case of C1 and C2, a weaker model quality was observed, which may be 373 
related to the higher values of curvature coefficients of these compositions, which indicates certain 374 
nonlinearity of the effect of the factors. Due to the weaker fit, the resulting models should be 375 
evaluated with cautions. The most considerable effect was exerted by the extruder speed (x3), but 376 
it was found significant only for C1 (Eq. 11). The results indicate higher extrusion rates may 377 
repulse water from the wet mass and so decrease the final MC of the pellets.  378 
 379 





2=0.8544 MSResidual=0.0045 Curv. coeff.=0.2038 381 
y32=0.670-0.178x1+0.063x2-0.143x3-0.050x1x2+0.060x1x3-0.033x1x2x3    (12) 382 
adjR
2=0.8899 MSResidual=0.0072 Curv. coeff.=0.1200 383 
y33=0.753-0.015x1 +0.068x2-0.125x3+0.040x1x2+0.043x1x3-0.033x1x2x3    (13) 384 
adjR
2=0.9688 MSResidual=0.0008 Curv. coeff.=0.0775 385 
 386 
According to the literature, Colley et al.  reported that increasing the moisture content of 387 
pellets is accompanied by increasing their breaking force up to a certain moisture content, and then 388 
further moisture will reduce their breaking hardness [30]. However, the increase in the moisture 389 
content in a formulation which contains macromolecules is problematic because it reduces the 390 
long-term stability and adversely affects biological activity [31]. Generally, the moisture content 391 
of all the prepared samples was good (max.1.1%) and could be maintained by appropriate 392 
packaging and storage conditions.  393 
 394 
3.2.3. Roundness and aspect ratio 395 
The preformulation study showed that the maximum spheronization time was one minute, 396 
therefore it was kept constant for all the prepared samples as a result of the incorporation of a 397 
higher amount of polyols, which are hygroscopic and have a tendency to develop electrostatic 398 
charges, thus increasing the spheronization time will lead to the sticking of the pellets [32,33]. 399 
The roundness of all the produced samples of C1 and C2 was good (˂1.2), while C3 showed 400 
slightly higher values (≤ 1.28). As known, the closer roundness is to 1, the closer the sample shape 401 
is to circular, thereby allowing the pellets to be coated effectively. According to the literature, the 402 
sphericity of the pellets is markedly affected by the quantity of the granulating liquid and the 403 
duration of spheronization time [34]. The liquid addition rate had a significant effect on pellet 404 
roundness for C1 and C2 (Eqs. 14 and 15), but significance should be evaluated with caution in 405 
case of C1, due to the poorer model quality. Interestingly, the increasing liquid addition rate 406 
increased the roundness of C1 and C3 while decreasing the roundness of C2. This could be 407 
attributed to the different material characteristics, especially to the different deformation 408 
characteristics of SDM. The fact that the impeller speed affected roundness significantly only for 409 
C2 and the significance of the curvature coefficient of the same composition indicate that the 410 




also had a significant effect on the AR of C2 and C3 (Eqs. 18 and 19), it was directly proportional 412 
to AR and the interaction of the tested factors was not significant.  413 
 414 
y41=1.143+0.010x2-0.005x3-0.010x1x2+0.005x1x3      (14) 415 
adjR
2=0.8252 MSResidual=0.00005 Curv. coeff.=-0.013 416 
y42=1.135+0.023x1-0.008x2+0.005x2x3+0.003x1x2x3      (15) 417 
adjR
2=0.9733 MSResidual=0.00002 Curv. coeff.=0.015 418 
y43=1.183+0.015x1 +0.005x2 +0.005x3 +0.010x1x2 +0.008x1x3 -0.005x2x3   (16) 419 
adjR
2=0.9419 MSResidual=0.00005 Curv. coeff.=0.058 420 
 421 
y51=1.15+0.005x2-0.005x3-0.013x1x2+0.003x1x3+0.003x1x2x3    (17) 422 
adjR
2=0.9072 MSResidual=0.00003 Curv. coeff.=-0.0200 423 
y52=1.181+0.016x1-0.009x2+0.009x3-0.004x1x2+0.004x1x3+0.004x2x3   (18) 424 
adjR
2=0.9774 MSResidual=0.00001 Curv. coeff.=0.0275 425 
y53= 1.203+0.033x1-0.013x2-0.013x1x2-0.005x2x3-0.001x1x2x3    (19) 426 
adjR
2=0.9376 MSResidual=0.0001 Curv. coeff.=0.0275 427 
 428 
3.3. Evaluation of the changes on the Process Design Space  429 
It is clear from the results of the previous chapter (3.2) that the different compositions showed 430 
considerable differences in the response to changes in process parameters, which greatly 431 
influenced the size and position of the process design space (DS) in the modeled knowledge space. 432 
The DS was determined according to the recommendations of the Appendix 2 of the ICH Q8 433 
guideline, using the following acceptance criteria in case of various CQAs: enzyme activity >75%, 434 
pellet hardness >15 N, moisture content <1%, aspect ratio <1.2, roundness <1.2. The contour plots 435 
of CQAs (Fig. S5-S49) and the scheme of the determination of the DS (Fig S50) can be found in 436 
the supplementary material, while Figure 7. shows the position of DS of different compositions at 437 





The results showed that the enzymatic activity and the moisture content were the less limiting 440 
factors, and the DS were mostly determined by the overlapping portions of the acceptance areas 441 
of hardness and shape parameters. Since increasing of the extruder speed generally reduced the 442 
hardness and worsened shape parameters, this resulted in a decrease in the size of the DS of all 443 
compositions. The results showed that DS only partially overlap in case of the different 444 
formulations. A liquid feed rate of 4-5 ml / min and an impeller speed of 1100-1300 rpm and an 445 
extruder speed of 70 rpm can be used as controls for samples C1 and C2, while for sample C3 a 446 
liquid feed rate of 4-5 ml / min and 750-800 rpm minutes impeller speed can be used at an extruder 447 
speed of 70-95 rpm. 448 
 449 
4. Conclusion 450 
The specially designed granulation chamber equipped with seven sensors was a useful tool 451 
to precisely monitor the changes in the temperature and RH% during the course of high shear 452 
kneading. Therefore, the chamber could be used effectively to produce proteins/peptides and other 453 
thermolabile drugs, and to correlate the processing conditions with the product quality of these 454 
drugs. The continuous monitoring of the changes in temperature and RH% enables the precise 455 
determination of the critical points of differently set processes and hence could be used as a novel 456 
tool for both process analytical technology (PAT) and QbD. 457 
This has a particular importance in case of strongly thermolabile drugs such as lysozyme. 458 
Nevertheless, despite the predominant concept according to which most technologist researchers 459 
think that the effect of mechanical attrition and elevated temperature on the processed 460 
macromolecules will end in an inactive product as a result of protein folding or deterioration, 461 
present work confirmed that lysozyme could be processed under high-shear conditions. 462 
Furthermore, we were able to prove our hypothesis that with careful design, enzyme activity can 463 
be maintained as desired even when working with less stable forms of enzyme, such as lyso-2. 464 
It could also be concluded that the investigation of the critical material attributes is essential 465 
not only for APIs but also for excipients during the development stage of macromolecular drugs, 466 
since they have a major impact on the process temperature, and therefore on biological activity, 467 
and other product properties, which became clearer when the mechanical energy input increased. 468 
Consequently, the evaluation of the omitted design space is crucial from the aspect of the properties 469 
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Table 1. Composition of prepared powder mixtures 
Excipients C1 (g) C2 (g) C3 (g) 
Lyso-1 10  10 - 
Lyso-2 - - 10 
CM 40  - 40 
SDM - 40 - 
MCC 50  50 50 
 
Table 2. Processing parameters of kneading, extrusion and spheronization 




500 (-1) 500 (-1) 1500 (+1) 1500 (+1) 1000 (0) 
Liquid addition rate 
(ml/min) (x2) 
5 (-1) 10 (+1) 5 (-1) 10 (+1) 7.5 (0) 
Purified H2O (ml) 60 60 60 60 60 
Chopper speed 
(rpm) 
500 500 500 500 500 
Extr./spheron.      
Extrusion speed (x3) 70 (-1) 120 
(+1) 
70 (-1) 120 
(+1) 
70 (-1) 120 
(+1) 
70 (-1) 120 
(+1) 
95 (0) 
Spher. speed (rpm) 2000 2000 2000 2000 2000 2000 2000 2000 2000 
Spher. time (min) 1 1 1 1 1 1 1 1 1 
Spher. amount (g) 17 17 17 17 17 17 17 17 17 
Sample code LysC*-11 LysC-12 LysC-21 LysC-22 LysC-31 LysC-32 LysC-41 LysC-42 LysC-c 
*C: referring to the composition; 1, 2 and 3 for the first (C1), second (C2) and third (C3) composition, 
respectively 
 
Table 3. Physical properties and biological activity of C-1-pellets 
Sample Activity% (y11) Hardness (N) 
(y21) 




Lys1-11 95.92 15.55   ±1.67 0.93   ±0.02 1.13   ±1.13 1.14  ±1.10 
Lys1-12 92.75 13.03   ±1.10 0.51   ±0.03 1.11  ±0.08 1.13  ±0.06 
Lys1-21 88.56 13.00   ±1.17 0.62   ±0.02 1.17  ±0.10 1.18  ±0.10 
Lys1-22 111.56 11.60   ±1.24 0.44   ±0.01 1.15  ±0.10 1.16  ±0.10 
Lys1-31 90.68 14.64   ±1.54 0.59   ±0.02 1.15  ±0.07 1.16  ±0.07 
Lys1-32 76.46 12.50   ±1.55 0.41   ±0.03 1.14  ±0.07 1.15  ±0.06 
Lys1-41 96.30 14.00   ±1.05 0.63   ±0.02 1.14  ±0.09 1.14  ±0.06 
Lys1-42 85.93 13.60   ±1.41 0.40   ±0.01 1.1 5±0.12 1.14  ±0.07 
Lys1-C 88.99 14.04   ±1.05 0.77   ±0.02 1.13  ±0.10 1.13  ±0.05 
 
 
Table 4. Physical properties and biological activity of C-2 -pellets 
Sample Activity% (y12) Hardness (N) 
(y22) 




Lys2-11 89.84 13.01   ±1.50 1.00  ±0.03 1.12  ±0.06 1.17  ±0.07 
Lys2-12 109.96 12.33   ±1.21 0.47  ±0.02 1.12  ±0.06 1.17  ±0.08 
Lys2-21 89.43 11.12   ±1.57 1.10  ±0.02 1.10  ±0.04 1.15  ±0.07 
Lys2-22 97.30 10.20   ±1.53 0.82  ±0.02 1.11  ±0.06 1.17  ±0.08 
Lys2-31 88.49 16.10   ±2.50 0.56  ±0.01 1.17  ±0.22 1.20  ±0.12 
Lys2-32 91.91 14.44   ±2.53 0.40  ±0.01 1.16  ±0.14 1.22  ±0.10 
Lys2-41 102.50 15.13   ±2.40 0.59  ±0.02 1.14  ±0.10 1.17  ±0.08 
Lys2-42 103.08 13.21   ±1.50 0.42  ±0.01 1.16  ±0.16 1.20  ±0.10 
Lys2-C 84.15 14.76   ±1.63 0.79  ±0.03 1.15  ±0.10 1.21  ±0.10 
 
Table Click here to access/download;Table;Tables.docx
Table 5. Physical properties and biological activity of C-3-pellets 










Lys3-11 79.00 15.23  ±1.64 0.93  ±0.03 1.17  ±0.13 1.18  ±0.11 
Lys3-12 76.47 13.35  ±2.02 0.55  ±0.02 1.17  ±0.10 1.16  ±0.07 
Lys3-21 84.81 15.26  ±2.10 0.94  ±0.04 1.17  ±0.13 1.17  ±0.10 
Lys3-22 74.51 13.28  ±1.58 0.65  ±0.02 1.16  ±0.10 1.17  ±0.10 
Lys3-31 87.18 15.95  ±2.61 0.67  ±0.05 1.16  ±0.08 1.24  ±0.10 
Lys3-32 77.66 14.21  ±2.26 0.59  ±0.03 1.20  ±0.16 1.28  ±0.14 
Lys3-41 92.79 12.83  ±2.18 0.97  ±0.03 1.21  ±0.14 1.22  ±0.12 
Lys3-42 79.17 11.01  ±1.32 0.72  ±0.07 1.22  ±0.11 1.20  ±0.10 
Lys3-C 66.67 13.77  ±1.48 0.83  ±0.03 1.24  ±0.20 1.23  ±0.10 
 
 
Declaration of interests 
 
☒ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☐The authors declare the following financial interests/personal relationships which may be considered 








Yousif H-E.Y. Ibrahim: Investigation, Formal analysis, Writing - original draft; Patience 
Wobuoma: Investigation; Katalin Kristó: Formal analysis, Writing – Review and Editing; 
Ferenc Lajkó: Software, Resources; Gábor Klivényi: Software, Resources, Béla Jancsik: 
Software, Resources, Géza Regdon jr.: Writing – Review and Editing, Klára Pintye-Hódi: 
Conceptualization, Writing – Review and Editing; Tamás Sovány: Conceptualization, 



















ANNEX - 3 
  
Table S1. Recorded temperatures and their differences in the kneading chamber 


























500 5 24.15 24.27 24.11 29.59 31.36 29.9 5.44 7.09 5.79 
500 10 27.49 27.16 27.2 29.98 31.13 29.8 2.49 3.97 2.6 
1500 5 23.67 23.58 23.57 53.18 56.09 53.52 29.51 32.51 29.95 
1500 10 24.38 24.62 24.54 43.72 47.61 45.33 19.34 22.99 20.79 
1000 7.5 25.63 25.42 25.24 40.48 43.32 41.16 14.85 17.9 15.92 
  
Table S2. Recorded relative humidities and their differences in the kneading chamber 
























500 5 33.93 33.51 34.36 88.23 103.84 92.99 54.3 70.33 58.63 
500 10 38.78 40.9 40.2 86.56 97.62 87.89 47.78 56.72 47.69 
1500 5 43.13 44.1 42.58 90.8 100.2 91.49 47.67 56.1 48.91 
1500 10 40.02 41.54 43.08 87.11 103.46 89.33 47.09 61.92 46.25 
1000 7.5 30.74 32.34 32.25 89.68 101.86 95.08 58.94 69.52 62.83 
 








T max. (°C) 
C 1. 
T max. (°C) 
C 2. 
T max. (°C) 
C 3. 
First  process 500 500 5 32.80 32.73 33.94 
Second process  500 500 10 31.40 31.40 31.75 
Third process 500 1500 5 55.30 49.63 56.13 
Fourth process 500 1500 10 43.50 42.80 48.00 
Fifth process 500 1000 7.5 35.85 35.12 45.50 
C1, C2 and C2 referred to the first, second and third composition respectively 
  
 
Fig. S1 schematic diagram of temperature versus time for C1- first process  
 
 
























Bottom 42mm 65mm 87mm channel 1 channel2 channel3 ProCepT
start of kneading 





















bottom 42mm 65mm 87mm ch1 ch2 ch3 ProCepT
 
Fig. S3 schematic diagram of relative humidity% versus time for C1- first process 
 

























































bottom 42mm 65mm 87mm ch1 ch2 ch3
 
Fig. S5 Contour plot of enzyme activity of C1 at an extruder speed of 70 rpm 
 
Fig. S6 Contour plot of enzyme activity of C1 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=35,83502
DV: Enzyme activity (%)  > 113 
 < 113 
 < 112 
 < 111 
 < 110 
 < 109 
 < 108 
 < 107 
 < 106 
 < 105 
 < 104 
 < 103 
 < 102 
 < 101 
 < 100 
 < 99 
 < 98 
 < 97 
 < 96 
 < 95 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 





























Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=35,83502
DV: Enzyme activity (%)
 > 102 
 < 102 
 < 101 
 < 100 
 < 99 
 < 98 
 < 97 
 < 96 
 < 95 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 
 < 89 
 < 88 
 < 87 
 < 86 
 < 85 
 < 84 
 < 83 
 < 82 
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Fig. S7 Contour plot of enzyme activity of C1 at an extruder speed of 120 rpm 
 
Fig. S8 Contour plot of pellet hardness of C1 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=35,83502
DV: Enzyme activity (%)  > 95 
 < 95 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 
 < 89 
 < 88 
 < 87 
 < 86 
 < 85 
 < 84 
 < 83 
 < 82 
 < 81 
 < 80 
 < 79 
 < 78 
 < 77 
 < 76 
 < 75 
 < 74 
 < 73 
 < 72 





























Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=,1584694
DV: Hardness (N)
 > 16,25 
 < 16,25 
 < 16 
 < 15,75 
 < 15,5 
 < 15,25 
 < 15 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 






























Fig. S9 Contour plot of pellet hardness of C1 at an extruder speed of 95 rpm 
 
Fig. S10 Contour plot of pellet hardness of C1 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=,1584694
DV: Hardness (N)  > 14,8 
 < 14,8 
 < 14,7 
 < 14,6 
 < 14,5 
 < 14,4 
 < 14,3 
 < 14,2 
 < 14,1 
 < 14 
 < 13,9 
 < 13,8 
 < 13,7 
 < 13,6 
 < 13,5 
 < 13,4 
 < 13,3 
 < 13,2 
 < 13,1 
 < 13 
 < 12,9 
 < 12,8 
 < 12,7 
 < 12,6 
 < 12,5 





























Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=,1584694
DV: Hardness (N)  > 14 
 < 14 
 < 13,9 
 < 13,8 
 < 13,7 
 < 13,6 
 < 13,5 
 < 13,4 
 < 13,3 
 < 13,2 
 < 13,1 
 < 13 
 < 12,9 
 < 12,8 
 < 12,7 
 < 12,6 
 < 12,5 
 < 12,4 
 < 12,3 
 < 12,2 
 < 12,1 
 < 12 
 < 11,9 
 < 11,8 
 < 11,7 






























Fig. S11 Contour plot of moisture content of C1 at an extruder speed of 70 rpm 
 
Fig. S12 Contour plot of moisture content of C1 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,0237069
DV: Moisture content (%)
 > 0,975 
 < 0,975 
 < 0,95 
 < 0,925 
 < 0,9 
 < 0,875 
 < 0,85 
 < 0,825 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 
 < 0,625 





























Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,0237069
DV: Moisture content (%)
 > 0,8 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 
 < 0,625 
 < 0,6 
 < 0,575 
 < 0,55 
 < 0,525 
 < 0,5 






























Fig. S13 Contour plot of moisture content of C1 at an extruder speed of 120 rpm 
 
Fig. S14 Contour plot of roundness of C1 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,0237069
DV: Moisture content (%)
 > 0,6 
 < 0,6 
 < 0,575 
 < 0,55 
 < 0,525 
 < 0,5 
 < 0,475 
 < 0,45 
 < 0,425 
 < 0,4 
 < 0,375 





























Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,0000944
DV: Roundness
 > 1,175 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 






























Fig. S15 Contour plot of roundness of C1 at an extruder speed of 95 rpm 
 
Fig. S16 Contour plot of roundness of C1 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,0000944
DV: Roundness  > 1,1675 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 
 < 1,12 
 < 1,1175 
 < 1,115 
 < 1,1125 
 < 1,11 





























Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,0000944
DV: Roundness  > 1,16 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 
 < 1,12 
 < 1,1175 
 < 1,115 
 < 1,1125 
 < 1,11 
 < 1,1075 
 < 1,105 
 < 1,1025 






























Fig. S17 Contour plot of aspect ratio of C1 at an extruder speed of 120 rpm 
 
Fig. S18 Contour plot of aspect ratio of C1 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0002028
DV: Aspect ratio
 > 1,185 
 < 1,185 
 < 1,1825 
 < 1,18 
 < 1,1775 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 





























Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0002028
DV: Aspect ratio
 > 1,1775 
 < 1,1775 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 






























Fig. S19 Contour plot of aspect ratio of C1 at an extruder speed of 120 rpm 
 
Fig. S20 Contour plot of the enzyme activity of C2 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0002028
DV: Aspect ratio
 > 1,17 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 
 < 1,12 
 < 1,1175 
 < 1,115 





























Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=74,05413
DV: Enzyme activity (%)  > 111 
 < 111 
 < 110 
 < 109 
 < 108 
 < 107 
 < 106 
 < 105 
 < 104 
 < 103 
 < 102 
 < 101 
 < 100 
 < 99 
 < 98 
 < 97 
 < 96 
 < 95 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 
 < 89 
 < 88 






























Fig. S21 Contour plot of the enzyme activity of C2 at an extruder speed of 95 rpm 
 
Fig. S22 Contour plot of the enzyme activity of C2 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=74,05413
DV: Enzyme activity (%)
 > 101 
 < 101 
 < 100 
 < 99 
 < 98 
 < 97 
 < 96 
 < 95 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 
 < 89 
 < 88 
 < 87 
 < 86 





























Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=74,05413
DV: Enzyme activity (%)  > 105 
 < 105 
 < 104 
 < 103 
 < 102 
 < 101 
 < 100 
 < 99 
 < 98 
 < 97 
 < 96 
 < 95 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 
 < 89 
 < 88 
 < 87 
 < 86 
 < 85 
 < 84 
 < 83 
 < 82 






























Fig. S23 Contour plot of the pellet hardness of C2 at an extruder speed of 70 rpm 
 
Fig. S24 Contour plot of the pellet hardness of C2 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=1,09205
DV: Hardness (N)  > 16,75 
 < 16,75 
 < 16,5 
 < 16,25 
 < 16 
 < 15,75 
 < 15,5 
 < 15,25 
 < 15 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 
 < 12,25 
 < 12 
 < 11,75 
 < 11,5 
 < 11,25 
 < 11 





























Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=1,09205
DV: Hardness (N)
 > 15,75 
 < 15,75 
 < 15,5 
 < 15,25 
 < 15 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 
 < 12,25 
 < 12 
 < 11,75 
 < 11,5 
 < 11,25 
 < 11 
 < 10,75 
 < 10,5 
 < 10,25 






























Fig. S25 Contour plot of the pellet hardness of C2 at an extruder speed of 120 rpm 
 
Fig. S26 Contour plot of the moisture content of C2 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=1,09205
DV: Hardness (N)
 > 15 
 < 15 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 
 < 12,25 
 < 12 
 < 11,75 
 < 11,5 
 < 11,25 
 < 11 
 < 10,75 
 < 10,5 
 < 10,25 
 < 10 
 < 9,75 





























Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,010625
DV: Moisture content (%)  > 1,225 
 < 1,225 
 < 1,2 
 < 1,175 
 < 1,15 
 < 1,125 
 < 1,1 
 < 1,075 
 < 1,05 
 < 1,025 
 < 1 
 < 0,975 
 < 0,95 
 < 0,925 
 < 0,9 
 < 0,875 
 < 0,85 
 < 0,825 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 






























Fig. S27 Contour plot of the moisture content of C2 at an extruder speed of 95 rpm 
 
Fig. S28 Contour plot of the moisture content of C2 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,010625
DV: Moisture content (%)  > 1,05 
 < 1,05 
 < 1,025 
 < 1 
 < 0,975 
 < 0,95 
 < 0,925 
 < 0,9 
 < 0,875 
 < 0,85 
 < 0,825 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 
 < 0,625 
 < 0,6 
 < 0,575 
 < 0,55 
 < 0,525 
 < 0,5 
 < 0,475 





























Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,010625
DV: Moisture content (%)
 > 0,875 
 < 0,875 
 < 0,85 
 < 0,825 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 
 < 0,625 
 < 0,6 
 < 0,575 
 < 0,55 
 < 0,525 
 < 0,5 
 < 0,475 
 < 0,45 
 < 0,425 
 < 0,4 
 < 0,375 






























Fig. S29 Contour plot of the roundness of C2 at an extruder speed of 70 rpm 
 
Fig. S30 Contour plot of the roundness of C2 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,000125
DV: Roundness  > 1,1775 
 < 1,1775 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 
 < 1,12 





























Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,000125
DV: Roundness  > 1,1725 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 
 < 1,12 
 < 1,1175 
 < 1,115 






























Fig. S31 Contour plot of the roundness of C2 at an extruder speed of 120 rpm 
 
Fig. S32 Contour plot of the aspect ratio of C2 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,000125
DV: Roundness  > 1,1675 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 
 < 1,1525 
 < 1,15 
 < 1,1475 
 < 1,145 
 < 1,1425 
 < 1,14 
 < 1,1375 
 < 1,135 
 < 1,1325 
 < 1,13 
 < 1,1275 
 < 1,125 
 < 1,1225 
 < 1,12 
 < 1,1175 
 < 1,115 
 < 1,1125 
 < 1,11 





























Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0003736
DV: Aspect ratio  > 1,2125 
 < 1,2125 
 < 1,21 
 < 1,2075 
 < 1,205 
 < 1,2025 
 < 1,2 
 < 1,1975 
 < 1,195 
 < 1,1925 
 < 1,19 
 < 1,1875 
 < 1,185 
 < 1,1825 
 < 1,18 
 < 1,1775 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 
 < 1,16 
 < 1,1575 
 < 1,155 






























Fig. S33 Contour plot of the aspect ratio of C2 at an extruder speed of 95 rpm 
 
Fig. S34 Contour plot of the aspect ratio of C2 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0003736
DV: Aspect ratio  > 1,22 
 < 1,22 
 < 1,2175 
 < 1,215 
 < 1,2125 
 < 1,21 
 < 1,2075 
 < 1,205 
 < 1,2025 
 < 1,2 
 < 1,1975 
 < 1,195 
 < 1,1925 
 < 1,19 
 < 1,1875 
 < 1,185 
 < 1,1825 
 < 1,18 
 < 1,1775 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 
 < 1,165 
 < 1,1625 





























Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0003736
DV: Aspect ratio  > 1,23 
 < 1,23 
 < 1,2275 
 < 1,225 
 < 1,2225 
 < 1,22 
 < 1,2175 
 < 1,215 
 < 1,2125 
 < 1,21 
 < 1,2075 
 < 1,205 
 < 1,2025 
 < 1,2 
 < 1,1975 
 < 1,195 
 < 1,1925 
 < 1,19 
 < 1,1875 
 < 1,185 
 < 1,1825 
 < 1,18 
 < 1,1775 
 < 1,175 
 < 1,1725 






























Fig. S35 Contour plot of the enzyme activity of C3 at an extruder speed of 70 rpm 
 
Fig. S36 Contour plot of the enzyme activity of C3 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=97,90415
DV: Enzyme activity (%)
 > 84 
 < 84 
 < 83 
 < 82 
 < 81 
 < 80 
 < 79 
 < 78 
 < 77 
 < 76 
 < 75 
 < 74 
 < 73 





























Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=97,90415
DV: Enzyme activity (%)
 > 89 
 < 89 
 < 88 
 < 87 
 < 86 
 < 85 
 < 84 
 < 83 
 < 82 
 < 81 
 < 80 
 < 79 
 < 78 
 < 77 
 < 76 
 < 75 
 < 74 






























Fig. S37 Contour plot of the enzyme activity of C3 at an extruder speed of 120 rpm 
 
Fig. S38 Contour plot of the hardness of C3 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Enzyme activity (%)
2**(3-0) design; MS Residual=97,90415
DV: Enzyme activity (%)
 > 94 
 < 94 
 < 93 
 < 92 
 < 91 
 < 90 
 < 89 
 < 88 
 < 87 
 < 86 
 < 85 
 < 84 
 < 83 
 < 82 
 < 81 
 < 80 
 < 79 
 < 78 
 < 77 
 < 76 





























Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=,006425
DV: Hardness (N)
 > 16,5 
 < 16,5 
 < 16,25 
 < 16 
 < 15,75 
 < 15,5 
 < 15,25 
 < 15 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 
 < 12,25 
 < 12 






























Fig. S39 Contour plot of the hardness of C3 at an extruder speed of 95 rpm 
 
Fig. S40 Contour plot of the hardness of C3 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=,006425
DV: Hardness (N)
 > 15,75 
 < 15,75 
 < 15,5 
 < 15,25 
 < 15 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 
 < 12,25 
 < 12 
 < 11,75 
 < 11,5 
 < 11,25 
 < 11 





























Fitted Surface; Variable: Hardness (N)
2**(3-0) design; MS Residual=,006425
DV: Hardness (N)
 > 14,75 
 < 14,75 
 < 14,5 
 < 14,25 
 < 14 
 < 13,75 
 < 13,5 
 < 13,25 
 < 13 
 < 12,75 
 < 12,5 
 < 12,25 
 < 12 
 < 11,75 
 < 11,5 
 < 11,25 
 < 11 
 < 10,75 
 < 10,5 
 < 10,25 






























Fig. S41 Contour plot of the moisture content of C3 at an extruder speed of 70 rpm 
 
Fig. S42 Contour plot of the moisture content of C3 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,0068944
DV: Moisture content (%)
 > 0,975 
 < 0,975 
 < 0,95 
 < 0,925 
 < 0,9 
 < 0,875 
 < 0,85 
 < 0,825 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 





























Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,0068944
DV: Moisture content (%)  > 0,9 
 < 0,9 
 < 0,89 
 < 0,88 
 < 0,87 
 < 0,86 
 < 0,85 
 < 0,84 
 < 0,83 
 < 0,82 
 < 0,81 
 < 0,8 
 < 0,79 
 < 0,78 
 < 0,77 
 < 0,76 
 < 0,75 
 < 0,74 
 < 0,73 
 < 0,72 
 < 0,71 
 < 0,7 
 < 0,69 
 < 0,68 
 < 0,67 






























Fig. S43 Contour plot of the moisture content of C3 at an extruder speed of 120 rpm 
 
Fig. S44 Contour plot of the roundness of C3 at an extruder speed of 70 rpm 
Fitted Surface; Variable: Moisture content (%)
2**(3-0) design; MS Residual=,0068944
DV: Moisture content (%)
 > 0,8 
 < 0,8 
 < 0,775 
 < 0,75 
 < 0,725 
 < 0,7 
 < 0,675 
 < 0,65 
 < 0,625 
 < 0,6 
 < 0,575 
 < 0,55 
 < 0,525 





























Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,0014944
DV: Roundness  > 1,225 
 < 1,225 
 < 1,2225 
 < 1,22 
 < 1,2175 
 < 1,215 
 < 1,2125 
 < 1,21 
 < 1,2075 
 < 1,205 
 < 1,2025 
 < 1,2 
 < 1,1975 
 < 1,195 
 < 1,1925 
 < 1,19 
 < 1,1875 
 < 1,185 
 < 1,1825 
 < 1,18 
 < 1,1775 
 < 1,175 
 < 1,1725 
 < 1,17 
 < 1,1675 






























Fig. S45 Contour plot of the roundness of C3 at an extruder speed of 95 rpm 
 
Fig. S46 Contour plot of the roundness of C3 at an extruder speed of 120 rpm 
Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,0014944
DV: Roundness  > 1,2325 
 < 1,2325 
 < 1,23 
 < 1,2275 
 < 1,225 
 < 1,2225 
 < 1,22 
 < 1,2175 
 < 1,215 
 < 1,2125 
 < 1,21 
 < 1,2075 
 < 1,205 
 < 1,2025 
 < 1,2 
 < 1,1975 
 < 1,195 
 < 1,1925 
 < 1,19 
 < 1,1875 
 < 1,185 
 < 1,1825 
 < 1,18 
 < 1,1775 
 < 1,175 





























Fitted Surface; Variable: Roundness
2**(3-0) design; MS Residual=,0014944
DV: Roundness  > 1,24 
 < 1,24 
 < 1,2375 
 < 1,235 
 < 1,2325 
 < 1,23 
 < 1,2275 
 < 1,225 
 < 1,2225 
 < 1,22 
 < 1,2175 
 < 1,215 
 < 1,2125 
 < 1,21 
 < 1,2075 
 < 1,205 
 < 1,2025 
 < 1,2 
 < 1,1975 
 < 1,195 
 < 1,1925 
 < 1,19 
 < 1,1875 
 < 1,185 
 < 1,1825 






























Fig. S47 Contour plot of the aspect ratio of C3 at an extruder speed of 70 rpm 
 
Fig. S48 Contour plot of the roundness of C3 at an extruder speed of 95 rpm 
Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0007361
DV: Aspect ratio
 > 1,27 
 < 1,27 
 < 1,26 
 < 1,25 
 < 1,24 
 < 1,23 
 < 1,22 
 < 1,21 
 < 1,2 
 < 1,19 
 < 1,18 
 < 1,17 





























Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0007361
DV: Aspect ratio
 > 1,28 
 < 1,28 
 < 1,27 
 < 1,26 
 < 1,25 
 < 1,24 
 < 1,23 
 < 1,22 
 < 1,21 
 < 1,2 
 < 1,19 
 < 1,18 
 < 1,17 






























Fig. S49 Contour plot of the roundness of C3 at an extruder speed of 120 rpm 
 
Fitted Surface; Variable: Aspect ratio
2**(3-0) design; MS Residual=,0007361
DV: Aspect ratio
 > 1,29 
 < 1,29 
 < 1,28 
 < 1,27 
 < 1,26 
 < 1,25 
 < 1,24 
 < 1,23 
 < 1,22 
 < 1,21 
 < 1,2 
 < 1,19 
 < 1,18 
 < 1,17 
 < 1,16 






























Fig. S50 Scheme of the determination of DS as an example of C3 95 rpm extruder speed 
The areas fit to the acceptance criteria of various CQAs were merged into one graph, and the 
overlapping area (black), where all CQA fits to requirements was selected as nonlinear 
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A B S T R A C T
The oral delivery of biopharmaceuticals requires the including of absorption enhancer, protease inhibitor and a
suitable carrier system. The aim of the present work was to formulate and characterize chitosan solutions/films
incorporating citric acid (CA) as potential excipient in comparison to the well-known acetic acid (AA)-based
films as a reference. Films were made by the solvent casting method with/without glycerol (G), propylene glycol
(PG) and polyethylene glycol (PEG-400) as plasticizers. The minimum film forming temperature (MFFT) of the
prepared solutions, film thickness, hardness/deformation, mucoadhesivity, moisture content, FT-IR spectra and
surface free energy (SFE) were investigated. Chitosan has been reported as a safe and effective paracellular
absorption enhancer for hydrophilic macromolecules, therefore there would be more rationale for incorporating
CA as a solubility enhancer, a permeation enhancer and an enzyme inhibitor. CA shows good cross-linking, an
ideal plasticizing property and increases both tensile strength and mucoadhesivity, thus its incorporation sim-
plifies the formulation while improving effectiveness. We concluded that CA (3.5, 4 and 5 w/v %)-based chitosan
solution could be used as a novel coating/subcoating polymer for oral macromolecule delivery, or as oral mu-
coadhesive films.
1. Introduction
Generally, numerous bioactive proteins and peptides are going
through the clinical trials or have already been approved by the Food
and Drug Administration (FDA) for marketing (Batista et al., 2018).
This attracts and encourages researchers to develop less costly, re-
producible and more applicable oral delivery systems because currently
biopharmaceuticals are restricted as injectable dosages for therapy
since they cannot be delivered orally (Goldberg and Gomez-
Orellana, 2003). Therefore, the commercial success of protein/peptide
drugs remains limited as their successful delivery requires the accom-
plishment of three key tasks: protection from degradation in the gas-
trointestinal tract (GIT), permeation through the intestinal barriers and
the absorption of molecules into the systemic circulation (Brown, 2005,
Choonara et al., 2014). The bioavailability of these molecules is de-
pendent on their molecular mass since bioavailability sharply decreases
if the molecular mass increases above 500-700 Da. (Muheem et al.,
2016). Therefore, the development of oral macromolecular drugs
requires a thorough understanding of the physicochemical properties of
drugs, such as molecular weight, hydrophilicity, ionization constants
and pH stability as well as knowledge about the barriers that act as
obstacles for absorption, like enzymatic degradation, membrane efflux
and pH variability (Mahato et al., 2003). Recently, Sovány et al. (2016)
investigated the possibility of the successful formulation of pellets
containing lysozyme using the quality by design approach (QbD) and
process analytical technology (PAT). They succeeded in recognizing
and specifying the design space for the pelletization process while
preserving the lysozyme activity . This study opens the field for the
production of solid dosage forms containing biopharmaceuticals.
However, it is still necessary to introduce helpful formulation excipients
that protect the labile drug against enzymatic activity and at the same
time enhance and control release through the GIT.
Chitosan is a linear polysaccharide composed of randomly dis-
tributed ß (1, 4) - linked D-glucosamine and N-acetyl-D-glucosamine
units, where the amount of D-glucosamine is greater than 50%. It is
mainly obtained by the partial deacetylation of chitin (Shah et al.,
https://doi.org/10.1016/j.ejps.2020.105270
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2018; Li et al., 2017; Liu and Li, 2018), which makes a natural and
sustainable pharmaceutical excipient. The most known source for
chitosan is the exoskeleton of marine organisms like squids and crus-
tacean shells, and in recent years it has been derived from insects and
fungi as well (Perinelli et al., 2018). This versatility of the sources to-
gether with its unique properties, e.g. biocompatibility, biodegrad-
ability, non-toxicity and low immunogenicity, makes chitosan the
second most abundant natural polymer in the world (Cao et al., 2018,
Rotta et al., 2009). Chitosan is a weak base, which is soluble in an
aqueous acidic media and produces highly viscous solutions suitable for
the preparation of free films and coatings (Rahmouni et al., 2018).
Chitosan exhibits excellent mucoadhesive properties due to presence of
reactive hydroxyl and amino groups providing excessive hydrogen
bonding as well as a positive charge, resulting in a unique linear
polycation with a high charge density (Agarwal et al., 2018). It was
found that the ionic bonds between the sialic acid residues of the mu-
cosa and the amino groups of chitosan play an important role in the
mucoadhesion process (Phanindra et al., 2013). Bioadhesion is the
adhesion of a natural, semi-synthetic or synthetic substance to a bio-
logical surface, whilst mucoadhesion is the adherence of a substance to
mucus or an epithelial surface (Rajaram and Laxman, 2016). Mu-
coadhesive drug delivery may include gastrointestinal, oral cavity,
nasal, ocular, vaginal and rectal drug delivery systems (Rajput et al.,
2010).
Moreover, chitosan, when protonated below pH 6.5, is able to in-
crease the paracellular permeability of macromolecules across the
mucosal epithelium by opening the tight junctions (TJs) and allowing
the penetration of macromolecular compounds like peptide drugs
(Hombach and Bernkop-Schnürch, 2009, Thanou et al., 2001). The
reversible TJs opening has been approved as a safe approach for per-
meation enhancement, therefore chitosan is regarded as a safe and ef-
ficient absorption enhancer for therapeutic macromolecules
(Sonaje et al., 2011, Fan et al., 2016). Furthermore, the use of chitosan
as a drug delivery system may enable the controlled release of the in-
corporated macromolecule, permeation enhancer and protease in-
hibitor at the absorption site and thus may prolong the drug action, and
due to its mucoadhesivity it can form a special microenvironment at the
mucosal membrane (Jiang et al., 2017).
During matrix preparation chitosan is usually dissolved in diluted
organic acids, usually in acetic acid (AA). However, its replacement
with citric acid (CA) would be advantageous, since it was reported that
CA can be used effectively to suppress the luminal serine proteases, and
recently it has been used to deliver some oral peptides. The rationale
behind this strategy is that incorporating a pH modifier can result in an
acidic microenvironment, which decreases protease activity
(Aguirre et al., 2016). Moreover, CA has been described to increase the
absorption of peptides by different mechanisms, such as permeation
enhancement by calcium chelation and protease inhibition
(Devendra et al., 2013; Welling et al., 2014). Recently, the absorption
enhancing effect of chitosan-citrate was confirmed by administering
chitosan-citrate gel vaginally to deliver poorly absorbable drugs such as
acyclovir, ciprofloxacin and high molecular weight hydrophilic mole-
cules such as FD4 (Bonferoni et al., 2008). The multicarboxylic struc-
ture of CA is responsible for its use as a compatibilizer, cross-linker and
plasticizer (Garcia et al., 2011). Citrate cross-linked chitosan films were
examined by Shu et al. (Shu, 2001). The swelling ratio of the chitosan/
citrate film and the drug release profile using brilliant blue and ribo-
flavin as model drugs were studied, and it was concluded the citrate/
chitosan film was valuable in drug delivery like targeted drug con-
trolled release in the stomach (Shu, 2001). Nevertheless, this study
achieved cross-linking of chitosan by the dipping of ready films into
sodium-citrate solution and not by direct dissolution of chitosan in ci-
tric acid solution.
In conclusion, it could be a logical approach when macromolecules
(like peptides/proteins) are suitably incorporated in a multifunctional
mucoadhesive polymer (e.g. chitosan/citrate), which will enhance
bioavailability by the different ways discussed above, and by the con-
trol of the release of the incorporated drug through forming a gel-ma-
trix, which is essential for macromolecules that have a short circulating
time due to the initiation of the immune response.
The main objective of this work was to formulate and characterize
chitosan/citrate films with the direct dissolution of chitosan in citric
acid solution and evaluate their applicability as functional mucoadhe-
sive subcoating of a controlled release multiparticulate drug delivery
system in comparison to chitosan/acetate films as a reference. As sec-
ondary objective the applicability of films as mucoadhesive oral carrier
film (MOF) is also tested as MOF is one of the most hopeful approaches
to deliver macromolecules sticking to the oral mucosa, providing rapid
absorption, bypassing the hepatic first-pass effect and offering ease of
handling (Rajaram and Laxman, 2016). As tertiary objective, the effect
of a high-amount plasticizers on the properties of chitosan solu-
tionsfilms was also studied. The obtained solutions were physically
characterized for minimum film forming temperature (MFFT) a crucial
property of coating formulations, while the prepared films were char-
acterized for their thickness, hardness/deformation behaviour, mu-
coadhesivity, moisture content and surface free energy (SFE).
2. Materials and Methods
2.1. Materials
Chitosan 80/1000 (Heppe Medical Chitosan GmbH., Germany)
(MW = 300000–350000 Da) was used as a film-forming polymer,
acetic acid 99.8% (Sigma-Aldrich, Germany) and citric acid mono-
hydrate (CA) (Molar Chemicals Ltd., Hungary) were used as solubility
enhancers for chitosan, glycerol (G), propylene glycol (PG)
(Hungopharma Plc., Hungary) and polyethylene glycol 400 (PEG-400)
(Sigma-Aldrich, Germany) were used as plasticizers, mucin 75–95 %
(Roth, Germany) was used as a reagent for the mucoadhesivity in-
vestigation and diiodomethane (VWR Prolabo, USA) was used as non-
polar liquid for the SFE investigation, all were of analytical grade.
2.2. Methods
2.2.1. Preparation of the Films
Chitosan films were prepared by the solvent casting method, by
dissolving the polymer (2 w/v%) in aqueous acetic acid (AA) solution
(2 v/v%) as prescribed by Liu et al. (Liu et al., 2013) as a reference, and
with the use of CA (2.5, 3, 3.5, 4, 5 and 7 w/v %). Plasticizers were
added to AA, CA 2.5% and CA 7%-based solutions in approx. five to ten
times excess (5 w/v% and 10 w/v%) compared to polymer, to obtain
significant modification of the surface characteristics, which could be
crucial if the obtained films are applied as subcoating. Films plasticized
with 5 or 10% of glycerol, propylene glycol or polyethylene glycol are
referred later as G 5%, G 10%, PG 5%, PG 10%, PEG 5% and PEG 10%,
respectively. The exact compositions of the prepared solutions/films are
shown below in Table 1, while the molar ratios may be found in Table
Table 1
Composition of prepared citric acid (CA)- and acetic acid (AA)-based solutions/
























- 0 2 2.5 3 3.5 4 5 7 2
G 5 2 2.5 - - - - 7 2
10 2 2.5 - - - - 7 2
PG 5 2 2.5 - - - - 7 2
10 2 2.5 - - - - 7 2
PEG-400 5 2 2.5 - - - - 7 2
10 2 2.5 - - - - 7 2
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S1. A magnetic stirrer was used to obtain 100 mL homogeneous solu-
tions. Heating to 50–58 °C for two hours was required to dissolve
chitosan containing a low amount of CA (2.5 and 3 w/v %), as the pH of
CA (2.5–3 w/v%) was around pH 4, which is higher compared to the pH
of the AA-based solution (pH of ~2.75). For AA and CA (3.5–7 w/v %)
heating was not required. After the whole polymer dissolved, the ob-
tained solutions were left to stand for 3 h to enable the entrapped air
bubbles to evolve. A portion (~ 25 mL) of each solution was taken for
MFFT testing, while the remaining amount was cast into gasket rings
(19.635 cm2 x 0.5 cm) as 10 g/ring. The rings were fixed onto Teflon
surface by applying a thin layer of the polymer solution at the bottom to
prevent any leakage. The cast solutions were dried under ambient
condition (25.5 ± 1 °C and 28 ± 1 RH%) for 48 h, the dried films
were carefully released from the plates and preserved in tightly closed
containers for further investigations.
2.2.2. Minimum film forming temperature (MFFT) investigation
MFFT was investigated with a Rhopoint MFFT-60 Bar tester
(Rhopoint, UK), the temperature bar consisted of a platen with an
electronically imposed temperature gradient, and the MFFT was in-
vestigated in the temperature range of 15–60 ºC. After temperature
equilibrium had been established, a cube applicator was used to make 5
parallel films of 75 μm thickness over the temperature bar. The hinged
Perspex cover was returned down to provide atmospheric and thermal
equilibrium whilst enabling the visual inspection of the applied films.
The films (n = 5) were then let completely dried and the result was
recorded manually by inspecting the cracked regions on the applied
films form on the graduating scale of the equipment.
2.2.3. FT-IR spectra
Infrared spectra for the films and the other excipients were obtained
by using an FT-IR (Avatar 330 FT-IR ThermoScientific, USA) apparatus
coupled with a Zn/Se HATR (horizontal attenuated total reflectance)
accessory. Each film was directly placed on an ethanol-cleaned crystal
of the equipment, the scanning was run in the wavelength range of
600–4000 cm−1, the spectra were collected from 128 scans to obtain
smooth spectra, at the spectral resolution of 4 cm−1 and applying CO2
and H2O corrections.
2.2.4. Film thickness
The thickness of films was measured at 10 randomly selected points
on each film (n = 10) by using a screw micrometre (Mitutoyo Co. Ltd,
Japan) with sensitivity of 0.001 mm, and the means and SDs were
calculated.
2.2.5. Hardness and mucoadhesion investigations
Hardness and mucoadhesive forces were investigated by a labora-
tory constructed texture analyser. The equipment and software were
developed at the Institute of Pharmaceutical Technology and
Regulatory Affairs, University of Szeged. The equipment is designed to
assemble different sample holders as well as different stainless-steel
moving probes depending on the test to be conducted, with a con-
trollable force, moving speed and direction.
2.2.5.1. Hardness and deformation process investigation. For the hardness
test, a needle-like probe with a half-sphere end was fixed at the top
movable part of the assembly and set to move downward with a
controllable speed toward the tested film, which was tightly fixed on a
sample holder enabling the moving probe to pass through the fixed film
until the film cracked. This test was repeated ten times for each film
(n = 10), and the means and SDs were calculated.
2.2.5.2. Mucoadhesion force measurement. The same texture analyser
with different setting and assembling parameters was used to
investigate mucoadhesion. A rod-like probe with an outer diameter of
9 mm represented the sample holder. A double-faced adhesive tape was
used to fix the polymer film with equivalent area on its surface. At the
equipment bottom, a circular flat disc with an outer diameter of 35 mm
was fixed, on which a few drops of freshly prepared 1 mg/mL mucin
solution were spread. The equipment was adjusted to move downward
to press the film with 50 ± 1 N force for 30 s to the mucin, which may
be followed as a steady state part in the related force-time curve
(Fig. 3). The probe then moves upwards, which is resulted in the drop
down of the force curve until the fixed film starts to detach from the
mucin, which is represented as a sharp peak on the force-time curve,
where the peak maximum represents the mucoadhesive force. This test
was repeated five times (n = 5), and the means and SDs were
calculated.
2.2.6. Moisture content measurement
The moisture content of the prepared films was measured by using a
Mettler–Toledo HR73 (Mettler–Toledo, Hungary) halogen moisture
analyzer. The moisture content of approximately 0.5 g of the films was
measured three times (n = 3) at a drying temperature of 105 °C until a
constant weight was obtained, and the means and SDs were calculated.
2.2.7. Calculation of SFE
SFE is one of the most essential parameters that could be used to
characterize the surface properties of the prepared films, especially if it
is involved in a coating process (Kristó et al., 2016). Therefore, by
measuring SFE the wetting behaviour and the applicability of the tested
polymer for the coating process can be evaluated. The SFE of a mu-
coadhesive polymer should be adequate to enable the wetting with the
mucosal surface (Andrews et al., 2009).
SFEs were calculated indirectly from the means of the contact angles
(Ɵ) of two liquids (Schuster et al., 2015), with known surface tension,
dispersive and polar components by using the optical contact angle-
measuring apparatus (OCA20-DataPhysics Instrument GmbH, Filder-
stadt, Germany), via the application of the sessile drop method. Dis-
tilled water (γtot = 72.8 mN/m, γd = 21.8 mN/m, γp = 51.0 mN/m)
and diiodomethane (γtot. = 50.8 mN/m, γd = 50.8 mN/m, γp = 0 mN/
m) were used as polar and non-polar reagents, respectively. One drop of
each liquid (10 μL of distilled water and 5 μL of diiodomethane) was
applied via a motor-driven micro-syringe on the prepared thin, plain
and smooth film of chitosan and the angles were measured auto-
matically for 30 s. The starting (0 s) and equilibrium (30 s) contact
angles (n = 10 of each liquid) were recorded, and the means and SDs
were calculated separately. The results were introduced into OCA-20
SFE-calculating-program by introducing the means and SDs of first and
equilibrium contact angles in every combination by applying the




























where Ɵ is the contact angle, γl is the liquid surface tension; γs is the
solid surface energy, and the superscripts indicate their polar (γp) and
dispersive components (γd). As the surface free energy of the film is the
sum of the dispersive part and the polar part, the polarity (percent of
hydrophilic groups formed during film formation) of the prepared films
could be calculated by the following formula (Eq. 2):
= ×Polarity Polarpart Surfaceenergy% ( / ) 100 (2)
2.2.8. Statistical analysis
The gathered data were analysed with according to a factorial
ANOVA method using Tibco Statistica v13.1 (Statsoft, Tulsa, OK, USA)
software.
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3. Results and Discussion
3.1. Visual Appearance of Prepared Solutions and Films
The pH of the obtained AA-based solutions (Table S2) was varied in
the 2.75 ± 0.25 range and all solutions were transparent. The addition
of plasticizers slightly increased the pH, but G 10% solution showed pH
was comparable to a plasticizer-free solution. The appearance of the
films was similar, smooth and transparent in colour, except for films
made with the addition of PEG-400, which had white, opalescent
colour, which may be attributed mainly to elevated light scattering as
result of the increased film thickness caused by the intercalation of long
plasticizer chains between chitosan backbone. The pH values of the
obtained CA 2.5%-based solutions were in a relatively higher range (pH
4.12-5.37) (Table S3), which explains why heating was necessary to
dissolve the polymer. Nevertheless, the visual appearance of solutions
and films with and without different plasticizers was totally comparable
with that of AA-based ones. The PEG-400-containing films were also
translucent and had a smooth waxy texture. To eliminate the problems
of the elevated pH, a series of CA-based solutions was made in the range
of 2.5–7 w/v% (Table S4). The pH of the solutions was decreased from
4.25 to 2.58 with the increment of the CA concentration, which was
comparable with the pH of AA-based solutions and enabled the dis-
solution of the polymer without heating. The visual appearance of the
films was also similar to the AA-based ones.
The effect of plasticizers on the properties of CA 7w/v%-based
chitosan films (Table S5) was comparable with that of AA-based ones,
the obtained films were of smooth texture and transparent colour, ex-
cept for the one made with PEG-400, which showed the same white,
opalescent colour and transparency degree as PEG-400 plasticized CA
2.5w/v%- and AA-based films.
3.2. Physical Properties of the Prepared Films
The minimum film forming temperature (MFFT) was less than 15 ºC
for all investigated compositions as shown below in Table 2. All films
applied on the temperature bar were dried as smooth, transparent and
continuous films, i.e. no cracking or other failures were observed,
which confirms the applicability of the compositions for the coating/
subcoating of protein-containing solid dosage forms, since the low
MFFT enables to perform a failureless coating process under gentle
temperature conditions (between 30–45 ºC), which may generally de-
crease the risk of temperature-induced misfolding of the processed
polymers. Furthermore, the low MFFT enabled the drying of the cast
films under ambient conditions.
The thicknesses of the prepared films are shown in Table 2. The
plasticizer-free AA-based chitosan films showed the least thickness
(0.07 mm), in accordance with the literature (Bhuvaneshwari et al.,
2011). The thickness of CA-based chitosan films was minimum the
double and proved to be directly proportional to the CA concentration
(0.13–0.27 mm), indicating dilatation in the polymer backbone as a
result of cross-linking by CA. A similar direct relation between lactic
acid quantity and the thickness of chitosan film was also reported by
Bujang et al. (Bujang et al., 2013). The addition of a plasticizer also
increases the film thickness up to a certain limit in the order of
G<PG<<PEG-400 in all cases (Table 2).
The increment in film thickness upon the addition of the plasticizer
is attributed to a good distribution of these plasticizers within the
chitosan backbone. The significantly (p < 0.001) higher thickness ob-
tained with PEG-400 may be due to the bigger molecular weight, and
higher chain length of this plasticizer, which was resulted in bigger
distance between chitosan chains and higher water retention capacity.
Generally, the film thickness of the chitosan film may be manipulated
and optimized by the amount of the plasticizer and the amount of
chitosan itself, as was also shown by Nady and Kandil (Nady and
Kandil, 2018).
The results also support that differences in film thickness may also
contribute in the difference of the moisture content (MC) of the various
samples as a weak positive correlation was revealed between these two
parameters. The MC of plasticizer-free chitosan films showed no sig-
nificant difference and was approximately 1% up to 5% CA content.
However, after a certain threshold, MC increases and may reach 9.15%,
as recorded for the CA 7%-based film. This may also be explained by the
cross-linking between CA and chitosan, which may result in the en-
trapment of water molecules within the polymer backbone. The addi-
tion of plasticizers significantly (p < 0.0001) increased MC in all cases
as a result of physical interactions enabling the solvent to be entrapped
within the polymer skeleton and also due to their hygroscopic and
Table 2
Physical properties of the various chitosan films (MFFT= minimum film forming temperature, MC= moisture content).
AA (v/v%) CA (w/v%) Plasticizer Plasticizer content (w/v%) MFFT (°C) Thickness (mm) Hardness (N) Mucoadhesion (N) MC (w/w%)
2 - - 0 <15 0.07 ± 0.02 44.63 ± 3.4 42.30 ± 3.60 01.20 ± 1.70
2 - G 5 <15 0.21 ± 0.04 2.39 ± 0.9 9.00 ± 4.62 13.83 ± 3.64
2 - 10 <15 0.32 ± 0.10 2.91 ± 1.1 8.34 ± 1.63 11.15 ± 0.54
2 - PG 5 <15 0.33 ± 0.01 6.66 ± 0.71 19.49 ± 3.20 06.41 ± 2.34
2 - 10 <15 0.13 ± 0.02 6.81 ± 0.72 10.37 ± 2.27 07.80 ± 1.90
2 - PEG 400 5 <15 0.21 ± 0.01 20.88 ± 1.7 13.68 ± 3.40 7.92 ± 2.71
2 - 10 <15 0.43 ± 0.03 18.48 ± 1.7 8.69 ± 2.89 13.27 ± 3.96
- 2.5 - 0 <15 0.13 ± 0.01 36.01 ± 3.70 47.57 ± 3.03 0.75 ± 1. 26
- 3 - 0 <15 0.15 ± 0.10 35.65 ± 3.36 35.41 ± 2.22 0.86 ± 2.54
- 3.5 - 0 <15 0.14 ± 0.01 48.52 ± 0.50 42.68 ± 3.10 1.14 ± 3.34
- 4 - 0 <15 0.16 ± 0.04 32.83 ± 4.78 41.10 ± 2.93 1.99 ± 2.82
- 5 - 0 <15 0.23 ± 0.02 39.20 ± 5.40 30.32 ± 1.84 1.05 ± 2.46
- 7 - 0 <15 0.27 ± 0.02 8.40 ± 1.98 25.65 ± 3.90 9.15 ± 3.84
- 2.5 G 5 <15 0.17 ± 0.02 1.04 ± 0.27 14.52 ± 1.28 0.86 ± 3.43
- 2.5 10 <15 0.20 ± 0.01 1.93 ± 0.89 13.71 ± 0.46 1.14 ± 3.03
- 2.5 PG 5 <15 0.21 ± 0.01 1.39 ± 0.43 13.77 ± 1.78 1.99 ± 2.50
- 2.5 10 <15 0.22 ± 0.01 4.95 ± 0.68 9.91 ± 2.18 1.05 ± 0.92
- 2.5 PEG 400 5 <15 0.26 ± 0.02 8.12 ± 3.95 8.67 ± 2.10 2.15 ± 1.56
- 2.5 10 <15 0.34 ± 0.01 6..22 ± 1.92 7.86 ± 3.86 2.75 ± 2.01
- 7 G 5 <15 0.10 ± 0.01 0.58 ± 0.64 11.07 ± 2.76 11.83 ± 4.52
- 7 10 <15 0.14 ± 0.01 0.64 ± 0.64 13.24 ± 1.10 17.36 ± 3.67
- 7 PG 5 <15 0.16 ± 0.01 1.33 ± 0.14 15.80 ± 0.84 8.33 ± 1.80
- 7 10 <15 0.18 ± 0.01 1.27 ± 0.25 12.20 ± 1.22 10.46 ± 2.67
- 7 PEG 400 5 <15 0.23 ± 0.02 2.75 ± 1.10 18.13 ± 2.57 4.55 ± 0.73
- 7 10 <15 0.33 ± 0.02 6.22 ± 1.80 16.79 ± 1.35 3.25 ± 2.22
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moisture retentive behaviour. From this aspect, G exhibited sig-
nificantly higher MC (p < 0.01) than PG or PEG, which may be con-
nected to the presence of unbounded OH groups. It is also notable that
MC showed considerable pH dependency since the CA 2.5%-based
samples exhibited significantly lower MC (p < 0.0001) than others,
which may be due to a lower degree of ionization.
Plasticizer-free films made with CA in different quantities (2.5, 3,
3.5, 4, and 5 w/v %) showed a high breaking force in the range of
32.83–48.52 N, which was comparable with AA-based chitosan films.
Nevertheless, a dramatic increase was observed in the time of elonga-
tion (Fig. 1) due to a viscoelastic change in the texture of films, found to
be proportional to the amount of CA. However, when CA reaches 7 w/v
%, a sharp reduction of hardness may be observed with a marked in-
crease in elasticity. In conclusion, CA may be a good plasticizer for
chitosan and the ideal mechanical property may be achieved when it is
used in the 3.5–5 w/v % range. Wan et al. (Wan et al., 1993) prepared
CA-based hydroxypropyl-methylcellulose (HPMC) and CA-based so-
dium carboxymethylcellulose (NaCMC) films containing theophylline,
and they concluded that the films made with 10% of CA were brittle
and CA should be beyond 30% to obtain a good plasticizing effect
(Wan et al., 1993). Shi et al. (2008) stated that CA used in a con-
centration of 5 wt% increases the tensile strength of polyvinyl alcohol/
starch films, and above this concentration (5–30 wt%) the excess of CA
acts as plasticizer and hence reduces tensile strength (Shi et al., 2008).
In present study CA exerts the plasticizing effect above 3 w/v% but
results in a significant decrease of hardness only above 7 w/v%, which
equals 150% and 350% CA content compared to the polymer, respec-
tively, which is higher compared to the above. Nevertheless, the dif-
ferent behaviour may attribute, to the weak alkaline nature of chitosan
forming stronger interactions and requiring much more CA than needed
by HPMC, NaCMC and polyvinyl alcohol/starch.
Independently from the original hardness, the addition of plastici-
zers significantly (p < 0.0001) decreased the hardness of all in-
vestigated films (Table 2), in the order of PEG-400<<PG<G. Never-
theless, despite the significant decrease in hardness, a notable visco-
elastic deformation was observed, which resulted in an increase of the
required time of elongation (Figs. 2 a,b). A comparable finding for
chitosan/G was obtained by Zaini et al. (Ziani et al., 2008).
As regards the hardness of films made with PEG-400, it was sig-
nificantly (p < 0.0001) better compared to the other plasticizers.
However, it is notable that the addition of PEG-400 affects hardness
inversely compared to PG or G, and a further decrease in hardness was
observed when the added quantity of PEG-400 was increased. In con-
trast, the increasing amount of PG and G resulted in a slight, but not
significant increase in hardness.
Regarding mucoadhesion, the plasticizer-free AA-based chitosan
films exhibited a high force of detachment (42.30 N) (Table 2), whereas
plasticizer-free CA 2.5 w/v%-based films showed even higher values
(47.57 N), possibly due to the lower degree of ionization, which enables
the formation of strong ionic interactions between the unionized amino
groups of chitosan and the sialic acid parts of mucin molecules (Bravo-
Osuna et al., 2007, Peppas and Huang, 2004). In contrast, the incre-
ment of CA content or the addition of a plasticizer significantly
(p < 0.0001) reduced mucoadhesive force (Figure 3). This could be
attributed to the interactions between chitosan and the plasticizers,
which decrease the number of free functional groups, or to the covering
of the pores at the film surface and retarding the wetting process.
Compared to the other films, CA 3.5, 4 and 5 w/v%-based films are the
most applicable depending on their tensile strength and mucoadhesion
in these concentration ranges, as CA showed an ideal plasticizing effect
as well as a good cross-linking effect on the chitosan molecule.
The obtained SFEs of the prepared films are shown in Table 3. The
plasticizer-free AA-based film exhibited moderate SFE (~27 mN/m),
while CA-based films showed significantly higher SFE around 40 mN/m
without any considerable difference regarding the CA content. The
polarity of CA-based films was also higher than that of the AA-based
one, however, the increasing CA content significantly decreased po-
larity, which may be related to the pH of the solution. The addition of
PEG-400 increased SFE as well as polarity, in both 5 and 10 w/v%
concentrations, which may be due to presence of polar oxygens in the
PEG backbone, which will be presented on the film surface after cross-
linking of the chitosan chains, or in a manner enabling the polymer to
dissolve in a relatively high amount of CA, resulting in ester formation
and at the same time saving some polar functional groups (OH groups)
at the surfaces when the films got dry. Despite these, the mucoadhe-
sivity of PEG-containing samples was relatively low, since the presence
of PEG may decrease surface porosity and the polar oxygens are weak
proton acceptors and therefore may poorly interact with mucin.
On the other hand, films made with the addition of G and PG de-
monstrated a strong decrease in both SFE and polarity. This may be
attributed to the inclusion of the polar groups of these plasticizers with
the carboxyl group of the acid, or involvement in hydrogen bonding
Fig. 1. Breaking curves of CA 2.5% (a), CA 4% (b), CA 5% (c) and CA 7%-based chitosan films.
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with chitosan and hydrocarbon backbone on the surface decreases po-
larity, surface porosity and therefore reduces wettability. All of these
events also participate in the reduction of the mucoadhesivity of these
films. As wetting is the first step of the mucoadhesion process,
Casariego et al. (Casariego et al., 2008) reported that the addition of a
hydrophilic plasticizer such as glycerol and sorbitol reduces the wett-
ability and adhesion coefficient of chitosan films (Casariego et al.,
2008). Overall, a plasticizer-free CA-based film may be chosen as an
oral film to deliver a macromolecule, as the values of hardness and SFE
were relatively adequate, while the good wetting and high mu-
coadhesivity enables the films to tightly adhere to the mucosal surface.
However, if the film would be utilized as the subcoating of an in-
testinosolvent coat, the PEG plasticized film seems to be best solution
due to its higher hardness and higher surface free energy, which will
enable better spreading and adhesion of the intestinosolvent coat on the
substrate surface.
3.3. Investigation of the Chemical Structure and Interactions
The FT-IR spectrum of chitosan biopolymer is shown in Fig. 4,
which reveals the fundamental absorption bands. The stretching vi-
brations of the –OH and N-H groups of chitosan are shown by a broad
band between 3800–3400 cm−1 and 3300 3000 cm−1, respectively.
The peak around 2870 cm−1 belongs to the symmetric stretching of the
CH3 group in the acetyl side chain, while that of 2715 cm−1 to the
symmetric CH2 stretching in the ring. The strong absorption band at
1660 cm−1 belongs to the C=O stretching of the acetylated carbon
amide group. The absorption bands around 1592 cm−1, at 1423 cm−1
and 1377 cm−1 belong to the presence of N–H, CeH and OeH bending
vibrations, respectively. The peak at 1170 cm−1 is attributed to the
asymmetric stretching of the (C–O–C) bridge.
Chitosan was dissolved in AA 2 v/v% due to the ionization of the
non-acetylated amide groups as it is shown by the right shift of the NeH
stretching and the left shift of the NeH bending absorption bands. The
appearance of a new band at 1750 cm−1 indicates the esterificaion and
hydrogen bonding of some hydroxyl groups, similarly to the right shift
of the broad OeH stretching peak at 3600–3000 cm−1 and the left shift
of the OH bending. The addition of plasticizers resulted in no con-
siderable change in the texture, but some signs of weak hydrogen bonds
were noticed in the order of G>PEG-400>PG, which may be due to the
number of free hydroxyl groups on the plasticizers.
The FT-IR spectra of CA-based chitosan films made with variable
amounts of CA (Fig. 5) indicates the presence of strong H-bonds be-
tween the OH groups of the polymer and the carboxyl groups of the acid
by right shift of OH stretching peak between 3600–3300 cm−1. The
more intensive right shift of the NeH stretching signal between
3300–3000 cm−1, the stronger left shift of the NH bending at
1590 cm−1 and the increasing intensity of the new broad peak at
2000 cm−1 indicate the stronger ionization of the amino groups with
the increasing CA content. In all the shown film spectra, the presence of
peak around 1400 cm−1 was due to carboxylate anion absorption
(–COO¯), indicating citrate salt formation. According to Llanos et al.
(Llanos et al., 2015), the peak around 1588 cm−1 is due to the proto-
nation of amine group NH+3 and its intensity can be used to estimate the
degree of protonation, while according to Lusiana et al. (Lusiana et al.,
2018), the appearance of a peak around 1580–1590 cm−1 indicates the
Fig. 2. Hardness of CA 2.5%-based chitosan film plasticized with 10 w/v% PG (a) or G (b).
Fig. 3. Mucoadhesion curves of CA 2.5% (a), CA 4% (b), CA 5% (c) and CA 7%-based chitosan films.
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modification of the amine groups in chitosan from primary amine to
secondary amine upon the addition of acid. However, according to our
knowledge, the secondary amine did not show NeH absorption in this
range. On the other hand, He et al. reported the characteristic peak
around 1588 cm−1 due to the N-H bending vibration of primary amine
-NH2 (He et al., 2011), which opinion corresponds with our point of
view.
When chitosan was dissolved in CA (Figs. 6 and 7), the addition of
plasticizers also resulted in the formation of weak H bonds, but in this
case in the order of PG>G>PEG-400, which also confirms the differ-
ences in the texture formation and interactions of AA- and CA-based
films. However, no considerable difference was observed between CA
2.5% and CA 7% films in this manner, which indicates that the
polymer-plasticizer interactions may be related mostly to the bonding
of -OH groups, and therefore the increasing ionization grade of chitosan
does not considerably affect the strength of these interactions.
Generally, it could be concluded that the addition of polyhydroxy
alcohols like G, PG and PEG-400 will result in the formation of weak H
bonds with the hydroxyl groups of chitosan, and the white opalescent
colour of chitosan/PEG-400-based films was only due to physical in-
teractions and may be not connected more intensive chemical change
(Thuran et al., 2001).
4. Conclusions
In the present study it was successfully proven that chitosan films
may be successfully prepared with the direct dissolution of the polymer
in CA solution, and the obtained films exhibited comparable properties
as AA-based ones. However, the achievable wider pH range enables the
tailoring of the ionization grade of chitosan which provides advantages
from the aspect to achieve an ideal mucoadhesivity. The lower degree
of ionization resulting from the higher pH of the solutions with a low
CA content increased mucoadhesivity compared to AA-based films. The
MFFT and SFE of chitosan citrate films, which are essential to be in-
vestigated before the coating process but had never been reported in the
literature before, were also investigated. Both AA and CA-based films
Table 3
SFE (γtotal), its dispersive (γd) and polar (γp) components and polarity of the prepared films.
AA (w/v%) CA (w/v%) Plasticizer Plasticizer content (w/v%) γtotal (mN/m) γd (mN/m) γp (mN/m) Polarity (%)
2 - - 0 26.58 ± 2.25 14.82 ± 0.65 11.80 ± 2.15 44.40
2 - G 5 15.55 ± 1.94 9.22 ± 0.78 6.33 ± 1.80 40.71
2 - 10 13.21 ± 1.85 8.21 ± 0.78 5.00 ± 1.70 37.85
2 - PG 5 14.95 ± 2.12 8.12 ± 0.94 7.33 ± 1.90 49.03
2 - 10 15.75 ± 1.84 12.39 ± 0.86 3.40 ± 1.38 21.61
2 - PEG 400 5 44.71 ± 2.74 22.38 ± 0.90 22.20 ± 2.60 49.65
2 - 10 47.30 ± 3.00 25.66 ± 1.50 22.10 ± 2.56 46.72
- 2.5 - 0 41.50 ± 1.90 18.33 ± 0.90 23.13 ± 1.70 55.73
- 3 - 0 44.31 ± 1.65 24.44 ± 0.70 19.87 ± 1.50 44.84
- 3.5 - 0 37.97 ± 1.80 17.12 ± 0.68 20.90 ± 1.63 55.04
- 4 - 0 43.34 ± 1.72 17.12 ± 0.74 20.76 ± 1.55 48.00
- 5 - 0 42.54 ± 1.71 23.98 ± 0.86 18.31 ± 1.50 43.04
- 7 - 0 39.40 ± 2.65 22.80 ± 2.01 16.59 ± 1.64 41.40
- 2.5 G 5 29.60 ± 2.02 16.54 ± 1.33 13.05 ± 1.50 44.10
- 2.5 10 27.23 ± 2.72 16.69 ± 2.01 10.54 ± 1.70 38.71
- 2.5 PG 5 47.66 ± 1.84 29.38 ± 1.12 18.30 ± 1.50 38.40
- 2.5 10 36.85 ± 1.80 19.15 ± 0.90 17.82 ± 1.54 48.40
- 2.5 PEG 400 5 57.40 ± 1.73 35.73 ± 1.00 21.70 ± 1.42 37.80
- 2.5 10 54.14 ± 1.60 35.16 ± 0.82 19.00 ± 1.33 35.10
- 7 G 5 40.10 ± 1.85 27.58 ± 1.27 12.50 ± 1.64 31.20
- 7 10 38.57 ± 1.52 24.98 ± 0.72 13.60 ± 1.33 35.30
- 7 PG 5 37.30 ± 2.04 26.78 ± 1.58 10.25 ± 1.31 27.50
- 7 10 36.63 ± 1.72 26.84 ± 1.15 9.80 ± 1.25 26.80
- 7 PEG 400 5 65.77 ± 2.11 34.37 ± 1.55 31.40 ± 1.43 47.74
- 7 10 68.11 ± 1.81 36.77 ± 1.23 31.35 ± 1.32 46.03
Fig. 4. FT-IR spectra of raw materials and AA-based films.
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showed MFFT less than 15 °C, which is quite good for the coating
process and ensures the required integrity of the coat even at low drying
temperatures, while the slightly higher SFE of CA-based formulations
enables the better tuneability to achieve the required properties of the
subcoating layer. However, the increasing CA content decreased hard-
ness but increased elasticity, which was directly proportional to the CA
quantity. It could be concluded that CA 3.5–5% w/v-based chitosan
solutions (without a plasticizer) represent novel solutions for the
coating process or for developing novel oral mucoadhesive films for
macromolecule delivery as at these concentrations they showed an
excellent cross-linking, plasticizing effect, MFFT, film thickness, higher
force of both deformation and mucoadhesion and suitable moisture
content, thus simplifying the formulation, and they seem to be sa-
tisfactory to make an acidic microenvironment sufficient to inhibit the
peptidases.
The addition of high amounts of various additional plasticizers, e.g.
G, PG and PEG, dramatically reduces the force of deformation, wett-
ability and mucoadhesivity for both CA- and AA-based films, while
enhancing elasticity; therefore, these films can be utilized as im-
permeable coats for site-specific drug delivery or even for food pre-
servation. Furthermore, high-dose plasticizers were effective in the
modification of the surface free energy of the films, which may be es-
sential to optimize film properties if they are used for the coating/
subcoating of various substrates. The addition of plasticizers affects film
thickness up to a certain limit in a manner proportional to the plasti-
cizer quantity and type. Also, CA quantity affects the film thickness in a
direct proportional manner, but to an acceptable extent. The addition of
PEG-400 results in an unsatisfactory appearance of the films made with
both CA and AA due to some opalescence but brings smaller decrease in
hardness or mucoadhesivity of both AA- and CA-based films a G or PG.
It also seems the magnitude of SFE has no relation to wettability in the
presence of G, PG and PEG for both AA- and CA-based films, as the
variation in SFE and just minimally affect mucoadhesivity, which
mainly depends on the wetting process.
Overall, it may be concluded that chitosan-citrate based formula-
tions may provide ideal platform in applications for oral macromolecule
delivery.
Declaration of Competing Interest
None.
Acknowledgement
This research was supported by the EU-funded Hungarian grant
EFOP-3.6.1-16-2016-00008.
Fig. 5. FT-IR spectra for 2.5, 3, 4, and 7 w/v% CA-based chitosan films.
Fig. 6. FT-IR spectra of raw materials and CA 2.5%w/v-based chitosan films.
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Obtained Sol. pH Film’s appearance 
2 - 0 transparent 2.75 transparent 
2 G 5 transparent 2.82 transparent 
2 G 10 transparent 2.70 transparent 
2 PG 5 transparent 2.81 transparent 
2 PEG 400 5 transparent 2.92 opalescent 
2 PEG 400 10 transparent 2.95 opalescent 
Table S2: The pH and visual appearance of prepared chitosan/AA-based solutions and films, 












pH Film’s appearance 
2 G 5 transparent 4.47 transparent 
2 G 10 transparent 4.12 transparent 
2 PG 5 transparent 4.86 transparent 
2 PG 10 transparent 4.92 transparent 
2 PEG 400 5 transparent 5.21 opalescent 
2 PEG 400 10 transparent 5.37 opalescent 












2 7 2.40 transparent transparent 
2 5 2.56 transparent transparent 
2 4 2.63 transparent transparent 
2 3.5 2.99 transparent transparent 
2 3 3.45 transparent transparent 
2 2.5 4.25 transparent transparent 












pH Film’s appearance 
2 G 5 transparent 2.58 transparent 
2 G 10 transparent 2.72 transparent 
2 PG 5 transparent 2.76 transparent 
2 PG 10 transparent 2.81 transparent 
2 PEG 400 5 transparent 2.79 opalescent 
2 PEG 400 10 transparent 2.89 opalescent 
Table S5: The pH and visual appearance of solutions and films made with CA7w/v% and 
different plasticizers 
 
 
